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Abstract 
The study of cell surface glycosylation has increasingly been seen to be an important 
area in recent years. A cells ability to carry out its specific function hinges on its ability 
to correctly glycosylate its surface proteins. The cell membrane has a large number of 
embedded surface glycoproteins. Correct glycosylation is imperative for correct protein 
folding to facilitate a number of cellular processes, including; cell-cell signalling and 
cell adhesion. Alterations to these cell surface glycans can have detrimental effects for 
the cell and lead to a change in certain cellular functions. It is also recognised that 
changes in cell surface glycosylation are early indicators of the cell becoming stressed or 
diseased. To date, antibody probes are primarily utilised to interogate the surface of a 
cell, usually recognising surface proteins. However, this strategy has not worked for the 
study of surface glycosylation as antibodies are unable to recognise and distinguish 
between neutral glycans. Therefore, in order to understand the specific changes to the 
cell surface glycosylation, new technologies, including new probes, need to be explored 
and expanded to identify possible changes as accurately as possible. 
  
This work aimed to develop and modify a number of recombinant lectin probes that 
could be used in unison with commercially available eukaryotic lectin probes to 
interrogate the cell surface glycosylation of two colorectal carcinoma cell lines. In 
cancer cells, altered glycosylation is believed to be amongst the earliest changes to 
occur. These changes could also indicate the specific stages of certain cancers and infer 
if a cancer is metastasising or not. This work also reports on the use of a panel of lectins, 
in combination with flow cytometry and fluorescent microscopy, to identify 
glycosylation changes between an SW480 and SW620 cell line. These paired cell lines 
are from the same patient with SW480 classed as non-metastatic and SW620 classed as 
metastatic. This work shows a significant change in the levels of sialylation, both in type 
and abundance, between the two different cell lines. With a decrease in lectin binding 
for sialic acid, there was a proportional increase in galactophilic lectin binding which 
highlights the altered glycosylation found on the cell surface of these cell lines.  
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1.1 Glycobiology 
In recent years the study of glycobiology has become increasingly important. 
Glycobiology is the study of all carbohydrates, or glycans, attached to proteins and other 
molecules throughout eukaryotic and prokaryotic life. The process of adding specific 
glycan chains to proteins, or other biomolecules, is called glycosylation and is deemed 
as one of the most important post translational modifications (PTM). In recent decades 
the study of glycosylation has increased exponentially. Since the human genome project 
was completed, the myth of one gene for one protein product was cast aside. The study 
of proteomics became more important and all PTMs, including glycosylation, needed to 
be studied in greater detail. Glycan structures have been shown to be pivotal in nearly all 
cellular functions; cell signalling (Ohtsubo and Marth 2006), cell-cell adhesion (Gu et al. 
2012), cell surface transport proteins as well as internal cytoplasmic signalling in the 
cell. Glycosylation is described as a non-template driven PTM, which in itself is 
interesting, as protein synthesis itself is fully template driven (Dwek 1998). Due to the 
role of glycosylation in a variety of important cellular functions, any alteration in glycan 
formation or glycan attachment can have detrimental effects on the cell. Most receptors 
and transfer proteins need to be correctly glycosylated to fulfil their specific function. In 
figure 1.1 the differences between hexose monosaccharides is the positioning of the H 
and OH groups on certain carbons in the six carbon structure. Using different hexose 
sugars, eukaryotes build up these glycans to suit their specific needs. 
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Figure 1.1: Fischer projections of four of the most common hexose sugars found in 
nature. D-mannose and D-galactose are pivotal building blocks for eukaryotic glycan 
formation. Image taken from Study blue (2017). 
 
 
1.2 Glycosylation 
In biology, glycosylation refers to the non-template driven process of covalently 
attaching a series of carbohydrate complexes, or glycans, to a protein, lipid or other 
organic molecule. The glycans can vary in size from a single carbohydrate to a large 
oligosaccharide depending on the functionality of the protein or lipid. This process is 
facilitated by a specific set of enzymes that selectively add and subtract 
monosaccharides to build the necessary glycan. These enzymes can be split into two 
distinct groups; these groups are glycosyltransferases and glycosidases. 
Glycosyltransferases are involved in transferring glycan structures and single sugars to 
existing glycan units or sites that allow glycosylation (Liarson et al. 2008). These 
enzymes use a glycosyl donor and join it to a glycosyl acceptor. This process creates a 
glycosylated acceptor and is explained in figure 1.2. Glycosyl donors, also called 
nucleotide sugars, are monosaccharides linked to a specific nucleotide.  
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Figure 1.2: Glycoslytransferase  activity. Glycosyltransferases use monosaccharides 
linked to a nucleotide or isoprenoid structure. Image taken from Varki et al. (2009).  
Glycosidase enzymes facilitate the subtraction of single monosaccharides or glycan 
structures from glycosyl acceptors (Boudabbous et al. 2016). Both sets of enzymes are 
equally important when it comes to formation of the correct glycan structure. Generally 
in eukaryotes glycans are built up with a higher number of sugar molecules, facilitated 
by various glycotransferases, than needed. Once these glycans have been built up, 
glycosidases cut down the glycan and mold it for the desired glycan complex (Bieberich 
2014).  
It is hypothesised that the majority of our proteins are glycosylated, or have sites that 
would allow glycosylation. Proteins and cells can undergo many different modifications 
but studies are showing that glycosylation is one of the most common and also the most 
diverse form of PTM. In a review by Lommel and Strahl (2009) it is stated that 13 
monosaccharides and eight amino acids are involved in at least 41 different types of 
carbohydrate-protein linkages in eukaryotes. With this information now available it is 
presumed that if the glycosylation of a protein is incomplete or flawed the resulting 
protein many have increased or decreased functionality and efficacy (Shental-Bechor 
and Levy 2008). Alterations in protein glycosylation are a very important area to study 
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when it comes to disease progression. This area will be explained in further detail in 
later sections 1.5.1 and 1.5.2. 
The intricacies of glycosylation and glycan formation are highlighted by the sheer 
number of enzymes, sugars and mechanisms involved. To facilitate all of these 
processes there are various classes of glycosylation. These classes depend on the specific 
glycosyl acceptor available. These classes are; 
 N-linked glycosylation: these glycans attach to the N (nitrogen) group of 
asparagine or arginine side chains. 
 O-linked glycosylation: these glycans attach to the hydroxyl O (oxygen) group 
which may be present on certain amino acid side chains like serine and 
threonine. It can also be the classification of glycans binding to the O on a lipid 
or other organic molecule. 
 Phospho-glycans: these bind through a phosphate. Phosphates may be present on 
a variety of different molecules. 
 C-linked glycosylation: this is a rare type of glycosylation where the glycan 
binds to the carbon side chain on the tryptophan amino acid. This type of 
glycosylation is rarer due to the fact oxygen and nitrogen are more reactive side 
groups. 
 Glypiation: this is the formation of a glycan link between proteins and lipids. 
This often allows for the transport between the two molecules. 
The last three classes here are usually viewed with less importance due to N- and O- 
linked glycosylation accounting for the majority of all glycosylation that occurs in 
eukaryotes. The sugars involved in eukaryotic glycosylation are; mannose, galactose, 
fucose, N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc) and N-
acetylnuraminic acid (sialic acid). The addition of Sialic acid to the end of any branch of 
a complex glycan signals that the glycan has been completed (Lodish et al. 2001). This 
process is also known as sialic acid capping or just capping. In diseased cells, such as 
cancer, this capping can occur at the incorrect time or may not occur at all and both of 
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these can cause significant problems for the protein’s intended function. These 
alterations will be discussed in section 1.5.1. 
Phospho-glycans are found in some bacteria as well as certain mammals including 
humans. Mannose phosphoserine glycans have been found in mice on the cell surface 
laminin receptor (Yoshida-Moriguchi 2010). C-glycosylation is usually found to be a 
mannose sugar added to the first tryptophan residue in the sequence W-X-X-W where X 
is any amino acid (Brenstrum and Brimble 2001).  
Glypiation, formation of a glycosylphosphatidylinositol (GPI) anchor, is a very 
important protein modification. Positioned at the C-terminus of a number of eukaryotic 
proteins, the GPI anchor facilitates anchoring to the outside of the cell membrane. These 
GPI anchored proteins have shown to play pivotal roles in a wide variety of biological 
processes (Paulick and Bertozzi 2008). There are more than 250 known proteins that 
contain a GPI anchor and are found on the cell surface. Important proteins such as 
alkaline phosphatase and CD14 are GPI-anchored proteins. The Manα1–4GlcNα1–
6myo-inositol-1-P-lipid is a universal substructure of all GPI anchors in eukaryotes 
(Varki et al. 2009). This form of “glycosylation” is very important for certain proteins 
and it helps anchor them to the membrane of the cell. There are relatively low amounts 
of proteins that contain these types of carbohydrate structures which lead to N- and O- 
linked glycosylation to be the more important types of glycosylation from an analytical 
point of view. 
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1.2.1 N-linked glycosylation 
While the three other classes of glycosylation are important in their own right, N- and O-
linked glycosylation are the two most prevalent forms of glycosylation (Zu and Ng 
2015). O-linked glycosylation will be described in greater detail in section 1.2.2. N-
linked glycosylation is the addition of glycans to the N group of asparagine or arginine 
residues. The targeting of N- glycans is recognised through a specific tri-amino acid 
sequence, which is asparagine-X-serine/threonine. The amino acid at postion X can be 
any amino acid with the exception of proline (Varki et al. 2009). In Eukaryotes all N-
linked glycosylation occurs in the endoplasmic reticulum (ER) and the golgi apparatus. 
The first sugar anchored to the asparagine is generally N-acetyl-D-glucosamine 
(GlcNAc). Once this sugar has been successfully attached to the N group of asparagine 
or arginine, the subsequent glycosylatransferases will facilitate continued glycan 
synthesis (Aebi 2013). First in the ER a large immature glycan complex is originally 
added to the specific protein. This allows the protein to fold correctly while some 
glycosidases begin to selectively reduce the glycan by cleaving individual 
monosaccharides. Once the protein has folded correctly it is transferred to the golgi 
apparatus to undergo a number of enzymatic steps to create mature glycans on the 
protein. Originally in the ER the immature glycan will have a number of mannose 
residues bound together with various linkages to allow branching of the glycans. The 
core residues of N-glycans are made up of the same sugar sequence. This sequence is 
Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asparagine-X-Serine/Threonine. 
These N-glycans can be catagorised into three types: the first is oligomannose, this is 
where the core of the N-glycan consists of only mannose residues with specific α- 
linkages. The second is a complex glycan; this is where the mannose core has been 
reduced by glycosidases and other glycotransferases have facilitated the addition of 
other monosaccharides via specific α- and β- linkages. The final type is a hybrid glycan 
complex where at least one branch point on the glycan retains its original mannose 
residues and at least one other branch consists of a number of other monosaccharides 
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again linked via α- and β- linkages (Varki et al. 2009). There are examples of all three 
types of these N-glycans in figure 1.3. 
 
 
Figure 1.3: Types of N-glycan complexes. This image shows the different types of N-
glycans observed in eukaryotes. The specific α- and β- linkages are also shown 
depending on which sugar molecule has been added at certain positions. Image taken 
from Varki et al. (2009). 
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Figure 1.4: N-glycan synthesis from the endoplasmic reticulum to the golgi 
apparatus. This image depicts the process of creating a mature N-glycan, via 
glycosyltransferases and glycosidases, in the ER and golgi. Image taken Taylor and 
Drickamer (2011). 
As explained in the previous section 1.2, glycans are anchored to GPI to allow for 
transport onto an immature protein. This early stage of glycosylation attaches a glycan 
complex to an unfolded protein. Due to the fact the protein is in an unfolded state, it is 
assumed that any Asn-X-Ser/Thr site can potentially become glycosylated. There are N- 
glycan recognition sites that can be buried in folded proteins that do not become 
glycosylated. Proteins can be modified to add additional glycan sites that would allow 
for increased N- or O- linked glycosylation. Erythropoietin is an example of a protein 
that has been modified to have more potential N-glycan sites (Su et al. 2010). As shown 
in figure 1.4 each individual sugar in added by its own glycosyltransferase enzyme. In 
mature N-glycans in eukaryotes there are no glucose sugars on the final product. 
Glucosidases act in the ER to remove the glucose molecules. Mannosidases then act in 
the golgi apparatus to trim the glycan to allow for the addition of the other sugars. 
Mature glycans can vary in size anywhere from a few sugars to a >20 sugar complex 
depending on the level of branching and extension that happens in the golgi apparatus 
(Grunwald-Gruber et al. 2017).  
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1.2.2 O-linked Glycosylation 
The other significantly important class of glycosylation is O-linked glycosylation. As 
briefly explained in section 1.2, O-linked glycosylation is the addition of glycan 
complexes to the hydroxyl group of a serine or threonine residue. There are other amino 
acids with hydroxyl groups, such as tyrosine, that can also have O-linked glycans, but 
this is observed less frequently. O-linked glycosylation occurs almost entirely in the 
golgi apparatus which differs from N-glycosylation (Varki et al. 2009). Early studies of 
O-linked glycosylation suggested that the majority of glycans began with a GalNAc 
sugar bound to the hydroxyl group of serine of threonine. Addition of GalNAc to 
Ser/Thr has been shown to occur only in the golgi. Later in this section it will be 
highlighted that in the last half a decade the study of O-linked glycans beginning with 
other monosaccharides has shown this not always to be the case. For instance up to 30% 
of all brain tissues in mammalian cells are O-mannosylated (Stalnaker et al. 2011). Some 
of these mannosyltransferases have been found to act in the ER, which changed the long 
held belief that O-glycosylation only occurred in the golgi and not the ER. O-linked 
glycosylation has been extensively studied in mucin proteins, as these proteins are 
secreted by the cell and have been shown to have a very high level of O-linked glycans. 
There are eight core O-glycans as well as the Thomsen-Nouvelle (Tn) antigen (GalNAc-
α-Ser/Thr) and Sialyl-Tn antigen (Sia-α-2,6-GalNAc-α-Ser/Thr). These core structures 
are shown in table 1.1 and figure 1.5. Mucin type glycoproteins are heavily glycosylated 
often with short O-glycans (Varki et al. 2009). These proteins were the first observed 
forms of O-glycosylation and have been studied extensively since their discovery.  
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Table 1.1: Structures of O-glycan cores found in mucin type proteins. This image 
depicts the variety of O-glycans, beginning with GalNAc-α-Ser/Thr, found in mucin 
proteins secreted by mammalian cells. Table taken from Varki et al. (2009).  
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Figure 1.5: Types of O-glycan complexes. This image shows the different types of core 
O-glycans observed in eukaryotes. The specific α- and β- linkages are also shown 
depending on which sugar molecule has been added at certain positions. Image taken 
from Nakayama et al. (2013). 
 
All O-linked glycans can branch in a similar fashion to N-glycans (Figure 1.5). Due to 
the fact this process occurs primarily in the golgi apparatus, all O-glycans are added to 
proteins that are already folded. Similar glycosyltransferases are then involved in 
transferring each individual monosaccharide onto the glycan chain. Differing from N-
glycosylation, this process builds up glycans from the base and doesn’t use glycosidases 
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to first trim the immature glycan. Though the study of mucins provided a lot of 
information about O-glycan sites and O-glycan synthesis, the increased study of 
glycosylation in the last few decades has shown O-glycosylation to be incredible diverse 
across different organisms. From prokaryotes to eukaryotes, O-glycosylation has been 
observed on essentially all amino acids that have a hydroxyl side group (Spiro 2002). In 
Eukaryotes the primary hydroxyl groups found to have this process occur are shown to 
be Ser/Thr. Even though a large portion of O-linked glycans begin with a GalNAc, there 
are more and more studies showing instances of GlcNAc, Mannose, Galactose and even 
Fucose being the primary sugar at the beginning of the glycan chain (Okajima and Irvine 
2002).  O-mannosylation has been shown to occur in a wide variety of cell types 
throughout a number of mammals, including humans. In a recent review carried out by 
Praissman and Wells (2014) there are a large number of different glycans found to begin 
with O-mannose. These core structures containing mannose as the primary sugar can be 
constructed in different ways. For instance a group of core O-mannosylated glycans are 
all single branched glycans beginning with a GlcNAc monosaccharide bound to 
mannose via a β1,2-linkage. A very common tetrasaccharide observed in this case is Sia-
α-2,3-Gal-β-1,4-GlcNAc-β-1,2-Man (Praissman and Wells 2014). Sialic acid capping of 
a galactose molecule indicates that there will be no more sugars added to this complex.   
Glycosylation with fucose as its primary sugar has been also investigated more 
thoroughly in the past decade. This is facilitated by two proteins named protein O-
fucosyltransferase 1 and 2 (POFUT 1 and 2). POFUT 1 was first described in 1998 and 
the gene was cloned in 2001 and was shown to be pivotal during development of both 
flies and mice. Later POFUT 2 was identified and characterised in 2006 (Lira-Navarrete 
et al. 2011). The existence and identification of these two proteins allowed for the study 
of O-fucosylation to increase. When studying the development of Drosophila embryos 
the Notch protein, and some of its ligands, it was found to be heavily fucosylated. A 
common tetrasaccharide was found on the Notch protein. This tetrasaccharide is similar 
to the O-mannosylation described previously; the sequence just replaces the primary 
mannose with a fucose sugar. The sequence is Sia-α-2,3-Gal-β-1,4-GlcNAc-β-1,3-Fuc 
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(Okajima and Irvine 2002; Lira-Navarrete et al. 2011). Although O-glycosylation 
beginning with a primary GalNAc sugar unit has been shown to be the most common 
version, these other versions of O-linked glycans provide very important roles in a wide 
variety of proteins.  
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1.3 Cell Surface Glycosylation 
In the previous section 1.2 the process of adding specific sugar molecules to proteins 
was explained in detail. Once this process is completed and the proteins are packaged 
and released from the golgi they are translocated to their intended destination, often 
ending up embedded in the cell membrane. Eukaryotic cell membranes contain a large 
number of embedded proteins and of these proteins a significant number of them are 
glycoproteins. The cell membrane’s main function is to protect the cell from its 
surroundings. It’s a selectively permeable barrier that can facilitate the movement of 
ions, organic molecules and other substances in and out of the cell (Alberts et al. 2002). 
Glycosylated proteins become embedded in the cell membrane and can end up in three 
different orientations. These orientations are; surface protein with a portion of the 
protein protruding on the inner membrane, surface protein with a portion of the protein 
protruding on the outer membrane and the protein protruding on both the inner and outer 
surfaces, i.e. transport proteins.  When a protein is transported and embedded into the 
cell membrane, its function dictates what orientation it needs to be in. Figure 1.6 shows 
a eukaryotic cell membrane with numerous proteins infused into the phospholipid bi-
layer. 
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Figure 1.6: Eukaryotic outer cell membrane. Integral membrane proteins are shown 
to be orientated in a multitude of ways on the inner and outer cell membrane. Image 
taken from the Khan acadamys online resources (Khan Academy 2016). 
 
In the case of glycoproteins, this outside section of the protein usually contains a number 
of glycans on its surface. These glycans facilitate a large number of cellular functions. 
Glycans on the surface of cells are found on receptors, transport proteins and signalling 
proteins to highlight a few (Christiansen et al. 2014). One of the main functions of cell 
surface glycosylation in the body is for our own immune system to recognise foreign 
pathogenic cells while not implicating our own healthy cells. The human immune 
system recognises the specific orientation of glycans on the surface of its own host cells. 
When an invading pathogenic cell is then encountered in the body the immune system 
can recognise it by the unfamiliar glycan pattern on its outer membrane (Turner 2003). 
This specific immune response is mediated by specific lectins that recognise these 
unfamiliar glycans and signal the cells to be targeted. This process and the lectins 
involved will be explained in greater detail in section 1.4. This highlights the importance 
placed on the cell’s ability to correctly glycosylate its surface proteins. 
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Glycoproteins on the surface can serve a variety of functions. Take the homing cell 
adhesion molecule (HCAM) protein, or more commonly known as CD44, for example. 
CD44 is present on the cell surface of the majority of mammalian cell types. In humans 
the CD44 gene is encoded on chromosome 11 and is a very interesting gene and 
glycoprotein because of its large number of isotypes, some of which can be seen in 
figure 1.6. There are 20 exons involved in CD44 and for this reason there are a wide 
variety of isoforms due to alternative splicing (Goodison et al. 1999). The group of 
CD44 splice variants play a role in various cellular functions, such as; cell division, 
migration, adhesion and cell-cell signalling. CD44 is a receptor protein for hyaluronic 
acid (HA) but can also interact with a number of other ligands. The proteins main role 
on the surface of cells is to ensure correct cell-cell and cell-matrix adhesion (Ponta et al. 
2003). Alternative splicing of the CD44 proteins leads to the addition or deletion of 
potential glycosylation sites. This glycosylation will impact the proteins ability to carry 
out its desired function. Some of the variable exons in the CD44 gene encode serine and 
threonine rich regions which increase the potential amount of O-glycan sites on the 
protein (Goodison et al. 1999). Due to the proteins nature as an adhesion molecule, 
CD44 has been increasingly studied in respect to tumour development. The protein has 
been shown to be upregulated in a number of different cancers (Basakran 2015).  
18 
 
 
Figure 1.7: CD44 molecular structure of two isoforms of CD44, CD44s and CD44v. 
Illustration of two of the different CD44 isoforms highlighting the variation of splicing 
the gene exons. Image taken from review by Basakran (2015). 
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1.3.1 Current Methods of Analysing Cell Surface Glycans 
Researchers have come up with a number of ways to effectively analyse glycans on the 
surface of cells or proteins. Some of the more important methods used to analyse these 
oligosaccharide structures are; Mass spectrometry, lectin microarray or lectin blotting, 
high performance liquid chromatography (HPLC) and the methods used in this project 
which were live cell lectin probing analysed on fluorescent microscopy and by flow 
cytometry (Varki et al. 2009). Fluorescent microscopy and flow cytometry will 
explained in later sections 1.7 and 1.8. There are a variety of ways to analyse glycans 
and some are more accurate than others, while some are more cost effective and time 
efficient than others. For this reason the methods are often used in unison and the 
selection of which method to use can often come down to specific glycans that need to 
be identified and characterised.  
HPLC is an analytical technique that is used to separate, identify and quantify 
components in a mixture. It uses the simple principles of traditional liquid 
chromatography but is pressurised to a significantly higher degree. The method uses a 
liquid solvent that is mixed with a sample that then is pumped into a pressurised column 
filled with a solid adsorbent material. Each compound or component of the sample 
mixture will interact differently with the adsorbent material which affects the flow rate. 
This change in flow rate is what causes the separation of compounds as they flow out of 
the column and are analysed. HPLC can monitor glycan samples once they are released 
from the glycoproteins. There are a number of different types of HPLC; size exclusion 
chromatography, ion exchange chromatography, reverse phase and normal phase that 
have been used in glycan analysis. These types of chromatography employ different 
methods to separate compounds based on the specific characteristics of the compounds 
in the mixture (Sirard 2012). For glycan analysis a specific strategy must be used in 
order to correctly identify different glycans that may only differ by linkages and or 
single sugar changes (Gohlke and Blanchard 2008). Using normal phase HPLC (NP-
HPLC) it was possible to obtain robust and reproducible separation of N-linked glycans 
with a high resolution (Campbell et al. 2008). Firstly the glycans needed to be released 
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from the specific glycoproteins being tested. This step used peptide:N-glycosidase F 
(PNGaseF) to cleave off the intact N-glycan off the surface of the glycoprotein. These 
released glycans can then be labelled with a specific fluorophore. One such fluorophore 
used is 2-aminobenzamide (Liu et al. 2010). The addition of this fluorophore allows 
detection at a femtomolar level. The process can be seen in figure 1.8, where the 
multistep process to release, label and ultimately detect specific glycans can be achieved 
using NP-HPLC. Some of the advantages associated with this method of glycan analysis 
are: (i) charged and neutral glycans can be analysed in the same mixture; (ii) since its 
one label per one glycan, the relative amount of individuals glycans can be quantified 
and (iii) this method can separate structures that have the same composition based on 
their sequence and the linkages involved (Campbell et al. 2008). The disadvantage of 
using HPLC is that the specific glycoproteins must first be isolated, and then the glycans 
must be removed intact and analysed. N-glycans containing a fucosylated precursor 
GlcNAc cannot be cleaved by PNGase F which is another drawback (Tarentino et al. 
1989). For these reasons HPLC may often be coupled with other methods of glycan 
analysis.  
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Figure 1.8: Overview of experimental strategy for glycan release, labelling and 
sequencing of glycans using HPLC. This diagram shows an effective way to identify, 
characterise and quantify glycans using HPLC. Image taken from Liu et al. (2010). 
 
Lectin microarrays and lectin blotting are methods used to determine the specific 
glycans on the surface of cells using proteins that specifically bind to carbohydrate 
molecules. The next section will explain what lectins are in greater detail and talk more 
about the specifics of certain lectins found both in eukaryotes and prokaryotes. These 
proteins have unique specificities for determining certain sugar units and their specific 
linkages. For this reason these proteins can be used in either a microarray format or can 
be used to blot glycoproteins in the form of western blots.  
Microarrays are often described as a lab-on-a-chip platform. The specific capture 
molecules, in this case different lectins, are immobilised onto the chip in an orientation 
that allows them to still remain active (Tateno et al. 2007). The large advantage of a 
microarray is that it can have a large number of different capture molecules on the chip 
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in duplicate or triplicate to allow for more accurate analysis (Pilobello and Mahal 2007). 
Specific lectins are chosen to accurately detect every different sugar molecule as well as 
account for the different branching and linkages that may be present in the glycan 
structures. For this method the glycoprotein can remain intact and the surface glycans do 
not need to be cleaved off (Hu and Wong 2009). The experimental overview for setting 
up a lectin microarray can be seen in figure 1.9. For this method the glycoprotein is 
labelled with a specific fluorophore and the glycoproteins can then be added to the chip 
(Hsu et al. 2008). Once the glycoproteins have been captured by the individual lectins, 
the fluorescence can be monitored through the use of a chip fluorescence reader. 
Fluorescence or non-fluorescence at a specific lectin site will show the presence or 
absence of certain carbohydrates or certain carbohydrate linkages (Zhang et al. 2016). 
 
Figure 1.9: Schematic view of lectin microarray. Protein samples are to be labelled 
with a fluorescent dye (Cy3) and are then applied to the chip that has the lectins 
immobilised onto it. Image taken from Zhang et al. (2016). 
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The advantages of using a lectin microarray are: (i) the glycoprotein can be left intact 
and there is no need to use glycosidases to cleave any glycans; (ii) specific glycoproteins 
or whole cells can be used on the chip and (iii) a large number of lectins can be used at 
the same time to account for the large diversity in glycan complexity. Lectin microarrays 
have proven to be a reliable and accurate tool for detecting carbohydrate complexes and 
going forward may be one of the more comprehensive ways to identify glycans. The 
main limitation of lectin microarrays is that the presence or absence of a specific glycan 
is often given in a strictly qualitative result. The fluorescence monitored on the chip 
passes a threshold and this allows for a ‘yes or no’ answer respectively. Limited 
quantification of the abundance of specific glycans can be a significant drawback in 
certain analysis.  
Lectin blotting is somewhat similar to a lectin microarray in that it uses lectins to probe 
glycans still attached to their proteins (Sato 2014). For lectin blotting the standard 
technique of Western blotting is used but instead of probing with a primary and 
secondary antibody, a lectin is used as the primary probe and possibly a secondary 
antibody or, in the case of a biotinylated lectin, a streptavidin linked dye. Western 
blotting is used to measure the presence and amount of certain proteins in a mixture of 
proteins run on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel. The gel is used to separate proteins based on size, the gel is then transferred, 
or blotted, onto a nitrocellulose membrane and the lectins can be used to probe the 
proteins now in the membrane (Mahmood and Yang 2012). In the same way as lectin 
microarrays, lectin blotting can use a wide variety of lectins to distinguish between 
various glycan patterns. The advantages of lectin blotting are: (i) again glycans do not 
need to be cleaved off in order to analyse; (ii) a large number of proteins in solution can 
be tested at the same time and (iii) relative quantification of the specific glycoprotein 
can be observed (Cao et al. 2013).  The disadvantages of this method are that the surface 
of a cell cannot be specifically tested for; whole cell lysates will contain a wide range of 
cytosolic glycoproteins. Even using membrane preparation methods, the membrane of 
the cell may present glycoproteins that have glycans from the inner membrane rather 
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than the outer membrane. In most cases lectin blotting is used as a precursor to other 
glycan profiling methods such as HPLC and mass spectrometry.  
Mass spectrometry has proven to be a very reliable method for glyco-profiling. Mass 
spectrometry (MS) is an analytical technique that ionises samples and sorts the ions 
based on their mass-to-charge ratio (m/z). Samples are essentially bombarded with 
electrons which ionises the components in the sample mixture and then separates them 
based on ionic charge by subjecting them to an electric or magnetic field (Schaeffer-
Reiss 2008). There are a large range of different MS types such as; time-of-flight (TOF), 
quadrupole, ion traps, tandem MS as well as many others. A mass spectrometers ability 
to accurately define each component in a mixture of samples makes it a very powerful 
identification tool. In respect to glycan analysis, the method to prepare the sample is 
similar to that of HPLC, where the glycans must be cleaved from the glycoprotein before 
analysis. The general types of MS used for glycan analysis are Matrix Assisted Laser 
Desorption/Ionisation (MALDI) –TOF and Electrospray Ionisation (ESI). Both of these 
are soft ionisation techniques, this means that the ionisation process allows for minimal 
excess energy to be imparted on the samples and thus causes less fragmentation of the 
glycans (Han and Costello 2013). Once the glycans can remain intact, the molecular ions 
can be easily observed. Both of these methods can be used to obtain an overall glycan 
profile. Using different methods to cleave different N- and O- glycans can help increase 
the efficiency of accurate glycan analysis. For N-linked glycans the regular PNGase-F 
method can be used to cleave the glycans, whereas O-linked glycans can be cleaved 
using reductive elimination. Glycans pose a problem when being characterised on MS. 
Sialylated glycans can lose their sialic acid caps in the ion source or after the ion 
extraction from this ion source. This loss in sialic acid proves to be an issue when trying 
to identify specific mature glycan profiles (Morelle and Michalski 2007). There have 
been various methods used to stabilise the sialic acid linkage for analysis in MS. The 
most common way used to stabilise sialic acid residues is to form methyl esters. Some 
methods use methyl iodide, this eliminates the labile proton, where others have used 
other methylation methods, such as treating the sample with 4-(4,6-dimethoxy-1,3,5-
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triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM). Both of these methods have 
stabilised the sialic acid on N-glycans for analysis using MALDI-MS (Wheeler et al. 
2009). 
To date MS proves to be the most comprehensive and accurate way to analyse glycans. 
Through the use of various different types of MS and sample preparation methods nearly 
all glycan types can be accurately characterised and to a large degree quantified (Morelle 
and Michalski 2007). The advantages of the different MS analysis methods for glycan 
characterisation are: (i) detailed analysis of complex glycan structures; (ii) defined 
linkage analysis; (iii) largely quantitative as well as qualitative; (iv) there are many 
different types of MS to choose between for specific analysis. The disadvantages 
associated with this method are: (i) specified proteins must be identified and the glycan 
must be cleaved off; (ii) cannot be used for live cell analysis; (iii) operation costs are 
high and require highly skilled users to prepare the samples, accurately design and carry 
out the method and perform the analysis on the data set provided. Mass spectrometry is 
currently the best way of identifying specific glycans on glycoproteins. In later sections, 
flow cytometry and fluorescent microscopy will be explained and it is our goal to 
highlight in this introduction and throughout the project that these methods can 
potentially be used as a tool, instead of or in unison with MS, to accurately glyco-profile 
the surface of live cells. 
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1.3.2 Limitation of Antibodies as probes for glycan profiling 
Antibodies are a widespread analytical tool used in clinical and research applications. 
Antibodies simply work by binding to a specific antigen or epitope on particular 
proteins. Antibodies are designed to bind a unique target with a high level of affinity and 
specificity. Since the emergence of monoclonal antibodies (mAbs) there has been a 
major increase in the number of different antibodies available for purchase. While this 
field has grown a huge amount in the last half a century, antibodies specific for 
carbohydrates have proven to be more difficult.  
Antibodies are designed to bind a specific epitope on a protein or bio-molecule and 
glycans with similar sugar make ups but differing linkages make them a less than ideal 
target for antibodies. Antibodies that show binding affinities for glycans often bind core 
N- and O- linked sugars (Bovin 2013). Even with glycans being difficult targets to bind, 
there are some commercial antibodies that have been shown to be very effective at 
binding their sugar target. An example of this is anti-GD2 which is used in treatment of 
neuroblastomas (Yang and Sondel 2010). GD2 is a disialoganglioside, meaning it 
contains an added sialic acid onto a galactose residue. One of the main issues with 
antibodies that have been characterised to bind to glycans is that they often bind mixed 
epitopes. This leads to a less specific identification (Sterner et al. 2016). Antibodies 
designed to bind specific carbohydrate complexes can be difficult to create and there are 
often a large number of glycoproteins on the surface of cells that may have the same, or 
similar, glycans that the antibody will bind to. Lectins (Section 1.4) are evolutionarily 
designed to bind to glycans.  
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1.4 Lectins 
In biology, lectin is the general term given to any protein that shows high specificity for 
binding carbohydrate moieties. The term lectin is derived from the latin word that means 
“to select”. There are studies dating back as far as the 19th century characterising lectins, 
but in the last 30-40 years studies have vastly increased our knowledge of lectins, what 
organisms produce lectins and what role lectins play in the biological functions of 
animals and plants. The first Lectin was isolated by the Russian scientist Peter Stillmark 
in 1888 from seeds of the castor tree Ricinus communis. This lectin was named “ricin” 
(Gorakshakar and Ghosh 2016).  Since the isolation of the first lectin there have been 
tens of lectins identified, characterised and purified for commercial use. Lectins can be 
as important as the glycans they target in their biological functions. The unique property 
of lectins is that each lectin has a specific affinity for a single sugar or sugar complex 
(Maupin et al. 2012). Due to the fact lectins have such a high specificity and affinity for 
sugar molecules in a complex glycan, lectins have been identified as good analytical 
tools for research (Hu and Wong 2009). Lectins binding affinity and specificity are often 
mediated by the presence of a metal ion (Abhilash et al. 2013; Ahmad et al. 1999). 
These metal ions are usually calcium (Ca
2+
) or magnesium (Mg
2+
) as well as others such 
as zinc and manganese. Lectin binding is facilitated through a series of hydrogen bonds, 
hydrophobic interactions and metal ions aid in this process (Sabin et al. 2006). As 
glycosylation became more and more important as a research topic, lectins too increased 
in popularity. In section 1.3 the methods currently used to detect glycans have employed 
the use of lectins in various capacities. Originally lectins were thought to only be located 
in plants but further research into the field began to reveal lectins in a number of 
organisms including plants, animals, fungi and bacteria (Fujihashi et al. 2003; Taskanen 
et al. 2001). The increase in the amount of different lectins available for research has 
helped to continually progress the area of glycobiology and glyco-profiling. Lectins are 
even being utilised in industrial processes, such as lectin chromatography, to screen bio-
pharmaceuticals for the specific glycoforms needed (O’ Connor et al. 2017).  
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1.4.1 Eukaryotic Lectins 
In Section 1.2 it has been highlighted that glycans in eukaryotes can greatly vary in 
complexity and structure. The cells ability to glycosylate proteins in such a multitude of 
ways allows for a need for highly selective lectin proteins to bind to every possible 
glycan they encounter. In eukaryotic glycosylation there are six main sugars, described 
in Section 1.2, that make up a wide variety of glycans through branching and various α- 
and β- linkages. The first lectins identified and characterised were all from plant sources, 
leading to a common misconception that lectins were solely confined to plant cells. 
Some lectins have been shown to be insecticidal when congregated in large numbers. 
This process helps to protect the plant cells from insects that could potentially destroy 
the cell. An example of this is Wheat Germ Agglutinin (WGA) which binds β-1,4 linked 
polyGlcNAc. This lectin is ingested and is poisonous to the insect (Schaller 2008). Due 
to the protective factor of WGA it is often found in very large quantities in the plants 
that express the protein. Other plants have lectins that show a similar protective function 
as a lot of plant lectins will bind the surface carbohydrates of invading pathogens. Some 
other eukaryotic lectins do not always have an obvious function like WGA. There are a 
large range of lectins that have been identified, characterised and purified from 
eukaryotic plant sources. A lot of these lectins have proven to be important research 
tools, as highlighted in lectin microarrays and lectin blotting. Specific lectins can be 
used when trying to identify unknown glycoproteins. To test for unknown glycans on a 
glycoprotein, lectins that bind common glycan complexes can be used, e.g. concanavalin 
A (Con A). Con A is derived from the jack-bean Canavalia ensiformis (Reeke Jr. et al. 
1975). It binds to terminal non-reducing α-D-mannosyl and α-D-glucosyl groups (Kim 
and Park 2001). Con A exhibits a high specificity for the core mannose structures found 
in all N-glycans. The majority of glycoproteins contain complex N-glycans, while 
testing for the presence of N-glycans Con A has proven to be an important lectin for 
identifying this. Table 1.2 shows the variability between different lectins in binding 
specificity as well as the necessity of a metal ion, size and number of subunits in the 
protein.  
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Table 1.2: Lectins from different organisms. Lectins from plants, fungi and bacteria 
are highlighted in this table. Along with the lectins name and source this table shows the 
molecular weight, glycan specificity, eluting/inhibitory sugar and the necessity of metal 
ions for the lectin. Table obtained from O’ Connor et al. (2017). 
Other plant lectins have been utilised to distinguish between blood groups in humans. 
There are four red blood cell types that are associated with humans, these are: A, B, AB 
and O blood types. Lectins can be used to discern exactly which blood group a person 
has. A lectin from Vicia villosa, named VVA, has proven to be an excellent anti-A blood 
type lectin. A lectin from Griffonia simplicifolia, named GSL I, has proven to be an 
excellent anti-B blood type lectin (Khan et al. 2002). These examples highlight the 
importance of certain plant lectins and show how applicable they have been and may 
prove to be in past and future research. 
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There is a lectin recognition pathway in the immune system of humans. This mannose 
binding lectin (MBL) is well studied to this point and proves to be an immensely 
important molecule in pathogen recognition and immune response. This mannose 
binding lectin binds to carbohydrates on the surface of bacteria and initiates innate 
immunity via the complement pathway (Wallis 2007). The understanding of the role 
MBL in immune response has grown rapidly over the past few decades and it has been 
recognised to have a role in a number of immune processes. As well as complement 
activation it has also been found to modulate inflammation, recognise alterations on self-
structures and has a role in apoptotic cell clearance (Dommett et al. 2006). Phagocytes 
have MBL-receptors on their outer membrane surface. The MBL binds to either an 
apoptotic cell or bacterium and remains bound until it can recruit a phagocyte. Each 
MBL has a MBL-associated serine protease (MASP) region that the MBL receptor binds 
to (Kravitz and Shoenfeld 2006). In figure 1.10 the process of MBL mediated 
phagocytosis is highlighted. 
 
 
Figure 1.10: Diagram of mannose binding lectin attaching to apoptotic and 
bacterial cells to initiate phagocytosis. MBL receptors on phagocytes bind to the 
MASP region of MBL and activate phagocytosis. Image taken from Kravitz and 
Shoenfeld (2006). 
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Other eukaryotic lectins of note are Aleuria aurantia lectin (AAL) or Helix pomatia 
lectin (HPA). AAL is a lectin purified from the Aleuria aurantia fungus and has 
specificity for fucose linked to GlcNAc or N-acetyllactosamine. HPA is a lectin purified 
from Helix pomatia which is a species of snail. HPA has a dual affinity as it can bind to 
O-linked GalNAc and O-linked GlcNAc (Ramburuth et al. 2012). HPA also has been 
shown to bind to Tn antigen, which is an O-linked GalNAc, and is commonly used to 
screen breast cancer cells. HPA has been used in studies for breast cancer and has 
indicated that binding of HPA results in a poorer prognosis (Brooks 2000). HPA studies 
prove lectins potential in determining glycosylation differences on cancer cells and this 
project will also try and utilise lectins as a probe to distinguish between cancer cell lines. 
All the lectins mentioned throughout this section are commercially available, and have 
been proven to be reliable research tools (Hagerbaumer et al. 2015).   
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1.4.2 Prokaryotic Lectins 
Early on in the study of lectins, it was believed that lectins were specifically confined to 
eukaryotes. Lectins are often large and complex proteins with multiple subunits, some of 
which need post translational modifications (PTM) such as glycosylation and 
phosphorylation (Colley and Baenziger 1987). For these PTMs, especially glycosylation, 
prokaryotic cells have been proven to have less complex modifications after and during 
protein synthesis. Unlike the other eukaryotic lectins, which mainly need to be expressed 
in their own host cell, prokaryotic lectins can be sequenced and transformed into a stable 
bacterial host cell and mass produced much quicker and cheaper. The emergence of 
various prokaryotic lectins has been important for the lectin and glyco-analysis industry. 
In prokaryotes, the lectins produced are often smaller proteins with a single binding 
domain. This is different to a lot of eukaryotic lectins that often have multiple binding 
sites (Kravitz and Shoenfeld 2006). The mannose binding lectin mentioned in the 
Section 1.4 has multiple binding sites for both fucose and mannose whereas a 
prokaryotic lectin, such as PA-IIL which, as a monomeric protein, has one binding site. 
These smaller proteins, with single binding sites and little to no PTMs have an 
advantage over eukaryotic lectins for these reasons.  
There have been a number of prokaryotic lectins discovered to date. Some pathogenic 
bacteria use lectins on their outer membrane surface to bind to the sugars on eukaryotic 
cells. Pseudomonas aeruginosa is an opportunistic pathogen that has been studied with 
respect to chronic airway and lung infections. This Pseudomonas strain synthesises two 
lectins PA-IL and PA-IIL, now named LecA and LecB (Funken et al. 2012). A lectin 
encoded in Escherichia coli called GafD was discovered in diarrhea-associated E. coli. 
This lectin was overexpressed in E. coli strains that were associated with pathogenicity 
causing diarrhea and other illnesses (Tanskanen et al. 2001). These are the lectins that 
have been discovered in different pathogenic bacteria. The function of these lectins is to 
bind the complex glycans on the surface of mammalian cells. In table 1.3 these bacterial 
lectins, as well as others, are detailed and their specificity given. 
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Lectin name (if applicable) Source Specificity 
Fimbriae Actinomyces naeslundii Galβ1–3GalNAcβ- 
FHA Bordetella pertussis Galα1–4GlcNac 
 Borrelia burgdorferi Heparan sulfate 
 Campylobacter jejuni Fucα1–2Galβ1–4GlcNAcβ- 
P fimbriae Escherichia coli Galα1–4Galβ 
S fimbriae Escherichia coli Gangliosides GM3 and GM2 
Type-1 fimbriae Escherichia coli Manα1–3(Manα6)Man 
K99 fimbriae Escherichia coli Neu5Gcα2–3Galβ1–4GlcNAc 
GafD Escherichia coli β-GlcNAc 
 Haemophilus influenza Neu5Acα2–3Galβ1–4GlcNAc 
BabA Helicobacter pylori Lewis B antigen 
SabA Helicobacter pylori Neu5Acα2–3Galβ1–4GlcNAc 
 Mycobacterium tuberculosis Neu5Acα2–3Galβ1–4GlcNAc 
 Neisseria gonorrhoeae Neu5Acα2–3Galβ1– 4GlcNAc 
 Propionobacterium Lactosylceromide 
PA-IL (LecA) Pseudomonas aeruginosa α-galactose 
PA-IIL (LecB) Pseudomonas aeruginosa Fucose/mannose 
RS-IIL Ralstonia solanacearum Mannose/fucose 
 Staphylococcus aureus Heparan sulfate 
 Streptococcus pneumoniae GlcNAcβ1–3Gal 
 
Table 1.3: Recombinant prokaryotic bacterial lectin panel. This table shows the 
bacterial lectins produced certain bacteria as well as giving the glycan binding 
specificity. Table generated during this work.  
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Companies that supply eukaryotic lectins 
EY Laboratories Vector Laboratories Sigma-Aldrich 
Sino Biological TCS Biosciences Thermo Fischer Scientific 
 
Table 1.4: Current companies that sell a multitude of eukaryotic lectins 
commercially. This table gives the names of six companies that sell commercial 
eukaryotic lectins for analytical use. Table generated during this work.  
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1.4.2.1 Prokaryotic Lectins, PA-IL and PA-IIL (LecA and 
LecB) 
The opportunistic pathogen Pseudomonas aeruginosa is involved in acute infections as 
well as chronic infections, especially in cystic fibrosis patients that already have 
significant issues with other pathogens. This bacterium expresses two lectins, LecA and 
LecB. These two lectins play a pivotal role in the bacteria’s pathogenicity (Chemani et 
al. 2009). These proteins adhere to the glycoproteins on the outer cell membrane of the 
host cell and initiate infection. LecA and LecB are found in high levels in the cytoplasm 
of the bacteria cells as well as large quantities on the outer surface of the bacterial cell 
membrane (Funken et al. 2012). LecA and LecB have been shown to be virulence 
factors for Pseudomonas aeruginosa and aid the bacteria in producing a biofilm. LecB 
deficient mutants of this Pseudomonas strain have shown an inability to effectively 
create a biofilm compared to the wild type bacteria (Tielker et al. 2005). These proteins 
have different binding specificities that have since been identified and the lectins have 
been characterised. Both LecA and LecB can be produced recombinantly and used as 
lectin probes for other glyco-profiling procedures. The ability to express these proteins 
in a bacterial host cell is an advantage of prokaryotic lectins over most eukaryotic 
lectins.  
LecA is a galactose binding lectin. Through various characterization experiments, LecA 
has been shown to bind to α-galactose, specifically with the linkages α-1-2 and α-1-3. 
The 3D structure of LecA is shown in figure 1.11. LecA was screened against bovine 
serum albumin (BSA) with α- and β- linked galactose containing different position 
linkages, i.e. 1-2, 1-3, 1-4 and 1-6. This characterization helped to promote this protein 
as a potential research tool in glyco-profiling (Keogh et al. 2014). This has been backed 
up by other research that shows specificity for terminal α- galactose of different 
linkages. Some N-glycans have terminal α- galactose and these N-glycans can be found 
on the surface of eukaryotic mammalian cells. LecA has been compared to other plant 
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lectins that bind specifically to galactose residues and it has been shown to bind with 
similar affinity and specificity as those other lectins (Kirkeby et al. 2006).  
 
 
      
Figure 1.11: 3D structure of prokaryotic lectins LecA and LecB. A) 3D structure of 
LecA, B) 3D structure of LecB. These images were created using the 3D protein 
modelling software PyMol.  
LecB is the main prokaryotic lectin that has been studied and used throughout the course 
of this project. LecB is an interesting lectin that has dual sugar specificity, meaning it 
binds two different sugars with similar affinities. The 3D structure of lecB is shown in 
figure 1.11. LecB binds L-fucose with a very high affinity and also binds to D-mannose 
but with a slightly lesser affinity (Hsu et al. 2008; Funken et al. 2012). LecB has a 
higher proclivity for fucose than it does for mannose but both of these monosaccharides 
may be used in inhibiting potential binding at certain concentrations. The binding of 
LecB to any carbohydrate complex or free sugar is mediated by calcium binding to the 
protein. LecB, as well as many other prokaryotic and eukaryotic lectins, requires a metal 
ion to facilitate binding. With lecB the metal ion is calcium, without calcium the protein 
cannot bind to its target (Sabin et al. 2006). The interaction between the protein and 
carbohydrate is established through coordination by calcium ions and hydrogen bonds 
A B 
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(Loris et al. 2003). Other lectins often establish binding through hydrophobic 
interactions, but lecB does not rely on these interactions to the same level. This makes 
lecB a unique and interesting protein while also highlighting the importance of metal 
ions in respect to lectin binding.  
Both lecA and lecB have been studied for their role in pathogenicity but in more recent 
studies these proteins have been identified as unique lectins for research and industry 
purposes. In the next section the production of recombinant lectin probes will be 
explored and both of these proteins have proven to be very good candidates for 
recombinant production.  
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1.4.3 Recombinant protein production in bacterial host cells 
One of the main advantages of prokaryotic lectins over eukaryotic lectins is that the 
proteins can be expressed in a bacterial host cell to achieve high levels of expression. 
Most eukaryotic lectins require eukaryotic PTMs which mean they cannot be produced 
from a bacterial host cell. Expression systems for recombinant eukaryotic proteins are 
often transformed into a eukaryotic host cell, such as Chinese hamster ovary (CHO) 
cells, so that all the complex PTMs are carried out (Wurm 2004). The use of mammalian 
cells adds a lot of extra costs and it’s a more complicated purification process due to the 
growth conditions of mammalian cells. Prokaryotic lectins, such as lecA and lecB, can 
be easily expressed in a bacterium, such as E. coli, and high yields of protein can be 
easily purified. In the majority of cases E. coli is used as the organism for expression. 
There are other organisms that can be used, ranging from bacteria to unicellular algae. E. 
coli has a number of advantages over other microbes when it comes to using it as an 
expression system. With optimal environmental conditions, the doubling time of this 
bacterium can be as little as 20 minutes (Sezonov et al. 2007). A large cell mass can be 
grown in a relatively short time, i.e. 6-24 hours. Other advantages for using E. coli are; 
the media needed for cellular growth is readily available and inexpensive and E. coli is a 
host that can have DNA plasmids easily transformed into the bacterium (Rosano and 
Ceccarelli 2014).  
Once the host organism is chosen there are other factors that need to be addressed for the 
protein of interest that is to be expressed. As mentioned E. coli is easily transformable so 
an appropriate plasmid vector must be chosen to carry the gene that expresses the 
desired protein, i.e. the lecA or lecB gene in the case of a prokaryotic lectin. Plasmid 
vectors are self-replicating, extra-chromosomal DNA loops found inside certain bacteria 
(Lodish and Zipursky 2001). There is a large library of vectors that have various 
characteristics that may be desired. Plasmids have selectable traits that may be necessary 
for selection purposes. Firstly, antibiotic resistance allows for selective growth of the 
bacteria. E. coli does not have natural antibiotic resistance, but if there is antibiotic 
resistance on the plasmid transformed into the host then it can be selectively grown on 
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nutrient agar containing the relevant antibiotics (Bennett 2008). As well as an antibiotic 
resistance gene, the plasmid must have a multiple cloning site (MCS) that allows for the 
addition of your specific gene and a selectable promoter region upstream of the protein. 
The MCS allows for a number of restriction enzymes to be used to open the plasmid and 
allow DNA to be ligated into the plasmid before transformation into the expression host. 
The promoter region of a plasmid needs to be upstream of the gene of interest so the 
gene can be selectively overexpressed to produce protein. By far the most common 
prokaryotic promoter used is the lac promoter or lac operon. The lac operon is the 
region of DNA in bacteria that facilitates the breakdown of lactose in the absence of 
glucose. E.coli contains the lac operon in its bacterial DNA. The inserted plasmid 
contains two lac operator regions where the lac repressor protein can bind. By using a 
lactose analogue, such as isopropyl β-D-1-thiogalactopyranoside (IPTG), the repressor 
can be constantly bound and this allows for unimpeded translation of the genes in the lac 
operon (Rosano and Ceccarelli 2014). This promoter region can be used in specific 
plasmids to ensure over expression of the gene added to the MCS. The last important 
trait that can be either added to the gene specifically or found on the plasmid is a ‘tag’ 
region to allow for affinity purification of the protein produced. In plasmids such as 
pQE30 and pQE60, there is a poly-histidine DNA region either upstream or downstream 
of the MCS to allow for an N- or C- terminally linked ‘His’ tag (Huang et al. 2006). 
In this project the plasmids selected for lecA and lecB expression were pQE30 and 
pQE60 that covered all the desirable traits needed for protein expression. These plasmids 
contained ampicillin resistance, a lac operon promoter region, MCS and tag on the N- or 
C- terminus of the protein. In figure 1.12 the gene map for pQE30 shows the desirable 
features contained within the plasmid.  
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Figure 1.12: pQE30 plasmid vector map. The pQE30 vector contains a number of 
desirable features for recombinant protein production such as the multiple cloning site 
(MCS), lac operator, T5 promoter, ampicillin resistance gene and the poly-histidine tag. 
Map generated using snapgene (Section 2.30). 
Proteins containing a poly-histidine tag can be easily purified in what can be described 
as a ‘single step’ purification by using immobilised metal affinity chromatography 
(IMAC). In this method metal ions such as copper, zinc and nickel are immobilised on 
activated resin and a solution containing a protein mixture is added to the resin. The 
poly-histidine tag has a high affinity to the metal ion and is held in complex with the 
metal ions. All other proteins without a poly-histidine tag will not interact, or will have 
very weak interactions with the metal ion attached to the activated resin. This version of 
chromatography is usually carried out in a specific column using resin bound with the 
metal ion. The protein samples are run over the resin and the resulting flow through 
contains the proteins that didn’t bind to the resin. The interaction between the metal ion 
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and the histidine is the protonated imidazole side group on histidine (Bornhorst and 
Falke 2000).  The use of free imidazole can then selectively elute the protein via 
competitive inhibition. Certain proteins may contain a naturally high level of histidines 
and may bind weakly to the resin, so low level imidazole washes are usually carried out 
before elution of the protein. The relative ease of purification of the tagged protein is a 
major advantage when using a prokaryotic expression organism.  
A significant amount of research has been carried out in respect to protein expression 
and purification. Through using E. coli as an expression host, a pQE30/60 plasmid as the 
expression vector and poly-histidine tag as the specific tag to aid in purification, any 
protein can be easily and inexpensively overexpressed and purified. Employing this 
method both lecA and lecB could be successfully expressed and purified. 
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1.4.4 Advantages of recombinant prokaryotic lectins over 
commercial eukaryotic lectins 
Recombinant protein production has revolutionised researchers and industry’s ability to 
mass produce certain proteins quickly, efficiently and with very little relative cost. For 
research purposes the use of recombinantly produced lectins over eukaryotic 
commercially purchased lectins is advantageous. Lectins purified from plants that are 
bought commercially have some significant disadvantages. The most important 
disadvantages stem from a low yield of lectin from its original source organism as well 
as batch-to-batch variation of wildtype lectins. Eukaryotic lectins can come from a 
number of organisms, such as plants, animals and fungi. These organisms that produce 
lectins, express the lectins at low levels to facilitate their biological function. Lectins 
obtained from seeds often found are in higher levels than those found in plants and 
animals (Lam and Ng 2011). Purifying lectins from their host organism can be difficult 
and require a multi-step purification that gives lower yields of protein. This in turn 
drives the cost for such lectins up and therefore makes them less viable as a large scale 
diagnostic tool. The other main disadvantage that eukaryotic lectins have over 
prokaryotic lectins is the fact that they often vary from batch-to-batch (Oliveira et al. 
2014). Lectins isolated from their natural source are often a heterogeneous mixture of 
lectin isoforms that each serves a specific biological function (Han et al. 2015). When 
using lectins as bio-diagnostic tools, this heterogeneity can cause varying results and this 
can result in significant issues. Also, as mentioned previously, the majority of eukaryotic 
lectins need eukaryotic post translational modifications, which means they cannot be 
produced recombinantly in a bacterium.  
The disadvantages for large scale production of these plant and animal lectins show the 
advantages of producing recombinant lectins from a microbial host organism. Batch-to-
batch variation has shown to not be an issue when producing recombinant prokaryotic 
lectins, such as lecA and lecB. These proteins are routinely expressed, purified and 
characterised and show the same level of binding specificity and affinity with each batch 
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(Keogh et al. 2014). The ability to produce non-varying batches of lectins increases their 
potential as biomedical and bioanalytical tools. In the previous section the selectable 
traits that are desired for recombinant protein production were discussed. Through the 
use of a selectable promoter and affinity purification tag, proteins can be programmed to 
overexpress inside the bacterial host strain and then once the cells have been lysed the 
protein may be efficiently purified with a single purification.  
Another major advantage of recombinant prokaryotic lectins is their amenability for 
mutagenesis. Through site directed mutagenesis a library of clones can be created for 
these lectins to try and improve the lectin. The improvements that can be selectively 
made using mutagenesis can range from trying to increase the stability or half-life of the 
protein, to increasing binding affinity or changing binding specificity (Keogh et al. 
2014). Subtle changes in the amino acid composition of the protein may lead to vast 
changes in binding affinity and protein solubility and stability. Employing site directed 
mutagenesis coupled with targeted 3D modelling of prokaryotic lectins, these proteins 
can be optimised as bio-analytic tools that would surpass some eukaryotic lectins.  
The search for efficient ways to detect glycans attached to glycoproteins, either 
cytoplasmic/ secreted proteins or embedded outer cell membrane proteins, has utilised a 
lot of different techniques. One of the drawbacks of using lectins in the past has been the 
batch-to-batch variation of eukaryotic lectins as well as the low yield produced in their 
host organism. Identification of lectins from bacteria has lead researchers to believe 
there are possibly more lectins out there that have various specificities. In the future 
replacing the use of eukaryotic lectins with prokaryotic lectins that have the same 
specificities may lead to an increased use in lectins for comprehensive glycan analysis.  
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1.5 Cancer, a brief overview 
Cancer has been and is one of the most well studied diseases to date. Cancer is defined 
as a group of diseases that involve the abnormal growth of cells with the ability to 
invade or proliferate into other parts of the body (National Cancer Institue 2017). The 
first distinction that needs to be mentioned is that not all tumours are cancerous. A 
cancerous tumour signifies the ability of the tumour to proliferate and spread throughout 
the body. Benign tumours that do not spread to other organs are often not classed as 
cancerous. The latest complete figures from the World health organisation (WHO) 
regarding cancer are for 2015. The five most common cancers between both men and 
women in 2015 were; Lung, Breast, Colorectal, Prostate and Stomach (World health 
organisation 2017). In 2012 alone there were approximately 14 million new cases and 
8.2 million cancer related deaths. This death toll rose to 8.8 million cancer related deaths 
in 2015. The majority of deaths from cancer are still observed in the developing world 
but cancer rates are increasing, not decreasing, in developed countries. The leading 
causes for this are; tobacco related, alcohol related and dietary. With the advancement of 
modern medicine it is surprising that the rate of cancer increases year to year. This could 
be due to better identification processes and awareness, but there are indications that the 
increase is due to the fact people in developed countries live an unhealthy lifestyle. The 
fact cancer rates are raising, highlights that more research needs to be done to identify 
and ultimately treat the more common forms of cancer. During this project the specific 
type of cancer studied was colorectal cancer. In section 1.5.3 this will be explained in 
more detail.  
There are believed to be six ‘hallmarks’ of cancer. These are; sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis (Hanahan and 
Weinberg 2000). These six characteristics of cancer progression are shown in figure 
1.13. Along with these six hallmarks, there is significant evidence to suggest there are 
two more that could be added to the list, these are; reprogramming of energy metabolism 
and evading immune destruction (Hanahan and Weinberg 2011). Essentially a cancers 
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ability to become a sustainable growth inside the body is facilitated by its need to remain 
alive even though the cells have forgone their primary function.   
 
Figure 1.13: Illustration of the six hallmarks associated with cancer. This image 
shows the original six hallmarks believed to characterise cancer in the early 2000’s 
(Hanahan and Weinberg 2000). 
For a cell to become cancerous it must first give up its primary function and try and fit 
another, self-reliant function. As explained section 1.2, glycosylation plays a big role in 
many different cell functions from cell adhesion to cell-cell signalling and interactions. 
This would allow the idea that glycosylation, or altered glycosylation, may prove to be a 
reliable and important biomarker for cancer progression.  
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1.5.1 Alterations in glycosylation 
Glycosylation is defined as a non-template driven post translational modification. This 
process is driven by the specific glycosyltransferases and glycosidases mentioned in 
section 1.2. If these enzymes are either up or down regulated the ensuing glycosylation 
can be significantly altered and will affect the protein from fulfilling its specific 
function. In the case of N-glycosylation, alterations to this process may result in 
incorrect folding of the protein. Before the 1990’s there was less understood about 
glycosylation and alterations in the process were much harder to identify and 
characterise. Numerous biological functions have been shown to be heavily dependent 
on correct glycan formation and a complete loss in the cells ability to glycosylate 
proteins correctly would result in the cell being unable to fulfil its function, or more 
often than not the cell or organism would not survive (Lyons et al. 2015). Complete loss 
of function for this reason has proven to be very rare. There is however instances where 
the glycosylation process is altered due to mutations or illness and the mechanisms are 
impacted. 
In the immune system there has been evidence to show that glycans appear to dictate a 
variety of aspects of the innate and adaptive immune system. In the innate immune 
system of humans the first process involved is to recruit immune cells to the site of 
infection. This recruitment of immune cells is facilitated by the inflammatory response. 
At this stage of immunity the cells that are first recruited are called leukocytes. 
Leukocyte rolling is the process of leukocytes connecting to selectins on the surface of 
endothelial cells close to the infection site (Maverakis et al. 2015). This process is 
mediated by glycoproteins on the surface of the vascular endothelium. Through specific 
mutations, the SLC35C1 mutation for example, the glycosylation on the surface of the 
endothelial cells is altered and the host is impacted. People with this mutation have what 
is known as leukocyte adhesion deficiency type 2 (Gazit et al. 2010).  
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Figure 1.14: Illustration of Leukocyte failing to bind to E-selectin on the surface of 
vascular epithelial cell. This image shows that the incorrect glycosylation of cell 
surface glycoproteins on leukocytes can impact their ability to function (Lyons et al. 
2015).  
Glycans have shown to be pivotal to a number of aspects in adaptive immunity also. For 
instance with B- and T- cells there are antigen receptors on the surface of these cells that 
are glycosylated and any alterations in the glycosylation can impact the cells ability to 
function. CD4 and CD8, which are important co-receptors for T cells, are glycoproteins 
and there is ample evidence to suggest that these must have the correct glycans on the 
surface to function correctly (Lyons et al. 2015). Highlighting the significant effects 
altered glycosylation can have on the immune system’s ability to effectively deal with 
infection, in both innate and adaptive immunity, shows how important correct glycan 
synthesis is. These instances of alteration in glycan synthesis generally stem from a 
mutation in a gene expressing a specific glycotransferase or glycosidase. Another way 
the glycosylation mechanism is impacted is through disease. When a cell becomes 
diseased it can often change its functionality and because of this it is believed altered 
glycosylation has a large role to play in how a cell may go about changing its function.   
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1.5.2 Alterations in glycosylation, specifically in cancerous cells 
When a cell becomes cancerous it forgoes its original function. Sections 1.2 and 1.5.1 
have explained how important the role of correct glycosylation is for the cells ability to 
carry out its specific function. These two points together would suggest that in order for 
cells to change their functionality they would first need to change their surface glycans. 
In a wide variety of cancers studies have been carried out to identify possible glycan 
changes on surface proteins as well as proteins secreted by the cell. Secreted proteins 
such as prostate specific antigen (PSA) and human chorionic gonadotrophin (hCG) are 
currently used as biomarkers to identify prostate and uterine cancers, respectively. PSA 
and hCG are both glycoproteins. The current method for identifying prostate cancer is to 
measure the amount of PSA in a sample of blood taken from a patient (Milford Ward et 
al. 2001). Prostate cancer is annually the most common newly diagnosed cancer among 
men (Drake et al. 2015). PSA is a serine-protease that is secreted by epithelial prostate 
cells. It has been identified as a biomarker due to the fact its secretion levels are elevated 
in prostate cells that have entered a cancerous state. As one of the first biomarkers 
identified and easily detectable it garnered wide spread use. PSA screening is still a 
commonly used identification method to date but in the few decades since it became a 
routine check, the drawbacks associated with using PSA were identified. Firstly the 
natural elevation of PSA secreted with increased age. According to the Irish Cancer 
Society the normal range for PSA in a blood sample raises from 2.5 ng/ml at age 40 to 
6.5 ng/ml at age 70. When trying to identify if a person has prostate cancer or not the 
levels of PSA can vary from 4-100 ng/ml. For this reason there has always been a high 
rate of false positives in prostate cancer diagnosis. Some elevated levels of PSA can 
signify benign prostate hyperplasia (BPH) which is a non-cancerous growth. In an 
attempt to overcome this high rate of false positives there have been many studies 
carried out to identify possible changes in PSA that may be synonymous with cancer. In 
a study carried out 15 years ago, through mass spectrometry analysis, there were 
differences found in the N-glycans present in secreted PSA from normal prostate cells 
and cancerous cells (Peracaula et al. 2003). Most N-glycans in vertebrates do not contain 
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GalNAc, though there are numerous exceptions in different animals. N-glycans on PSA 
commonly contain up to 20% GalNAc but analysis of PSA secreted from cancerous cells 
can have N-glycans made up of up to 65% GalNAc (Peracaula et al. 2003). Along with 
differing levels of fucose and sialic acid, the PSA glycoproteins secreted by cancerous 
prostate cells have distinct carbohydrate differences than PSA secreted from healthy 
cells. In more recent studies there has been increased emphasis on the level of core 
fucosylation and sialyation in diagnosing prostate cancer. A recent study from 2016 has 
identified that PSA secreted from prostate cancer cells has decreased core fucose and 
increased α-2,3-sialic acid percentages when compared to healthy prostate cells and 
BPH cells (Llop et al. 2016).  
Human chorionic gonadotrophin is another potential glycoprotein biomarker that shows 
elevated secretion levels in uterine cancer. This hCG protein is commonly used for 
pregnancy confirmation. Many standard pregnancy lateral flow detectors measure the 
level of hCG in urine samples of women. Increased levels of hCG are associated with 
pregnancy but have also been shown to be elevated in certain choriocarcinomas 
(Stenman et al. 2004). Due to the fact hCG is upregulated in pregnancy and 
chriocarcinomas are not very common, the level of hCG alone cannot signify the 
presence of cancer. This is where the analysis of the glycoprotein itself can be used to 
identify the presence or absence of cancer. When the glycan structures on the hCG 
proteins were analysed between healthy pregnant women and women who had been 
diagnosed with chriocarcinoma, there were a number of differences found. The hCG 
protein is a dimer made up of an α and β subunit, each subunit contains two N-glycans. 
In healthy pregnant women the N-glycans on the α- subunit were never shown to be 
fucosylated and often showed minimal to no branching, i.e. the glycans remained mono-
antennary. There are different forms of choriocarcinomas, these are; hydatidiform moles 
and invasive moles. Hydatidiform moles are considered to be benign lesions, whereas 
invasive moles are considered to be more metastatic with the ability to invade 
surrounding tissues. The hCG from hydatidiform moles were glyco-analysed and 
showed the same glycan structure as the hCG secreted from healthy pregnant women. 
50 
 
The interesting changes appeared in the cases of invasive moles. In figure 1.15 there are 
eight glycan structures shown, labelled A through H. The normal hCG only appears to 
have glycans E, F and H, whereas the invasive molar cells secrete hCG that has all eight 
glycan structures (Kobata and Amano 2005). This highlights the upregulation of two 
glycosyltransferases. One of these glycosyltransferases facilitates additional 
fucosylation. The other glycosyltransferase forms the GlcNAc-β-1,4-Man-α-1,3 group 
found in glycan structures A-D in figure 1.15. This linkage does not appear in hCG 
secreted by healthy pregnant women and therefore can be fully associated with the 
progression of the disease. 
 
Figure 1.15: Glycans found on hCG protein in healthy and choriocarcinoma cells. 
This image shows eight glycans found through analysis of N-glycans on the hCG 
glycoprotein when investigating uterine cancer (Kobata and Amano 2005). 
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These two examples show how a secreted glycoprotein can be used to analyse the type 
and progression of certain cancers. Not all cancers will secrete a glycoprotein that can be 
easily targeted as a biomarker but the fact cancers have been shown to upregulate certain 
glycosyltransferases gives a mandate for other studies.  
As explained in the previous sections, cell surface glycosylation is pivotal to cell 
functionality. If the glycan structures on secreted proteins can change, then it can be 
deduced that the glycan structures of the cell membrane glycoproteins may also be 
altered.  
One glycan that is found commonly on the surface of various cancers is the Thomsen-
nouvelle (Tn) antigen. The Tn antigen is the most basic form of glycosylation and 
represents cells that are growing too quickly in a very simple way. The Tn antigen is an 
O-glycan made up of just a single GalNAc sugar on a serine or threonine (Varki et al. 
2009). This is caused by alterations in expression levels of both GalNAc transferases 
and other transferases that may build up this glycan. There are variations of the Tn 
antigen, namely the T-antigen and the sialyl Tn or T antigen (Loureiro et al. 2015). 
Sialyl Tn antigen is a disaccharide glycan which contains a single sialic acid residue 
attached to the first GalNAc. T-antigen is another disaccharide glycan which contains a 
single galactose residue attached to the first GalNAc. All of these structures can be seen 
in figure 1.16. There is the sialylated version of T-antigen also where it has a sialic cap 
making it a tri-saccharide glycan.  
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Figure 1.16: Structure of Tn, Sialyl Tn/T and T antigen. This image depicts the 
shortened glycans known as Tn, sialyl Tn and T-antigen. These glycans are often linked 
with various types of cancer. Image taken from review by Loureiro et al. (2015). 
 
Breast cancer is one of the most common cancers worldwide and has the highest 
instance of new cases in women each year. There have been many studies carried out to 
identify specific causes for breast cancer and a lot of different ways to identify it as early 
as possible. There are three main groupings of breast cancer, these are; oestrogen or 
progesterone receptor-positive (ER+), HER2-positive and Triple negative (negative for 
oestrogen, progresterone and HER2).  Tn antigen has been associated with certain types 
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of breast cancer and is used as a biomarker to try and highlight metastasis and invasive 
potential (Brooks and Carter 2001). There has been a difficulty in creating a quick, 
accurate and cost effective technique to identify the presence of any of the Tn and T 
epitopes. In section 1.3, CD44 was mentioned as a specific cell surface glycoprotein that 
is involved in a number of cellular processes. Its importance in cell-cell and cell-matrix 
adhesion makes it an ideal candidate to study when looking at tumour metastasis. CD44 
is found to be over expressed in a number of cancers including breast cancer. It’s 
overexpression in cancer can be linked to its ability to cause disruptions in adhesion or 
promote cell adhesion in new locations during metastasis. In breast cancer, along with a 
number of other cancers, CD44s glycosylation has been shown to be altered and possess 
the sialyl-Tn (sTn) and sT antigens (Hauselmann and Borsig 2014). The presence of 
these antigens, as well as the increased number of CD44 on the surface, is associated 
with high metastatic potential and a poorer prognosis.  
Another important area that has been investigated in breast cancer metastasis is the N-
acetyl-glucoaminyl transferase 2 (GCNT2) pathway. In metastatic breast cancer tumour 
cells there has been shown to be an upregulation of the GCNT2 gene. The changes this 
causes for the glycans on the surface of the cells provokes cell detachment from the 
extra cellular matrix and promotes cell migration and invasion (Kolbl et al. 2015). 
Different types of breast cancer can exhibit different glycosylation patterns on the 
surface. For instance there is different glycans found on the cell surface of ER+ and ER- 
breast cancers. In a 2011 study it was shown that sialyl-Lewis antigen x (sLe
x
) was 
overexpressed in all ER- breast cancers (Julien et al. 2011). Sialyl-Lewis antigen x is a 
tetra-saccharide consisting of GlcNAc, fucose, galactose and sialic acid. The structure 
for sLe
x
 can be seen in figure 1.16. This increase in surface sLe
x
 antigen can be 
accounted for by measuring specific glycotransferase genes that are upregulated in ER- 
breast cancers. Three enzymes found to be overexpressed in ER- cells are ST3 beta-
galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6) and fucosyltransferase 3 and 4 
(FUT3, FUT4). These genes being overexpressed facilitates the increased amount of 
sLe
x
 found on the cells. Both increased and decreased sialyation of terminal glycans can 
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have a significant effect on the proteins ability to carry out its function. The sLe
x
 glycan 
is found on healthy leukocytes but is now shown to be expressed in cell types not 
synonymous with this glycan pattern. ER- breast cancer cells can be partially identified 
using sLe
x
 as a biomarker but some ER+ cells have been shown to also express this 
antigen. These ER+ tumours showed increased bone metastasis when compared to ER- 
tumours expressing sLe
x
 antigen (Julien et al. 2011). Less than a quarter of high sLe
x
 
antigen expressing ER- tumours showed bone metastasis while essentially all ER+ 
tumours with high sLe
x
 antigen expression showed bone metastasis. For these two 
reasons the presence of this glycan can be used to help identify ER- tumours while also 
alluding to the metastatic potential of ER+ tumours.  
 
 
Figure 1.17: Structures of Lewis antigens. This image shows the tri- and tetra- 
saccharide glycans in the lewis antigen family. Image taken from Pinho et al. (2013).  
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1.5.3 Glycosylation alterations in colorectal cancers 
Section 1.5.2 highlights the changes observed in various types of cancer. In males 
colorectal cancer (CRC) represents the third most commonly diagnosed cancer, while it 
also represents the second most commonly diagnosed cancer in females. Statistics 
supplied by the WHO from 2012 show that there are over 1.3 million cases of newly 
diagnosed colorectal cancer in the year prior with nearly 700,000 deaths related to the 
disease (World Health Organisation 2017). CRC is one of the leading causes for cancer 
related mortality. Even though the majority of deaths are registered from third world 
countries, where diagnosis is often carried out when the disease has progressed to stage 
III or stage IV, CRC is still one of the leading causes of cancer-related deaths in the 
developed world. For instance, in Ireland there are approximately 2,500 newly 
diagnosed cases each year and it accounts for the second most common cause of cancer 
related death (Irish Cancer Society 2017). There are various causes of colorectal cancer, 
some being hereditary while some are caused by lifestyle factors, i.e. dietary or alcohol 
related (de Freitas Junior and Morgado-Diaz 2016). CRC progression occurs through a 
series of histopathological stages. These stages range from single lesions, through small 
polyps often to malignant cancers. As with all cancers early diagnosis is pivotal to 
ensuring effective treatment. The five year survival rate for CRCs diagnosed in stage I or 
II are very high, between 80-90%. As the stages progress the five year survival rate 
drops significantly. Once the disease has progressed to stage III this usually means the 
CRC has become invasive and often metastases in other organs. In figure 1.18 the five 
year survival rate for stage III is approximately 63% while the stage IV survival is as 
low as 7% in males. These statistics show a need for earlier diagnosis and preventative 
measures to try and stop metastasis of the cancer.  
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Figure 1.18: Five year survival rates for men and women at different stages of 
colorectal cancer. This image shows the decreasing survival rate as the CRC progresses 
from stage I to stage IV.  Image taken from Cancer Research UK website (Cancer 
Research UK 2016) 
 
As with prostate and breast cancers there, has been a lot of research carried out in 
regards to the cells ability to carry out correct glycosylation. Glycosylation has been 
shown to be extremely important in epithelial cells ability to correctly adhere to each 
other. One of the main glycoproteins on the surface of epithelial cells is E-cadherin and 
numerous studies have suggested that altered N-glycosylation of this protein contributes 
to the cells inability to correctly adhere. E-cadherin has four N-glycan sites which 
appear to be involved in calcium dependent cell-cell adhesion at amino acid positions 
554, 556, 618 and 633 (Zhao et al. 2008). Incorrect glycosylation at any of these sites 
can play a crucial role in the cells ability to adhere and can lead to the cells ability to 
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become metastatic or invasive. Two specific changes to the N-glycans of this protein can 
affect the adhesion differently. Increased β-1,6- branched N-glycans destabilises the 
cell-cell binding and consequently aids in tumour progression. This increase is catalysed 
by an overexpression of the mannoside acetylglucosaminyltransferase 5 (MGAT5) gene 
(Pinho et al. 2009). There is another MGAT gene that leads to alterations in the N-
glycans present on the E-cadherin protein (MGAT3). MGAT3 is the glycotransferase 
gene involved in β-1,4- mannosyl linkages which leads to increased branching and 
bisecting of glycans. The regulation of both of these genes has profound roles in many 
different types of epithelial cell cancers ability to adhere and in their tumour 
progression. They show ability to effect the stability of cell-cell adhesion as well as cell-
matrix adhesion, i.e. they also affect the cells ability to adhere to the extra cellular 
matrix. The family of glycoproteins affected in the case of cell-matrix adhesion are 
integrins. Depending on the expression of these transferases there can be increased 
invasive potential, increased cell migration as well as the affects to cell adhesion (de 
Freitas Junior and Morgado-Diaz 2016). The changes in E-cadherin mediated cell-cell 
adhesion of human colorectal cancer cells has been studied and these changes, while 
found in other epithelial cell cancers, have proven to be involved in the CRCs ability to 
destabilise cell-cell adhesion. Adheren junctions (AJs) stability in CRCs are heavily 
affected by altered N-glycosylation and these alterations have been associated with CRC 
progression (de Freitas Junior et al. 2011).  
In the majority of studies to date these changes have been monitored using a mix of 
mass spectrometry, microscopy and gene expression analysis. Lectins have the ability to 
monitor some of these changes in a cheap, quick and effective way. Increased branching, 
change of alpha- and beta- linkages as well as incorrect mono/oligosaccharide 
addition/subtraction can be identified by using specific lectins to monitor these changes. 
In the case of colorectal cancer, there has been a lot of research into specific glycan 
changes that allows for the use of lectin staining, either through lectin micro-arrays or 
fluorescent microscopy, to identify binding. Both micro-arrays and fluorescent 
microscopy are limited in their quantitative analysis and largely qualitative, so the use of 
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lectin staining coupled with flow cytometry will give a better understanding of the 
quantitative differences in cell surface glycosylation between healthy and cancerous 
cells, as well as different stages of cancer.  
 
 
 
1.5.4 Colorectal carcinoma cell lines SW480 and SW620 
In research the use of immortalised cell lines is very common. The breakthrough in the 
1950’s that resulted in the first human cancer cell line to be immortalised was of an 
ovarian cancer sample taken from a middle aged woman named Henrietta Lacks 
(Masters 2002). The subsequent cell line was called HeLa and is still used routinely in 
research to this day. This breakthrough opened the field to identify and characterise a 
large number of different cancer cell lines and essentially immortalise a variety of 
different types of cancer. In the 1950’s there were many misconceptions about what 
cancer was and it was even hypothesised that a series of viruses were the cause of many 
cancers. The breakthrough of culturing a reproducible human cancer cell line 
revolutionised the study of human cancers.  
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Figure 1.19: Timeline showing the development of human cancer cell lines. This 
image shows the beginning of modern cell culture and the emergence of reproducible, 
immortalised cell lines. Image taken from Masters (2002). 
 
Two cell lines that were immortalised were the colorectal carcinoma cell lines SW480 
and SW620. These cell lines were originally derived from the same individual one year 
apart. The fact these cell lines were originally cultured from the same person has made 
them a unique research tool and the perfect paired cell line. These cell lines were 
originally cultivated and characterised in the 1970s and have been used in research ever 
since (Leibovitz et al. 1976). 
 
The SW480 cell line was derived from a primary colorectal cancer. The donor was a 50 
year old Caucasian male who had been originally diagnosed with a Dukes’ type B 
colorectal adenocarcinoma, which is defined as an invasion through the bowel wall 
penetrating the muscle layer but not involving the lymph nodes. The Dukes’ 
classification of colorectal cancers is less commonly used in modern times and the 
SW480 cell line can be classed as a stage 2 colorectal carcinoma. As a stage 2 carcinoma 
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it is characterised as a tumour that has not metastasised yet and the cancerous tissue is 
confined to a single area. This cell line, before it became cancerous, was originally a 
colorectal epithelial cell. Epithelial cells on the outer lining of the colon/rectum have a 
certain morphology. These cells must create a barrier to only allow specific molecules 
pass through the epithelial lining. Due to this the cells will appear to grow in a 
‘pavement’ like fashion, where all the cells adhere to a standard cell culture plate and 
create a growth where all the cell membranes are directly attached to each other 
(Peterson and Artis 2014). The SW480 cells have a similar morphology to that of 
healthy epithelial cells. This morphology can be observed in figure 4.1 in chapter 4.  
The SW620 cell line was also derived from a primary colorectal carcinoma from the 
same patient as the SW480 cell line as mentioned previously. This tissue was harvested 
from a metastatic site in the lymph node. In the same original study carried out by 
Liebovitz (1976) this cell line was authenticated and established as the metastatic form 
of the SW480 colorectal carcinoma. This cell line was originally classed as a Dukes’ 
type C colorectal adenocarcinoma. A Dukes’ type C colorectal cancer is believed to 
have spread through the mucosa layer of the colon and has spread to at least one nearby 
lymph node. Again, the Dukes’ classification system is somewhat outdated and this 
cancer is now deemed a stage 3 colorectal carcinoma. As a stage 3 cancer it is believed 
to have metastasised to at least one of the nearby organs, in this cause the lymphatic 
system. As explained in section 1.5.3, the five year survival rates between the 
progressive stages of cancer show a decrease in short and long term survival. 
Morphologically SW620 cells do not exhibit the same phenotype as SW480 cells or 
healthy epithelial cells. Through the progression of the cancer the cells have taken on a 
different shape and size and even growth rate. The cells first appear noticeably smaller 
and more spherical than SW480 cells. The cells appear to become more elongated and 
can show a more spherical or stretched shape when they have correctly adhered to the 
plate and reach an adequate confluency. This phenotypic change highlights the change in 
the cell which led it to metastasise and invade other tissues. This phenotype can be 
observed in figure 1.19.  
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1.6 Non-fixed versus fixed cells for cell surface glycan 
interrogation 
Cells that are interrogated using fluorescent microscopy or flow cytometry (Sections 1.6 
and 1.7) can be prepared in two ways, fixed and non-fixed. To fix cells, the cells are 
subjected to a fixative agent which will preserve the cell in its specific cellular state. 
Fixation causes all cellular biochemical reactions to stop. Common fixative agents used 
are formaldehyde / paraformaldehyde or glutaraldehyde. Formaldehyde acts as a 
chemical crosslinker for cellular proteins. The proteins are crosslinked via their free 
amine groups which preserves the cellular morphology (Hoff 2015). Cells are fixed for a 
large number of reasons; to stop proteolytic activity of the cells, to allow for analysis 
over a number of days and weeks using the same sample and to increase cellular 
permeabilisation. The crosslinking of cell surface proteins can interfere with antigen 
sites for antibodies due to unnatural surface protein linkages. Cells that are fixed using a 
chemical fixing agent, such as formaldehyde, are permeabilised and allow for 
internalisation of certain probes like antibodies.  
For analysis of any cell surface antigens or glycans probing non-fixed live cells is 
recommended (Holmes et al. 2001). To determine the differences between cell surface 
glycans between cell types using either microscopy or flow cytometry, the cells must not 
be permeabilised. Cytoplasmic proteins and membranes contain a wide variety of 
glycans which can also be detected if probing the fixed cells with lectins. Fixation 
processes that cause protein cross-linking can also alter or change the potential glycan 
sites on the surface of the cell. Fixation and increased permeabilisation has proven to be 
a very useful method for intracellular staining with antibodies or other molecules that 
cannot permeate the cell membrane.  
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1.7 Fluorescent Microscopy for Glyco-analysis 
Fluorescence microscopy is a method that uses fluorescence to study the properties of 
organic and inorganic substances. With the use of different fluorescent filters, 
conjugated fluorophores can be excited with the correct wavelength of light and then 
visualised on the microscope (Galdeen and North 2011). The use of fluorescence in 
microscopy allows for a user to visualise specific things happening in, and around, a 
cell. The most commonly used dye for staining a cell nucleus is 4’,6-diamidino-2-
phenylindole or DAPI. This is a fluorescent stain that binds strongly to regions of DNA 
that contain high levels of A-T (Tarnowski et al. 1991). It’s capable of permeating the 
cell membrane in live cells and for this reason is used extensively in fluorescent 
microscopy. DAPI fluoresces in the blue light spectrum. DAPI is routinely used as 
nuclei counter stain when probing cells with other fluorescently labelled molecules. 
Cells are then viewed under the different fluorescent channels and the other fluorescent 
molecules can be detected and visualised (Johnson and Criss 2013). Merged images then 
can show the fluorescence of different components on one image with a nuclear stain as 
the control. Cells are either probed with an antibody or other protein with an attached 
dye or they produce proteins that have been fused to fluorescent proteins (Spector and 
Goldman 2006).  
In respect to glyco-profiling, lectins are often used as the probe and are chemically 
labelled with fluorophores. As mentioned in sections 1.3 and 1.4, lectins serve as good 
analytical tools for probing the surface of live cells. In this study where adherent cells 
are the only cell type being used setting up these lectin probing experiments is relatively 
simple. Using a DAPI counter stain to visualise the nucleus of the cell, lectins can be 
used to interrogate the cell membrane of live cells. In figure 1.20 this process of nuclear 
staining merged with lectin surface staining can be observed (Peiris 2012).  
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Figure 1.20: Lectin binding to SW480 and SW620 as viewed under a fluorescent 
microscope. These cells highlight surface lectin binding of WGA, ConA and PHA-E 
while also showing the DAPI nuclear counter stain. Green fluorescence indicates lectin 
binding. Blue fluorescence indicates the DAPI nuclear stain. Image taken from Peiris 
(2012). 
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The advantages to using fluorescent microscopy as an analytical technique for 
identifying glycans on the surface of cells are: (i) Glycans can be analysed intact on the 
cell surface and do not need to be cleaved; (ii) Multiple lectins can be used in the same 
experiment, i.e. a 12 well plate with cells in each well can have 12 different lectins used 
on the same cell type; (iii) Competing sugars can be used to selectively inhibit binding 
of the lectins to show glycan specificity. While this technique has proven to be a very 
useful tool in glyco-profiling it does have limitations. These limitations are: (i) The 
method is largely qualitative and the quantification can be highly subjective and (ii) cells 
grown in the presence of serum can have high background due to the fact a large number 
of serum proteins are also glycosylated and can attach to the surface of the wells or 
dishes used for cell culture. Both of these limitations will be further analysed in the 
discussion of the results section pertaining to the fluorescent microscopy carried out in 
the project.  
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1.8 Flow Cytometry for Glyco-analysis 
Flow cytometry is a laser-based technology that is used to accurately count cells, sort 
cells and detect fluorescently labelled biomarkers or probes on cells. This process is 
carried out on an instrument named a flow cytometer. The flow system is designed to 
create a constant stream of droplets which each contain a single cell. These single cells 
are then interrogated by a laser and measurements can be taken based on forward scatter, 
side scatter and the excitation of fluorescent fluorophores (Ormerod and Novo 2008). 
Forward scatter is used to measure the size of the cell, whereas side scatter is used to 
measure the internal complexity of the cell. Both of these parameters can help in 
determining the health or viability of the interrogated cells and help in distinguishing 
dead cells or debris from the viable cells. Through the use of different filters and the full 
light spectrum, a large number of fluorophores can be used to interrogate cells. This 
process is highlighted in figure 1.21. 
 
Figure 1.21: Schematic of a Flow Cytometer interrogating cells. A cell suspension is 
separated into single cells that are interrogated by a laser and specific measurements are 
recorded. Image taken from abcam.com website (Abcam 2017). 
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Side scatter and forward scatter can also determine different cells in a cell suspension 
based on size but if cells are roughly the same size then specific fluorescent probes, such 
as antibodies or lectins, may be used to identify the different cell groups. The laser 
excites the specific fluorophores used to probe the cells and these results can be 
distinguished from the unstained population (Tao et al. 2008). In figure 1.22 the 
difference between fluorescently positive and negative populations is highlighted. The 
fluorescent voltage settings are set up against the unstained population as a control. As 
the technology continues to be modified and enhanced, the number of fluorophores 
available for purchase and detectable by various cytometers continues to increase. Some 
fluorophores have excitation and emission spectra that are very close and cannot be 
easily distinguishable from each other. The ability to compensate for this is one of the 
more powerful functions of modern flow cytometers. Through the use of specific 
software this compensation can be applied to the measurements where a large number of 
different fluorophores are being used on the same type of cells. This compensation 
allows for the use of multiple fluorophores interrogating cells while accounting for and 
removing the possibility of false positives. The histograms displayed in figure 1.22 are 
only using a single fluorophore to detect fluorescence. The use of multiple fluorophores 
is usually better visualised using scatter or dot plots instead of histograms. An 
experiment carried out using three different fluorophores to identify three cell 
populations can be observed in figure 1.23 (Sukhdeo et al. 2013). Antibodies to date 
have been the most common probes used on cells to be visualised by flow cytometry, 
but the use of lectins in cell probing has become increasingly routine.  
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Figure 1.22: Flow cytometric analyses of cells using lectins showing positive and 
negative binding via histograms. Jacalin at different concentrations binds to these cells 
while UEA-I at different concentrations does not bind to these cells. The shift in peak 
relative intensity identifies positive and negative populations. Image taken from Tao et 
al. (2008). 
 
Figure 1.23: Flow cytometric analyses of cells using antibodies to highlight different 
cell populations in a solution. Three colorectal cancer cell lines are identified by the 
specific antibody bound to each of them. HCT116 are FITC positive, SW480 are 
Horizon V450-A positive while SW620 is negative for both fluorophores. All the cells 
are APC positive. Image take from Sukhdeo et al. (2013). 
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With regards to glyco-profiling, lectins can be chemically labelled with specific 
fluorophores and then used to probe cells. This process is similar to the process used in 
fluorescent microscopy but without the need for a nuclear counter stain. Forward scatter 
and side scatter are used to determine cell viability rather than the visualisation of an 
intact nucleus. The advantages of using flow cytometry for lectin probing of live cells 
are: (i) the cells are live and can be gated accurately to ensure only viable cells are 
analysed; (ii) a large number of cells can be interrogated in a very short period of time 
(thousands of cells per minute) to give a large sample size for analysis; (iii) The results 
are qualitative and quantitative, this allows for relative fluorescence to be calculated and 
can infer the amount of specific glycans; (iv) Some lectins can cause cytotoxicity and 
cells that are dead or undergoing apoptosis can be removed through specific gating 
strategies (Batisse et al. 2004). There are some disadvantages to using a flow cytometer 
for lectin probing, and these are: (i) Cytotoxicity caused by lectin binding may decrease 
the number of viable cells in a sample and (ii) lectins may have different levels of 
fluorophores per individual protein. These two disadvantages can be largely overcome 
by using intelligently designed gating strategies and limiting variabilities between 
samples. For these reasons flow cytometry appears to be an underutilised method for 
glyco-analysis and this project will attempt to prove this can be a useful method for 
identifying surface glycans in the future.  
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1.9 Summary 
Throughout this introductory chapter the significance of glycosylation has been 
identified. Cells require correct protein glycosylation to fulfil their desired function. 
Cells have a large number of glycoproteins embedded in their cell membrane with 
glycan complexes on the outer surface of the cell. These glycans help to facilitate many 
different functions cells in different tissues and organs have. Problems then arise when 
cells cannot correctly glycosylate their proteins and the functions of these proteins get 
effected. Alterations in glycosylation can occur as a result of mutations in genes 
associated with glycosylation or through diseases that force cells to change their 
function, such as cancer. Glycans can be identified and characterised using a number of 
different methods, some of which can use live cells in vitro or others that cleave off 
glycans for analysis. Alterations in glycosylation have been linked to a large number of 
different cancers and these alterations can highlight early stage cancer and even infer 
metastatic potential of certain cancers. In order to accurately diagnose cancerous cells 
early in the diseased state, the techniques employed to identify and characterise glycans 
are continually being upgraded and advanced. In the present study, the advancement of 
lectin based probing platforms has yielded more efficient and cost effective ways to 
accurately test for surface glycosylation of cells. Lectins have the unique ability to bind 
specific monosaccharides in complex glycan structures with a large degree of specificity 
and affinity. With the increasing number of lectins being identified from microbial 
sources, the ability to regularly produce reliable, accurate prokaryotic lectin probes has 
continued to increase. Coupled with the eukaryotic lectins that are already commercially 
available for purchase, comprehensive glyco-profiling can be achieved using lectin 
based methods such as microarrays, lectin blots, fluorescent microscopy and flow 
cytometry. Creating a qualitative and quantitative profile of the surface glycosylation of 
certain cancer cells may lead to rapid identification of cancers at certain stages of 
growth, as well as identifying invasive potential of the cancer. Throughout the 
introduction the importance of different areas in glycobiology were explored, these areas 
included; glycosylation, surface glycosylation, interrogation techniques for determining 
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glycosylation, lectins both eukaryotic and prokaryotic, cancer and how alterations in 
glycosylation may be a biomarker for cancer or disease. Through understanding all of 
these topics, a plan to try and interrogate surface glycans, using recombinantly produced 
lectins and commercially available lectins, using fluorescent microscopy and flow 
cytometry was conceived.  
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1.10 Aims and objectives of this project 
The aim of this project has been touched on throughout this introductory chapter. The 
study of alterations of surface glycosylation in cancerous cells has become increasingly 
important in recent years. Strong evidence now indicates that alterations in cell surface 
glycosylation are amongst the earliest changes that occur when cells begin to go 
cancerous. For research to continue to grow in this area more comprehensive analytical 
techniques to investigate cell surface glycosylation need to be developed and utilised. 
Identifying new lectins from prokaryotic sources that have the ability to act as surface 
probes would add to the library of commercial eukaryotic lectins and increase the 
potential for lectin based analysis of cell surface glycosylation. Two of the major aims 
for this project are: (i) to use recombinant DNA technology to alter a prokaryotic lectin, 
lecB, to possibly alter its binding specificity, affinity, stability and develop an active 
lectin probe with a fluorescent fusion partner protein and (ii) to use fluorescent 
microscopy and flow cytometry to analyse cell surface lectin binding and (iii) create a 
comprehensive glyco-profile for both SW480 and SW620 so as to compare relative 
binding.  
 
To achieve both of these aims there were a number of technical objectives that needed to 
be carried out. These objectives were; 
 Utilising site directed mutagenesis to create a library of four lecB clones for 
characterisation. 
 Successfully express and purify these lecB variants and characterise their binding 
potential.  
 Identify viable lecB variants for in vitro cell glycan analysis. 
 Perform qualitative glycan analysis of SW480 and SW620 cells using fluorescent 
microscopy with a panel of lectins both commercial eukaryotic lectins and 
recombinantly produced prokaryotic lectins. 
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 Perform qualitative and quantitative glycan analysis of SW480 and SW620 cells 
on a flow cytometer again using a panel of lectins both commercial eukaryotic 
lectins and recombinantly produced prokaryotic lectins. 
 Confirm binding specificity by using a competing free sugar to inhibit binding of 
each lectin while also using a non-competing free sugar to show that it will not 
inhibit binding. 
 Analyse data and compare lectin binding between both SW480 and SW620 to 
infer glycan differences on the surface of each cell type.  
 Highlight the use of recombinant prokaryotic lectins for in vitro glycan analysis.  
 
With all of these objectives in place the experiments described in this thesis were 
designed to achieve project aims in a reproducible and scientifically accurate manner. 
Thus the overall aim of this work was to develop a new way of investigating cell surface 
glycosylation using a combination of  unique lectin probes and flow cytometry.  
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Chapter 2 
Materials and Methods 
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2.1 Vectors, Primers, Constructs and Bacterial Strains: 
 
 
Figure 2.1: pQE30 vector from Qiagen. This 3.4kb DNA plasmid vector was supplied 
by Qiagen and contains the following features; a multiple cloning site (MCS) preceded 
by a poly-histidine tag, this His6 tag allows the protein to be expressed with an N-
terminal His6 tag, a beta lactamase gene which allows for ampicillin resistance and a T5 
promoter/lac operon for inducible expression of the inserted protein. The vector image 
was obtained via the Qiagen website (www.qiagen.com).  
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Table 2.1: Primer sequences 
Primer Name Sequence (5’-3’) Mutation 
LecB_S24Tf GCCAACTCGACCGGAACCCAGACGGTGA
AC 
S24T 
LecB_S24Tr GAAGGCGGTGACGCCGAACCG -- 
LecB_S23A;S24A;
G25Af 
GCCAACGCGGCCGCAACCCAGACGGTGA
ACGTG 
S23A;S24A;
G25A 
LecB_S23A;S24A;
G25Ar 
GAAGGCGGTGACGCCGAACCG -- 
LecB_3Kf AAAAAGAAATCCATGGCAACACAAGGAG
TGTTCACC 
Three lysine 
insertion 
LecB_Kr TCCGTGATGGTGATGGTGATG -- 
 
Regions highlighted in blue are the regions containing the mutations. 
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Table 2.2: Plasmid Constructs 
Construct Name Description Source 
pQE30 Expression vector for N-
terminally tagged His6 
proteins, T5 promoter/lac 
operon, ampR, ColE1 origin 
Qiagen 
pQE30_eGFP pQE30 plasmid containing 
enhanced GFP ORF 
ISSC 
pQE30_PA-IL pQE30 plasmid containing 
PA-IL ORF 
ISSC 
pQE30_PA-IIL  pQE30 plasmid containing 
PA-IIL ORF 
ISSC 
pQE30_PA-IIL_S24T pQE30 plasmid containing 
PA-IIL ORF with S24T 
mutation 
This Work 
pQE30_PA-IIL_ 
S23A;S24A;G25A 
pQE30 plasmid containing 
PA-IIL ORF with 
S23A;S24A;G25A 
mutations 
This Work 
pQE30_PA-IIL_3K pQE30 plasmid containing 
PA-IIL ORF with an 
additional three lysine 
residues between the poly-
histidine tag and start codon 
of the gene 
This Work 
pQE30_eGFP-PA-IIL pQE30 plasmid containing 
eGFP fused to PA-IIL via 
the N-terminus 
This Work 
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Table 2.3: Strains of bacteria used 
Strain Description Use Source 
E. Coli JM109 
 
 
 
 
 
 
 
FΔtraD36, proAb+ 
lacIq, ΔlacZ M15 
endA1 recA1 
hsdR17 (rk-, mk+) 
mcrA supE44 – 
gyrA96 relA1 Δ 
(lacproAB) thi-1 
All-purpose cloning 
strain that produces 
stable plasmid DNA 
at a high copy 
number. 
Sigma 
E. Coli KRX traD36, ΔampP, 
proA+B+, lacIq, 
Δ(lacZ)M15] 
ΔompT, endA1, 
recA1, gyrA96 
(Nalr), thi-1, 
hsdR17 (rk-,mk+), 
relA1, supE44, 
Δ(lac-proAB), 
Δ(rhaBAD) ::T7 
RNA polymerase 
Protease deficient 
expression strain. 
High transformation 
efficiency.  
Promega 
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Table 2.4: Cell lines used  
Cell line SW480 SW620 
Organism Human Human 
Tissue Colon Colon; derived from metastatic 
site: lymph node 
Morphology Epithelial Epithelial 
Culture 
Properties 
Adherent Adherent 
Biosafety Level 1 1 
Disease Dukes’ type B colorectal 
carcinoma 
Dukes’ type C colorectal 
carcinoma 
Age / Gender 50 / male 51 / male 
Ethnicity Caucasian Caucasian 
Cell images 
 
 
Passage no. 65-70 60-65 
 
 
 
 
 
 
79 
 
2.2 Microbiological and Cell Culture Media 
The chemicals and solutions used were all ACS grade and were supplied by Sigma-
Aldrich unless otherwise stated. Sterilisation was achieved by autoclaving at 121 °C for 
20 minutes. The distilled water (dH2O) is from a Milli-Q® Academic system with a 
MILLIPAK™ 0.22 µm filter. 
 
 Luria Bertani Broth (LB) 
 Tryptone     10 g/L 
 NaCl      10 g/L 
 Yeast Extract     10 g/L 
 pH      7.0 
NaOH is used to adjust the mixture to pH 7.0. This is done before the solution is brought 
to its final volume. Sterilised by autoclaving (121
 
°C for 20min.). 
*For the production of solid agar plates 15 g/L of Scharlau® bacterial agar was added 
prior to sterilisation. 
 
 Terrific Broth (TB) 
 Tryptone     12 g/L 
 Yeast Extract     24 g/L 
 Glycerol     4 ml/L 
The volume is brought up to 900ml and then autoclaved (121
 
°C for 20min.). Once 
cooled to room temperature, 100ml of 1M phosphate buffer was added aseptically in 
order to buffer the solution down to a neutral pH (7.4). 
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 Super Optimal broth (SOB) 
 Tryptone     20 g/L 
 NaCl      500 mg/L 
 Yeast Extract     5 g/L 
 KCl      2.5mM 
 pH      7.0 
The pH was adjusted using HCl or NaOH depending on the pH of the final solution. 
This media was then sterilised by autoclaving. 
 
 Supplemented RPMI 
 RPMI 1640, GlutaMAX™   500 mL 
 Fetal Bovine Serum    50 mL 
 Penicillin / Streptomycin   5 mL 
Penicillin / Streptomycin contains 10,000 units/mL of penicillin and 10,000 µg/mL of 
streptomycin. 
 
Cell Freezing Stock Solution 
 RPMI 1640, GlutaMAX™   7.5 mL 
 DMSO      1.5 mL 
 Fetal Bovine Serum    1 mL 
This solution was stored at -20
 
°C. RPMI 1640, GlutaMAX™ supplemented and Fetal 
Bovine Serum were bought from Gibco™. Penicillin and Streptomycin mix were bought 
from Sigma™. 
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2.3 Solutions and Buffers: 
 TE Buffer 
 Tris-HCl     10 mM 
 Na2-EDTA     1 mM 
 pH      8.0 
 
1M Potassium Phosphate Buffer 
KH2PO4     21.3 g/L 
K2HPO4     12.4 g/L 
pH      7.4 
The buffer was sterilised by autoclaving. 
RC Buffer 1: 
RbCl      100 mM 
CaCl2      10 mM 
CH3CO2K     30 mM 
Glycerol     15% (v/v) 
pH      5.8 
Made using Ultrapure water. MnCl2 was added after adjusting the pH with KOH 
accordingly. The solution was filter sterilised through a 0.22 µm filter. The solution was 
stored at 4
 
°C. 
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RC Buffer 2: 
MOPS      10 mM 
RbCl      10 mM 
CaCl2      75 mM 
Glycerol     15% (v/v) 
pH      6.8 
The pH was adjusted using KOH. The solution was filter sterilised through a 0.22 µm 
filter. The solution was stored at 4
 
°C. 
  
Phosphate Buffered Saline 10x (PBS) 
Na2HPO4     10.9 g/L 
NaH2PO4     3.2 g/L 
NaCl      90 g/L 
For PBST the detergent Tween-20 was added to give a final concentration of 0.1% (v/v). 
 
Tris Buffered Saline (TBS) 
Tris      20 mM 
NaCl      150 mM 
CaCl2      1 mM 
MgCl2      1 mM 
pH      7.6 
The pH was adjusted to 7.6 with HCl prior to the addition of MgCl2 at a concentration of 
1mM. For TBST the detergent Tween-20 was added to give a final concentration of 
0.1% (v/v). 
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SDS-PAGE Buffer (5x) 
 Tris-HCl     15 g/L 
 Glycine     72 g/L 
 SDS      5 g/L 
 pH      8.3 
 
 SDS-PAGE Sample Buffer (10x) 8ml 
 SDS      3.2ml (10% (w/v) stock) 
 2-Mercaptoethanol    0.8ml 
 Tris-HCl     2.0ml (0.5M stock, pH 6.8) 
 Glycerol     1.6ml 
 Bromophenol Blue    0.5% (w/v) 
 H2O      0.4ml 
A colorless dye was also made with the same recipe but without the addition of 
Bromophenol blue. 
 Coomassie blue stain solution 
 dH2O      50% (v/v) 
 Methanol     40% (v/v) 
 Acetic Acid     10% (v/v) 
 Coomassie Blue    0.25% (w/v) 
 
 Coomassie blue de-stain solution 
 dH2O      45% (v/v) 
 Methanol     45% (v/v) 
 Acetic Acid     10% (v/v) 
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Western Blot Semi-dry Transfer Buffer 
Tris base     5.8 g 
Glycine     2.9 g 
Methanol     200 mL 
SDS      0.37 g 
The volume was brought up to 1 L with dH2O and stored at 4 °C. 
 
 Lysis Buffer 
 NaH2PO4     20mM 
 NaCl      0.5M 
 Imidazole     20mM 
 pH      7.4 
*Imidazole concentrations vary from 20mM to 250mM for protein elution using 
immobilised affinity chromatography (IMAC). 
 
Tris Acetate EDTA Buffer 50x (TAE) 
 Tris      242 g/L 
 EDTA (0.5 M)    100 ml/L  
 Glacial Acetic Acid    57.1 ml/L 
 pH      8.0 
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0.7% Agarose Gel 
TAE Buffer     1 L 
Agarose     7 g/L 
Gel was autoclaved to ensure all agarose was dissolved into solution. Various 
concentrations of 0.7-2% agarose gels were used when necessary. This gel solution can 
be kept at 60
 
°C for up to 2 weeks for re-use. 
 
 Agarose Gel Loading Dye 
 Bromophenol Blue    0.25% (w/v) 
 Xylene Cyanol    0.25% (w/v) 
 Ficoll Type 100    0.25% (w/v) 
Loading dye was sterilised by autoclaving for 20 minutes at 121
 
°C. 
 
 Ethidium Bromide Solution 
A 10 mg/mL stock solution of ethidium bromide in dH2O was stored at 4
 
°C in the dark 
in a metal container. For staining of agarose gels, 100 µL of stock solution was mixed 
into 1 L of dH2O. The staining solution was kept in a plastic tray, with a plastic top to 
protect it against light. Once used the ethidium bromide stain was exhausted and the 
ethidium bromide was extracted by mixing with a de-staining bag (GeneChoice, 
Gentaur) overnight. The clear liquid was disposed of routinely while the ethidium 
bromide was incerated. For alternatively staining gels that were used to excise DNA 
bands, SYBR® safe DNA gel stain (Invitrogen™ - S33102) was used. SYBR® safe 
DNA gel stain is less harmful than ethidium bromide.  
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 TMB Citrate Solution 
 Citric Acid     1.37 mL, 0.1 M Stock 
 Sodium Citrate    3.63 mL, 0.1 M Stock 
 dH2O       5 mL 
One 3,3,5,5-Tetramethylbenzidine (TMB) tablet (Sigma T3405) was dissolved in the 10 
mL citrate solution to create the TMB solution and 2 µL of H2O2 was added directly 
before use. 
2.4 Antibiotics: 
Ampicillin was prepared in dH2O at a concentration of 100 mg/mL and was stored at -20
 
°C. This was used at a working concentration of 100 µg/mL for solid and liquid media 
for growth of E. Coli.  
2.5 Storing of Bacteria: 
Bacterial stocks were stored as 27% (v/v) glycerol stocks. 1 mL of a 5 mL overnight 
culture (late log phase) was aseptically added to 500 µL of sterile 80% (v/v) glycerol. If 
the bacteria contained a plasmid with antibiotic resistance then appropriate antibiotic 
was added to the 5 mL overnight culture. Permanent stocks were stored at -80 °C while 
working stocks were stored at -20 °C. Working stocks were stored on agar plates at 4 °C. 
2.6 Culturing of Bacteria: 
A loop full of culture from a thawed glycerol stock or a loop from a single colony on a 
transformation plate was streaked onto a fresh LB agar plate containing the relevant 
antibiotics. This plate was then incubated at 37
 
°C overnight for 18-22 hours. Once 
removed from the 37 °C incubator, the plate can be stored at 4 °C for up to two weeks. 
Single colonies can be used from this plate to create subsequent plates. A single colony 
from these plates is used to inoculate 5 mL of LB, with the relevant antibiotic, to create 
glycerol stocks. 
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2.7 Isolation of Plasmid DNA:  
Plasmid DNA was isolated using a Sigma™ plasmid mini-prep kit (PLN350). The kit 
was used according to the manufacturer’s instructions. The procedure was as follows: 
1.5 mL of an overnight bacterial culture was placed in a microfuge tube and centrifuged 
at 13,000 rpm (rotations per minute) for 2 minutes to pellet the cells. The supernatant is 
then discarded and the pellet re-suspended in 200 µL of labelled re-suspension solution, 
this was mixed using a vortex. Once re-suspended 200 µL of lysis solution was added 
and mixed by inversion. This mixture was left for 5 minutes at room temperature to 
effectively lyse the cells. After 5 minutes, 350 µL of neutralisation solution was added 
and mixed by inversion to precipitate all cellular components while leaving plasmid 
DNA in solution. This mixture was incubated for 5-10 minutes at room temperature. 
After this time the precipitate was collected by centrifugation at 13,000 rpm for 5 
minutes. To prep the spin column, 500 µL of column prep solution was added. This was 
spun at 13,000 rpm for 1 minute and the flow through was discarded. The supernatant 
from the cell precipitate was then added to the prepped spin column in a collection tube. 
This was then centrifuged for 30 seconds to bind the plasmid DNA to the column. Flow-
through was then discarded and the column was washed with 750 µL of wash solution 
and again centrifuged at 13,000 rpm for 1 minute. The flow-through was again removed 
and the columns were centrifuged again for 2 minutes at 13,000 rpm to remove any 
excess wash solution and to dry the matrix. The collection tube was then discarded and 
the spin column was added to a fresh microfuge tube and eluted in 80-100 µL TE buffer 
(if the samples were being sent for sequencing then elution takes place using dH2O). 
This sample was centrifuged for 1 minute at 13,000 rpm and the flow-through contained 
the desired purified plasmid.   
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2.8 Agarose Gel Electrophoresis: 
DNA was analysed by gel electrophoresis. This was carried out in a BioRad™ 
horizontal gel apparatus connected to a Labnet Power Station™ 300 power supply. 
Agarose was prepared by adding an appropriate amount of agar to TAE 1x buffer (see 
Section 2.3) and was dissolved by boiling at 100 °C (or autoclaving at 121 °C). The 
levels of agarose varied from 0.7-2% depending on the separation requirements of the 
DNA. Agarose solutions up to 2% are stored at 60 °C. The agarose solution is poured 
into plastic trays and allowed to set with a plastic comb fitted to create wells that the  
DNA samples can be loaded into. The hardened agarose gel was placed in the 
electrophoresis apparatus with TAE 1x buffer used as running buffer. DNA samples 
were prepared by mixing them with loading dye using a pipette. Usually 1.5 µL of 
loading dye is added to 7 µL of sample before loading. Loading dye is coloured so 
visually it can be seen how far the DNA has migrated through the gel. The glycerol in 
the loading dye also aids the DNA to sit in the wells and not float into solution. Each 
well can hold between 10-20 µL of DNA/loading dye sample. Gels were run at 120 V 
for 20-30 minutes depending on the size of the gel. After completion the gels were 
stained in an ethidium bromide staining solution (see Section 2.3). Ethidium bromide 
binds to DNA and can be viewed under UV light. Pictures of these gels were obtained 
by using a UV transilluminator coupled with an image analyser to capture and print the 
image. Each gel included a 1kb NEB (New England Biolabs) DNA ladder as a 
molecular size marker (see figure 2.2). Gels containing SYBR® safe are prepared for 
DNA extraction from agarose. SYBR safe stain is added to the liquid agarose at a ratio 
of 1:10,000 and this allows the DNA to be visualised without staining with ethidium. 
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a)                                                         b) 
                                    
Figure  2.2: DNA size marker. a) The DNA ladder is used as a molecular marker. 
Image obtained from NEB website (www.neb.com). b) This is an example of plasmid 
DNA on a 0.7% agarose gel containing a DNA ladder. Lane 1; NEB 1kB ladder, Lane 2; 
Plasmid sample, Lane 3; Plasmid sample. 
 
2.9 Gel extraction procedure for the isolation of plasmid DNA from 
agarose gels 
To isolate DNA from agarose gels the Gel/PCR DNA extraction kit from GE 
healthcare® was used. Again this kit was used according to detailed instructions 
included by the manufacturer. The procedure was as follows: DNA was run on a 1% 
(w/v) agarose gel pre-stained with SYBR® safe DNA gel stain. The DNA band was 
excised from the gel using a scalpel. Up to 300 mg of the gel slice was transferred to a 
microfuge tube. 500 µL of capture buffer was then added to the sample and mixed by 
vortexing. The sample was then statically incubated at 55 °C for 10-15 minutes 
(incubation took place in either a thermoblock or waterbath). This sample was mixed 
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every 2-3 minutes to make sure the gel fully dissolved into solution. Once the sample 
was fully dissolved it is added to a spin column and collection tube. This spin column 
was then centrifuged at 13,000 rpm for 30 seconds to bind the DNA to the column. The 
flow-through was then discarded. 500 µL of wash solution was added and again 
centrifuged at 13,000 rpm for 30 seconds. The flow-through was discarded and the spin 
column was centrifuged for 1 minute at 13,000 rpm to dry the matrix and remove any 
lasting wash solution. This DNA was eluted in 25-50 µL of elution buffer or dH2O. The 
elution buffer was added directly to the spin column matrix. This was statically 
incubated at room temperature for 2 minutes and then centrifuged for 30 seconds at 
13,000 rpm. Isolated DNA was stored at -20
 
°C to insure the DNA integrity.  
 
2.10 DNA sequencing 
Recombinant clones and potential mutants were verified by DNA sequencing. 
Commercial sequencing services were provided by MWG-Biotech/Eurofin genomics. 15 
µL of purified DNA (see section 2.7) at concentrations specified by the company was 
necessary for sequencing. Included with the plasmid DNA were the suitable sequencing 
primers. Each sample was sent twice, one with the forward primer for a forward reading 
and the other with the reverse primer for the reverse reading. 
 
2.11 Site specific mutagenesis 
Mutations were introduced into the open reading frames (ORF) on plasmid constructs by 
PCR amplification using complementary phosphorylated primers. The phosphorylated 
primers carried the designed specific mutation. A standard PCR mixture was set up, as 
described in section 2.12. The PCR was carried out using Q5 taq polymerase. The 
standard cycle for Q5 taq polymerase was used, see Section 2.12. An extension time of 3 
minutes was used to amplify 3.5-4 kb plasmids. After introducing a mutation to the 
plasmid DNA, the template DNA was digested using DpnI restriction endonuclease (See 
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Section 2.13). DpnI selectively digests the template DNA from any dam+ strains of E. 
Coli over the newly synthesised DNA. DpnI is biased towards a methylated recognition 
sequence. The use of phosphorylated primers protects the new strands of DNA from 
DpnI. A ligation (see Section 2.14) is then carried out to circularise the newly mutated 
plasmid. This ligation is facilitated by the phosphorylated primers. 
 
Figure 2.3: Site directed mutagenesis and Insertion through PCR. A) The forward 
primer contains the desired mutation in blue and does not anneal correctly to the plasmid 
DNA, B) the DNA to be inserted is added to the 5’ region of the primer and through 
amplification in a PCR mixture, the mutation and insertion take place.  
 
 
 
 
A) B) 
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2.12 PCR 
2.12.1 Standard PCR reaction mixture: 
Template DNA     1 µL 
dNTPs (10µM of each nucleotide)   1 µL 
Primers (10µM)     1 µL  (of each forward/reverse) 
Buffer (5X)      10 µL 
dH2O       35 µL 
DNA polymerase (Q5®)    1 µL 
The final volume of the mixture can vary depending on how much PCR product is 
required. During this project all PCR reactions were carried out with a final volume of 
50 µL. Once the PCR reaction was complete the DNA products wereviewed on an 
agarose gel. Q5® taq polymerase is a high fidelity polymerase purchased from New 
England Biolabs®. This ensures that even at low concentrations it will work efficiently. 
It was standard to dilute the taq polymerase 1:3 before use in the PCR.  
 
2.12.2 PCR programme cycle used for Q5 polymerase reactions 
Stage 1:  step 1;   95
o
C for 10 minutes 
Stage 2: step 1;   95
o
C for 30 seconds 
  step 2;   varying annealing temperatures for 30 seconds 
  step 3;   72
o
C for 30 seconds per kb to be synthesised. 
Stage 3: step 1;   72
o
C for 10 minutes 
Stage 2 was repeated for 30 cycles. Extension time may vary depending on the size of 
DNA or plasmid being amplified. The annealing temperature was chosen depending on 
the melting points of both the forward and reverse primers. 
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2.13 Enzymatic reactions 
All the enzymes used and relevant buffers were obtained from Invitrogen Life 
technologies®, New England Biolabs® or Sigma Corporation and were used according 
to the manufacturers specifications. 
 
Restriction Digest: 
Buffer 10x      5 µL 
Restrction Enzyme     2 µL 
Template DNA (PCR)    43 µL 
The final volume was 50 µL in this case. The reaction mixture was incubated at 37 °C 
for 120 minutes. All of the reaction is then loaded onto an agarose gels. The correct band 
is then excised to be recovered using the isolation from gel protocol (see section 2.9). If 
there is below 43 µL of template DNA, the volume can be adjusted using dH2O. 
 
2.14 Ligation reaction 
During the PCR the use of phosphorylated primers facilitates the ligation of the plasmid 
DNA (see section 2.11). Using a simple ligation reaction with T4 DNA ligase the 
plasmid can be re-circularised. T4 DNA ligase and associated buffer were purchased 
from New England Biolabs® and were used according to the manufacturers’ 
specifications. 
 
 
 
 
94 
 
Typical ligation reaction: 
Template DNA (PCR + restriction)    40 µL 
T4 DNA ligase      2 µL 
Ligase Buffer (10X)     5 µL 
dH2O       3 µL 
Ligation reactions were incubated at room temperature for 3 hours or overnight at 4
 
°C. 
This ligated plasmid can then be used in transformations into competent cells. If the 
amount of template DNA is less than 40 µL, the volume is adjusted using dH2O. 
 
 
2.15 Transformations 
2.15.1 Preparation of highly Competent Cells 
The Rubidium Chloride (RC) method: 
This method was first described by Hanahan (1985) and is in brief; 5 mL of LB, with 
antibiotics as appropriate, was inoculated with a single colony of the relevant bacteria 
(JM109 and KRX E. Coli strains) and left to grow overnight at 37 °C in a shaking 
incubator at 200 rpm. 2 mL of the overnight culture was then added to 200 mL of LB in 
a 1 L flask and placed back in the shaking incubator at 37 °C and 200 rpm. The culture 
was allowed to grow to an OD600 of ~0.5 (early-mid exponential phase). Once OD600 is 
reached the flask is removed from the shaker and placed on ice for 10 minutes to cool. 
All of the following steps took place at 4 °C. The culture was spun down at 5,000 rpm 
for 5 minutes to pellet the cells. The supernatant was decanted off and the cell pellet was 
very gently re-suspended in 75 mL of 4 °C RC buffer 1 (see section 2.3). Once re-
suspended the suspension was left on ice for 90 minutes. The cells were again collected 
by centrifugation at 3,000 rpm for 5 minutes. The supernatant was again decanted off 
and the pellet was gently re-suspended in 10 mL of 4 °C RC buffer 2 (see section 2.3). 
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The cell suspension was separated into 400 µL aliquots in sterile 1.5 mL microfuge 
tubes. These were flash frozen using a metal block which had already been cooled down 
to -80 °C. The competent cells were then stored at -80
 
°C until use.  
 
2.15.2 Transformation of Competent Cells 
A 400 µL aliquot of competent cells were removed from the -80
 
°C freezer and thawed 
on ice until fully defrosted. 200 µL of competent cells were mixed with plasmid DNA or 
ligation reaction. 2-5 µL of DNA was used depending on the concentration in 
nanograms of DNA. The mixture was then kept on ice for 30 minutes. After 30 minutes 
the mixture was subjected to a heat shock at 42
 
°C in a water bath for 45 seconds and 
quickly returned to ice for 2 minutes. 800 µL of LB broth or SOB media were added 
aseptically and statically incubated at 37
 
°C in a water bath for 1 hour. After 1 hour, 200 
µL of the mixture was removed and aseptically spread on an LB agar plate, containing 
the relevant antibiotics if necessary. The remaining 800 µL was concentrated by 
centrifugation at 13,000 rpm for 2 minutes. The supernatant was discarded and the pellet 
was re-suspended in 100 µL fresh LB and spread on an agar plate also. The plates were 
then incubated upside down overnight at 37
 
°C. 
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2.16 Standard expression culture 
2.16.1 Protein expression for large scale purification 
An LB plate with the appropriate antibiotic was streaked from a glycerol stock or single 
colony from a spread plate of the strain containing the expression plasmid. These plates 
were streaked for single colonies and incubated upside down overnight at 37 °C. One 
colony was then selected to inoculate 5 mL of LB broth containing the appropriate 
antibiotic. The culture was then grown at 37 °C overnight in a shaker at 200 rpm. While 
this culture is growing overnight a 1 L flask with 200 mL of TB broth is also incubated 
shaking at 37 °C overnight to insure the TB is free of contaminants. After both have 
grown overnight and the TB is proven to be contaminant free, 2 mL of the overnight 
culture is added to the 200 mL TB, this is a 1% (v/v) inoculation. This is again placed in 
the 37
 
°C shaker and allowed to grow for 2-3 hours to allow the OD600 reach between 
0.4-0.6, confirmed using a spectrophotometer (model number). Once this OD600 has 
been reached the culture is induced using isopropylthio-β-galactoside (IPTG). IPTG was 
added to a final concentration of 50 µM to induce expression of the desired protein. This 
culture was then allowed to grow at 30 °C overnight after IPTG had been added. This 
culture was then added to a sterile centrifuge tube and spun down at 5,000 rpm for 10 
minutes to pellet the cells. The supernatant was removed, autoclaved and then discarded. 
The pellet can be processed immediately or stored at -20 °C for future use.  
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2.16.2 Small scale protein expression to identify viable colonies 
Before growing up a larger culture, the starter colony must be screened for maximum 
expression. Colonies were re-streaked from a transformation plate for single colonies. 10 
colonies were streaked onto 10 separate plates for single colonies. All of these colonies 
were then tested to calculate protein expression. An overnight culture using TB, 1 M 
phosphate buffer, ampicillin (100 µg/ml) and IPTG (50 µg/ml) was made to a final 
volume of 8 mL. These overnight cultures were inoculated with a single colony and 
incubated at 37 °C overnight. The following equation was used; 
0.7/OD600 x 300 = volume of culture in µL to be harvested 
This equation was used to ensure all samples had the same number of cells. The samples 
were all run on a 15% resolving SDS-PAGE gel. Due to each sample containing the 
same number of cells, the protein bands are directly comparable to each other and a 
specific clone is selected.  
 
2.17 Preparation of cleared lysate for protein purification 
2.17.1 Cell Lysis by Sonification 
A cell pellet from 200 mL expression culture (see section 2.16) was re-suspended in 80 
mL lysis buffer containing 20 mM imidazole, pH 7.6 (see section 2.3). The cells were 
disrupted with a 3 mm micro-tip sonicator (Sonics & Materials Inc.) using 2.5 s, 40 kHz 
pulses for 60 seconds. This step was carried out three times. The lysate was then 
centrifuged at 5,000 rpm for 20 minutes at 4 °C (using a GSA rotor) to pellet any 
insoluble material. The cleared lysate was then transferred to a fresh container. The 
lysate was vacuum filtered through a Whatman type 1 filter (0.11 µm). The filtered 
lysate is stored at 4 °C for protein purification. 
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2.17.2 Cell Lysis by Cell disruption 
A cell pellet from 200 mL expression culture (see section 2.16) was obtained. The pellet 
was re-suspended in 80 mL of 20 mM imidazole lysis buffer with 0.01% anti-foam. The 
cells were fully homogenised in this buffer. This solution was disrupted using a constant 
systems cell disruptor at 15 kpsi (15 kpsi is suggested for E. coli disruption). The sample 
is collected and run through the cell disruptor for a second time to ensure total lysis. 
After the second disruption, 50 mL of 20 mM imidazole lysis buffer was run through the 
machine to ensure the entire sample was retrieved. The lysate was then added to a high 
speed centrifuge tube. The lysate was centrifuged at 13,000 rpm for 40 minutes to pellet 
the insoluble material. For this project the protein was soluble and was found 
predominantly in the cleared lysate. The cleared lysate was then filtered through a 
Whatman type 1 filter (0.11 µm filter). The filtered lysate is stored at 4 °C for protein 
purification.  
 
2.18 Purification of recombinant protein 
Immobilised Metal Affinity Chromatography (IMAC) was used to purify the 
recombinant proteins as they contained an N terminus poly histidine tag (His6). The 
principal behind IMAC is that the protein will form a covalent bond with the metal ions. 
The metal ions used were Ni
2+
 and this metal has a high affinity for histidine residues. 
The type of resin used in this project was HyperCell™, supplied by Pall Life Sciences. 
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2.18.1 IMAC purification 
Charged resin (see section 2.18.2) is stored in 20% (v/v) industrial methylated spirits 
(IMS). The resin was washed with 10 column volumes (CV) of dH2O. The column was 
then equilibrated with 10 CV’s of lysis buffer containing 20 mM imidazole (see section 
2.3). Once the column was prepared the filtered lysate (see section 2.17) was gently 
added to the nickel-nitrilotriacetic acid resin (Ni-NTA). During this step all the His6 
tagged protein will bind to the resin and the other cellular proteins will be collected in 
the flow through. Some proteins with high levels of surface histidine may also bind to 
the resin. The column was then subjected to various wash steps with lysis buffer 
containing 10 mM, 20 mM, 50 mM and 80 mM imidazole. These wash steps cause any 
other proteins with weaker, non-specific binding to be washed off. To elute off the 
recombinant protein various concentrations of imidazole were used. These 
concentrations varied from 125 mM – 500 mM depending on the protein. A lysis buffer 
containing 250 mM imidazole was typically used. Five CV’s of elution buffer were used 
to elute the bound protein. The eluted protein was collected in 1 mL fractions. These 
fractions were tested using SDS-PAGE to identify which fractions have the highest 
purity and concentration of protein. The fraction (or fractions) with the highest 
concentration of protein will be buffer exchanged to concentrate the protein in a smaller 
volume into a buffer which would not damage the protein. 
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2.18.2 Stripping and Recharging the IMAC Resin 
The resin was stripped and recharged every 5 uses to maximise protein retention. The 
resin was first washed with 2 CV of dH2O followed by 2 CV of 50% (v/v) ethanol or 
IMS. The resin was then stripped of any metal ions by washing with 2 CV of 100 mM 
EDTA, pH 8.0. Any remaining impurities on the resin were removed with 2 CV of 200 
mM NaCl and rinsed with 2 CV of dH2O. This was followed by a 10 CV wash with 30% 
(v/v) isopropanol over the 30 minutes. The resin was then again washed with 10 CV of 
dH2O and recharged with 1 CV of 100 mM NiSO4. Finally, the column was washed with 
10 CV of dH2O and stored in 20% (v/v) IMS. 
2.19 Buffer exchange/ Desalting of purified protein 
2.19.1 Buffer exchanging samples from imidazole to PBS using 
VIVASPIN columns 
After each fraction was collected using IMAC the samples that contained the highest 
level of pure protein were buffer exchanged into PBS. This buffer exchange was carried 
out using a special type of microfuge tube and filter, a VIVASPIN 500 manufactured by 
Sartorius Stedim. The sample was added in 500-800 µL volumes and centrifuged at 
13,000rpm for 7-10 minutes. This step was repeated until all the fractions containing 
relevant purified protein have been centrifuged through the filter column. Each time the 
flow through was discarded and the column was placed back inside the collection tube 
for further centrifugation. 700 µL of PBS was used to wash through and again this is 
centrifuged at 13,000rpm for 7-10 minutes. This step was repeated three times. PBS 
washes were used to ensure all imidazole was removed from the sample. Once the 
sample was washed through thrice, it is re-suspended in PBS and transferred to a sterile 
1.5 mL microfuge tube. Protein samples were stored at 4 °C, -20 °C and -80 °C.  
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2.19.2  Buffer exchanging samples from imidazole to PBS using dialysis 
tubing 
Alternatively to section 2.19.1, VIVASPIN columns are not always the optimal choice 
for buffer exchanging and dialysis was used as an alternative protocol. To prepare 
dialysis tubing, strips of dialysis tubing (Sigma D9777) were cut and boiled for 30-60 
minutes and then left in 100 mM EDTA at 4
 
°C for short term storage. Before use each 
piece of tubing was washed out with dH2O. The IMAC fractions containing the highest 
concentration of protein were pooled and added to the tubing and sealed. The sealed tube 
was then added to a 5 L beaker of 1x PBS and left for 24-48 hours. If a large sample was 
used in the dialysis tubing, the 5 L of PBS was removed after 24 hours and fresh PBS 
was added. After buffer exchange has occurred the tubing is removed from PBS and 
placed on polyethylene glycol (PEG). This PEG step concentrated the sample and 
reduced the total volume of the sample. The tubing is left on PEG for 1-2 hours. After 
this time the tubing is cut open and the sample is transferred to microfuge tubes and 
stored at -20
 
°C for short term storage or -80 °C for long term storage. 
 
2.20 Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE) 
All protein samples were analysed via SDS-PAGE. Various percentage resolving gels 
were employed. Typical esolving gels were; 10% (v/v), 15% (v/v) or 20% (v/v) 
acrylamide. A 4% (v/v) stacking gel was also used for the loading of samples. The 
recipes were as follows; 
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     10%  15%  20%  4% 
30% Acrylamide (mL)  2.5  3.75  5  0.325 
H2O (mL)    3  1.75875 0.5  1.54 
1.5M Tris-HCl pH 8.8 (mL)  1.875  1.875  1.875  - 
0.5M Tris-HCl pH 6.8 (mL)  -  -  -  0.625 
10% APS (µL)   37.5  37.5  37.5  12.5 
10% SDS (µL)   75  75  75  25 
Temed (µL)    3.5  3.5  3.5  2.5 
Temed is the last solution to be added to the mixture. Once temed is added the gel must 
be poured. All percentages are (v/v). 
 
2.20.1 Sample preparation 
To prepare a sample to be run on a SDS-PAGE gel some SDS-PAGE loading dye must 
be added to the sample. 18 µL of the sample was mixed with 2 µL of 10X SDS-PAGE 
sample buffer (see section 2.3). The samples were then boiled at 100
 
°C for 5 minutes. 
The β-mercaptoethanol present in the loading dye and the boiling of the mixture work in 
unison to denature and unfold the protein. 
 
2.20.2 Sample Application 
15 µL of each sample were added to each well, while one well is retained for the relative 
molecular weight protein marker (Broad range protein marker, NEB). 15 µL of the 
ladder was added to the reserved well. If the gel was to be used for Western Blot 
analysis pre-stained protein markers were used (PageRuler™ Plus pre-stained Protein 
ladder, 10-250 kDa, Life technologies and Expedeon Runblue prestained dual colour 
marker, see figure 2.4).   
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(a)                             (b)   (c)   (d) 
        
Figure 2.4: broad range protein markers: (a) Broad range protein marker 2-212 kDa, 
NEB (image obtained from www.neb.com), (b) PageRuler Plus pre-stained protein 
ladder, Life technologies (image obtained from www.lifetechnologies.com), (c) Expedeon 
Runblue prestained dual colour marker (NXA05160), (d) Color-coded Prestained 
Protein Marker, Low Range (1.7-42kDa), Cell Signaling Technology®. 
 
2.20.3 SDS-PAGE gel electrophoresis 
Once the wells have been loaded with sample, the gel was run on an Atto AE-6450 
vertical gel apparatus connected to a Labnet Power Station™ 300 power supply. Initially 
each gel was run at 15 mA for 15 minutes to allow the sample migrate out of the well 
and through the 4% stacking gel. The ampage was then increased to 30-35 mA per gel 
for 50-75 minutes to allow the sample separate out in the resolving gel. Once the 
tracking dye has run off the gel the electrophoresis apparatus is stopped and the gel was 
removed for staining.  
 
kDA 
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2.20.4 Gel visualisation 
Polyacrylamide gels were removed from the electrophoresis chamber and first washed 
with dH2O. The gels were then stained with Coomassie blue stain solution (see section 
2.3) for 1-2 hours. The stain was then removed and the gels were washed again with 
dH2O. Coomassie blue de-stain solution (see section 2.3) was then added and left 
overnight to de-stain the gel. Further de-stain solution may be added if the gel has not 
fully been de-stained. Once de-stain is removed the gel was washed one more time with 
dH2O and then stored in dH2O and an image was taken.  
 
2.21 Protein Quantification 
Protein quantification was carried out using two methods. The first method used was a 
bicinchoninic acid (BCA) assay. This is a colormetric method where the reagent used 
will bind to the protein in the sample and a change in colour is observed proportional to 
the protein concentration. The other method used was quantification by 
spectrophotometry. Using absorbance readings at 280 nm, the protein can be quantified 
based on its ability to absorb ultraviolet (UV) light.  
 
2.21.1 Protein quantification using BCA assay 
Once the protein samples have been run on an SDS-PAGE gel and buffer exchanged 
(see sections 2.19 and 2.20), the protein must be quantified. The Pierce™ BCA Protein 
Assay Kit (Thermo Scientific 23227) was used to accurately quantify the total protein in 
the sample. The kit was used in accordance with the manufacturer’s instructions. The 
BCA working reagent (WR) was created by mixing reagent A with reagent B (50:1). 
This assay was carried out using a 96 well microplate (F96 MAXISORP NUNC immune 
plate) where 200 µL of WR was added to 25 µL of protein sample or BSA standard and 
repeated in triplicate. The BSA standards were made up in a working range of 20-2,000 
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µg/mL. The 96-well plate was placed on a shaker for 30 seconds to ensure the contents 
of the wells were thoroughly mixed and the plate was then incubated at 37
 
°C for 30 
minutes. After 30 minutes the plate was removed from the 37 °C incubator. The 
absorbance was measured at a wavelength of 570 nm (the suitable range is 540-590 nm) 
using a BioTek ELx808 plate reader. A standard curve was created using the BSA 
standards and its linear trend line equation was used to calculate the protein samples 
concentration.  
 
2.21.2 Protein quantification using 280nm readings 
Protein samples were spun down at 13,000 rpm for 10 minutes to remove any debris that 
may be in the solution. The UV lamp on the spectrophotometer was set to 280 nm and 
was blanked using the same buffer the protein was stored in. Protein samples were read 
in triplicate and an average absorbance was determined. The concentration of the protein 
was then calculated using the Beer-Lambert law; 
A = ɛcl 
Beer-Lambert law used to determine protein concentration using 280 nm 
absorbance readings. A = absorbance, ɛ = extinction coefficient of individual protein, c 
= concentration (in units corresponding to ɛ) and l = path length (cm). 
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2.22 Biotinylation of recombinant proteins 
The Thermo Scientific EZ-Link® Sulfo-NHS-LC-Biotin kit (21327) was used to 
biotinylate recombinant proteins. N-Hydroxysuccinimide (NHS) activated biotins react 
with primary amine groups, -NH2, in pH 7-9 buffers and form stable amide bonds. 
Biotin is a useful label as it is small, 244 Da, and can be conjugated to many proteins 
without altering their biological activity. 
The kit was used according to the manufacturer’s instructions. The biotin was removed 
from the freezer and a 10 mM biotin solution was prepared by adding 180 µL of dH2O 
to 1 mg of biotin in a microtube. Equation 3 was used to calculate the amount of biotin 
to add for a 20-fold molar excess which was then used, in equation 4, to calculate the 
volume of biotin to add. 
 
Biotin mmol =
protein mmol
Biotin mmol 20
x 
protein mg
protein mmol
x  
protein mL
protein mg
  protein  xmL  
 
Biotin μL =
mmol 10
L
 x
L
μL 1,000,000
 Biotin  x   mmol       
 
The appropriate volume of biotin was added to the protein and incubated on ice for 2 
hours or at room temperature for 30 min. The sample was buffer exchanged, to remove 
excess biotin, and concentrated using a 10,000 Da molecular weight cut off (MWCO) 
spin column, see Section 2.19. 
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2.23 Enzyme Linked Lectin assay  
50 µL of a glycoprotein solution, at a concentration of 5 µg/mL in PBS, was added to 
the wells of a NUNC Maxisorp 96 well plate. The plate was incubated at 4
 
°C overnight 
to allow protein bind to the plate. The unbound glycoprotein was removed by inversion 
and tapping onto blotting paper towel, then the plate was blocked using 150 µL of a 
0.5% polyvinyl alcohol (PVA) solution for 2 hours at 25
 
°C. The plate was then washed 
four times using TBST. 50 µL of 5 µg/ml lection solution, diluted in TBS containing 1 
mM CaCl2, was then added to the plate and incubated for one hour at 25
 
°C. The plate 
was then again washed four times with TBST. 50 µL of a HRP-labelled murine anti-
biotin or anti-histidine antibody, diluted to 1:10,000 in TBST, was added to each well. 
The plate was further incubated for one hour at 25
 
°C. Following this incubation step the 
plate was washed four times with TBST. The assay was developed by adding 100 µL 
TMB solution to each well and left to react for 3 - 10 minutes. The reaction is then 
stopped by adding 50 µL of 10% H2SO4. The absorbance was measured at 450 nm using 
a BioTek ELx808 plate reader. Each lectin was probed in triplicate and an average was 
taken over the three wells to get the final absorbance reading. The standard deviation of 
these triplicates is then calculated and used to create error bars and the ELLA data were 
presented in a bar chart format.  
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Figure 2.5: Schematic of an ELLA. The ELLA follows the same principal of an 
anzyme linked immunosorbent assay (ELISA). The glycoprotein target is placed on the 
surface of the plate and probed with a labelled lectin which is detected colormetrically at 
a wavelength of 450 nm. The image was obtained from Thompson (2011). 
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2.24 Lectin specificities   
Lectin Name Specificity 
AAL α-1-6-Fucose 
UEA I α-1-2-Fucose 
Con A Core mannose 
RCA Terminal β-galactose / lactosamine 
Jacalin T-antigen / β-1,3-N-acetylgalactosamine 
GSL I α-N-acetylgalactosamine / α-galactose 
GSL II Terminal GlcNAc 
WGA GlcNAc, NeuNAc 
MAL I Galactose ((β-1,4) N-acetylglucosamine 
MAL II α-2,3-NeuNAc 
SNA α-2,6-NeuNAc 
ECL Galactosyl (β-1,4) N-acetylglucosamine 
SBA Terminal GalNAc 
HPA GalNAc, Tn antigen, GlcNAc 
DBA Terminal GalNAc 
GNL  Terminal mannose / high mannose 
PNA β-1,3-galactose 
LCA α-linked mannose  
NPL α-linked mannose, α-1,6-mannose 
DSL β-1,4-GlcNAc (oligomers preferred) 
Table 2.5: Specificities of eukaryotic lectins. All commercial lectins were purchased 
from Vector Labs. Vector Labs supplied information for what buffers and ions were 
needed for each individual lectin, as well as stating the free sugar need to inhibit binding 
and the required concentration to inhibit. 
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Lectin Name Specificity 
LecA (PA-IL) α-galactose 
LecB (PA-IIL) Fucose, mannose 
AAL-2 GlcNAc 
Table 2.6: Specificities for prokaryotic lectins. As generated in this project. 
2.25 Routine cell culture, seeding/ reseeding cells and cell stocks 
2.25.1 Taking Adherent Cells from stock 
A vial of the desired cells was removed on ice from liquid nitrogen storage. An aliquot 
of supplemented RPMI media (Section 2.2) was incubated until its temperature reached 
37
 
°C prior to use. 1 mL of the cell stock is added to 4 mL of pre-incubated media. This 
cell mixture was centrifuged at 300 g for 5 minutes to collect a cell pellet. The 
supernatant was removed and the cells were re-suspended in 15 mL of supplemented 
RPMI. This 15 mL cell suspension was added to a T-75 flask (TC Flask T75, Cell+, 
Vented Cap, Sarstedt) and placed in a 37
 
°C static incubator to allow cells to grow and 
proliferate. SW480/SW620 cell lines are between passage numbers 60-70. Cells were 
passaged a maximum of 15 times before a new stock was used.  
2.25.2 Culturing, reseeding and stocking Adherent Cells 
Mammalian cells were cultured in supplemented RPMI media (see section 2.2). Media, 
Trypsin-EDTA (Trypsin-EDTA solution, Sigma) and sterile PBS were pre-incubated at 
37
 
°C for 30 minutes prior to use. A flask containing cells at 75-90% confluency was 
removed from the incubator, sprayed with 70% IMS and placed in the sterile laminar 
flow hood. The spent media was taken off and placed in a waste vial and the cells were 
washed with pre-incubated sterile PBS for 5 minutes. This wash step removes any dead 
cells and trypsin inhibitors that may be left over from the spent media. 5 mL of 0.5% 
trypsin-EDTA was added to the flask and the flask was placed back in the static 
incubator at 37
 
°C for 5-10 minutes. Once the cells had visably detatched from the 
bottom of the flask, the flask was then removed from the incubator, again sprayed with 
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70% IMS, and placed in the laminar flow hood. 5 mL of supplemented media was added 
to the flask to inhibit the trypsin-EDTA solution. This mixture was removed from the 
flask and placed in a sterile 25 mL tube. The cells were collected by centrifugation at 
1,000 rpm for 5 minutes. The supernatant was removed and the cells were re-suspended 
in 5 mL of media. A cell count (Section 2.25.3) was performed and cells were re-seeded, 
at a concentration of 5 x 10
5
 cells in 15 mL of supplemented media, into a fresh T-75 
flask. These cells were left to proliferate for 2-3 days before re-culturing and seeding.  
To create a cell stock, a T-75 flask of 75-90% confluency was cultured. Once the cell 
pellet was collected and the supernatant removed, the cells were re-suspended in 5 mL 
of cell freezing stock solution (see section 2.3). 1 mL aliquots were produced containing 
approximately 10
6
 cells. These stocks were stored in liquid nitrogen.  
2.25.3 Performing a Cell Count 
A cell count is performed using a cell haemocytometer; 
(a)                                                                              (b) 
           
Figure 2.6: Haemocytometer. A haemocytometer is used to accurately count the total 
cell number in a cell suspension (image obtained from www.phe-
culturecollections.org.uk). (a) total haemocytometer, (b) middle section of the 
haemocytometer. 
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A cell count is carried out on the re-suspended cells detailed in section 2.26.2. 100 µL of 
the cell mixture is mixed with 10 µL of Trypan blue (trypan blue solution, Sigma) in a 
sterile microfuge tube. 20 µL of this mixture is added to the haemocytometer capillary 
tube and, in unison with the cover slip, the mixture migrates into the chamber. This 
mixture can now be viewed in the middle section of the haemocytometer under a 
microscope at 40x magnification. Each smaller grid in the centre chamber is 4 x 4 
squares and is part of a larger 5 x 5 square grid. A total cell count of each of the 25 
squares was performed in order to calculate accurately the total cell number in solution. 
Cells with an intact membrane, i.e. live cells, will not allow trypan blue stain their 
nucleus while any damaged cells encountered will appear blue.  
Cell Viability; number of healthy / healthy + unhealthy cells = % cell viability. 
Cell Count; middle chamber count x dilution factor x 10
4
 = cell number per mL. 
Once a cell count has been performed the cells can be re-seeded in a T-75, 6 well plate, 
12 well plate, 96 well plate or collected in a microfuge tube for further analysis.  
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2.26 Fluorescent Microscopy for live cell analysis 
Cells were seeded at a concentration of 50,000 cells per well in a 6 or 12 well plate 
coated for adherent cells (see section 2.25.2). 3 mL of supplemented media containing 
the cells were added to each well and allowed to proliferate overnight. The following 
day the 3 mL of spent media was removed and the cells were washed 3 times with pre-
incubated sterile PBS to remove all traces of media, which contained serum. The cells 
were not fixed using any fixative agent. The cells were then probed with lectins (Vector 
Laboratories®), coupled with/or pre-incubated with a fluorescent dye (dyelight-488), 
and were incubated for 30-60 minutes. The lectins were used at 5-10 µg/mL. The plates 
were statically stored at room temperature, in the dark. After the incubation time the 
cells were again washed 3 times with pre-incubated sterile PBS. Finally 1 mL of PBS 
was added to each well before the cells were to be viewed under the microscope. Prior to 
being viewed under the microscope one drop of NucBlue® is added to each well as a 
nucleic acid counter-stain. NucBlue® Live ReadyProbes® Reagent was purchased from 
Thermo Fisher Scientific and was used according to the manufacturers’ specifications. 
The microscope used was the Nikon Eclipse Ti. The Nikon Eclipse Ti has three 
fluorescent filters, FITC (green), DAPI (blue) and TRITC (red). NucBlue® fluoresces in 
the blue channel, therefore red or green fluorophores are used for the lectins used.  
The experiments for fluorescent microscopy were repeated 3 times, with the exception 
of the inhibiting sugar controls that were repeated twice. The images are purely 
qualitative and were repeated in order to identify positive and negative lectin binding 
and not to compare lectin binding between cell types. Each image represents one 
experiment. 
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2.27 FluoroFire-Blue ProViaTox Assay 
Similar to an MTT assay the FluoroFire-Blue ProViaTox assay measures cell viability. 
This assay utilizes the redox dye resazurin, which is not fluorescent, but upon reduction 
by metabolically active cells, a highly fluorescent product is formed. Any living cells 
can readily reduce this non-toxic reagent and the resulting fluorescent intensity can be 
monitored using a plate reader.  
2.27.1 FluoroFire Blue Assay 
 A cell count is performed (see section 2.23.3) and the total number of cells per mL was 
worked out. A serial dilution of cells in supplemented media is plated out, in triplicate, 
on a 96 well plate coated for adherent cells. The serial dilution begins at approximately 
500,000 cells per mL and is diluted 1:2 for each of the first 11 wells. Well 12 contains 
no cells as a negative control. 200 µL of cells in media at a concentration of 500,000 
cells per ml was loaded into well 1. 100 µL of fresh supplemented media was added to 
each of the corresponding wells. 100 µL from well 1 is removed and added to well 2 and 
gently mixed. This process was continued until the serial dilution was complete and 100 
µL of cell suspension in well 11 was discarded to leave each well containing 100 µL 
total volumes. Incubate the 96 well plate for at least 1 hour to allow cells to adhere to the 
plate. Suspension cells do not require an incubation time. After incubation add 20 µL of 
FluoroFire-Blue solution and incubate at 37
 
°C for 3-5 hours, in a humidified, 5% CO2 
incubator. An absorbance reading is taken every 90 minutes at two different 
wavelengths, 570 nm and 600 nm. The resulting data can be plot onto a graph and the 
cellular viability can be worked out using the equation given by the suppliers.  
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% Reduction of the FluoroFire Blue ProViaTox assay reagent = 
(Eoxi600 x A570) – (Eoxi570 x A600) x100 
(Ered570 x C600) – (Ered600 x C570) 
 Eoxi570 = molar extinction coefficient (E) of the oxidized FluoroFire Blue ProViaTox 
assay reagent at 570 nm = 80586 
Eoxi600 = E of the oxidized FluoroFire Blue ProViaTox assay reagent at 600 nm = 
117216 
A570 = absorbance of test wells at 570 nm 
A600 = absorbance of test wells at 600 nm 
Ered570 = E of reduced FluoroFire Blue ProViaTox assay reagent at 570 nm = 155677 
Ered600 = E of reduced FluoroFire Blue ProViaTox assay reagent at 600 nm = 14652 
C570 = absorbance of negative control well (media + reagent, no cells) at 570 nm 
C600 = absorbance of negative control well (media + reagent, no cells) at 600 nm 
 
2.27.2 FluoroFire Blue assay using Lectin Probes                     
A serial dilution to determine lectin toxicity on cells was also performed using the 
FluoroFire Blue assay. The protocol explained in 2.24.1 was followed with this 
additional step. Starting at a concentration of 100 µg/mL, the lectin was diluted 1:2 
through 11 wells, with well 12 having no lectin as a negative control.  The lectin range 
therefore was 0-100 µg/mL. Each well will now contain 5,000-10,000 cells and the 
serial diluted lectin in supplemented or serum free media at a final volume of 100 µL. 20 
µL of FluoroFire Blue reagent was then added to the 100 µl and the equation used in 
section 2.27.1 was implemented to show cell viability after 3-5 hours.  
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2.28 Flow Cytometry for live cell analysis 
Flow cytometry is the study of cells using a flow cytometer to visualise individual cells. 
The flow cytometer used is the FACs Aria 1.0. Thousands of cells can be processed 
through the system per minute, and each cell was interrogated by the lasers individually. 
The lasers measure forward scatter, side scatter and there are fluorescent lasers that can 
measure fluorophores at a variety of wavelengths. Forward scatter measures the size of 
the cell while side scatter measures the internal complexity.  
2.28.1 Sample preparation 
A cell count is performed (see section 2.25.3) and the total amount of cells per mL was 
calculated. Cells had been cultured for 48 hours prior to experimentation. Typically, 
each tube for flow cytometer analysis contained 300,000-500,000 cells. Epindorfs 
containing the cells were spun down at 300 g for 5 minutes to pellet the cells. After the 
cells have been pelleted, the supernatant is removed and the cells are re-suspended and 
washed in 200 µL of sterile PBS. The cells are again spun down at 300 g for 5 minutes 
to pellet the cells. The supernatant was removed and the cells were probed with either a 
fluorescently tagged antibody or lectin probe. All the lectins were biotinylated and pre-
incubated with a streptavidin-linked fluorescent dye.  The concentration of lectin used 
was 5 µg/mL diluted in TBS, containing 1mM CaCl2, and the concentration of antibody 
used is in accordance with the data sheet provided by the supplier. The cells were 
statically incubated in the dark at room temperature for 20-30 minutes. The cells were 
again spun down at 300 g for 5 minutes and the supernatant was removed. The cells 
were re-suspended in 500 µL of PBS or TBS and were ready to be processed the flow 
cytometer. 
Four different controls were prepared to accurately assess lectin binding; (i) TBS + 1 
mM CaCl2 only, (ii) TBS + 1 mM CaCl2 with DyLight-488 only, (iii) TBS + 1 mM 
CaCl2 with Dylight-488, lectin and inhibitory sugar, (iv) TBS + 1 mM CaCl2 with 
Dylight-488, lectin and non-inhibitory sugar. 
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2.28.2 Sample interrogation and acquisition 
The flow cytometer was turned on and set up for acquisition of cells. All the lasers 
needed for the specific fluorophores used are turned on. The cytometer is set up in 
accordance with the protocol distributed by manufacturer, FACS Aria 1.0 protocol. 
Once the cytometer has connected and fluidics is turned on, a new experiment is opened 
using FACs DIVA software on the associated computer. The parameters are set for the 
specific samples, i.e. if the FITC channel is only required then remove all other channels 
from the parameters. The flow rate was to 2 or 3 and the sample was loaded. The 
voltages for forward scatter, side scatter and the desired fluorescence channel were set. 
The voltages were set to ensure all cells were visible in the dot plots and histograms that 
were produced. Dot plots for forward scatter area versus side scatter area, as well as 
forward scatter area versus forward scatter height were selected. Histograms measuring 
fluorescent intensity were also selected. Once the voltages were correctly set up and all 
the cells were be visualized, the sample acquisition was recorded. The amount of cells 
recorded was 10,000. Experimental files were saved and exported as FCS3.0 files for 
later analysis.  
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2.28.3 Flow cytometric data analysis and gating strategy 
Flow cytometry data, FCS3.0 files, were opened and analysed using FlowJo. Each FCS 
file holds the information for a single sample tube. A workspace was created in FlowJo 
to analyse files from a single experiment or multiple experiments. Within the workspace 
samples were grouped and sorted based on various attributes, permitting operations to be 
performed on every sample in a group. The gating strategies implemented were 
manually applied and followed guidelines set out by Herzenberg et al. (2006). 
The gating strategy outlined in figure 2.8 was applied to all data throughout the project. 
Dead cells and cellular debris can be gated out of the cell population using side scatter 
area (SSC-A) versus forward scatter area (FSC-A), while the exclusion of cell doublets 
can be gated out using FSC-H versus FSC-A. Gates were originally constructed around 
the unstained/unprobed cell populations. This removed dead cells and debris from the 
sample that has not been probed with anything, i.e. lectins or antibodies. This gate was 
then applied to all subsequent samples. A histogram was created showing the 
fluorescence intensity recorded in the FITC-A channel of unstained cells. A single peak 
was typically observed as these cells have very little to no fluorescence intensity; this 
histogram was used to separate FITC positive and FITC negative populations. The FITC 
positive/negative gate was constructed against the unstained cell population, as this 
unstained population was used as the baseline value for positive and negative intensity. 
This gating permits the percentage of positive versus negative intensities to be 
determined. This gate was also applied to all histograms of cells probed with lectins to 
determine the percentage of positive and negative populations. This can be seen in figure 
2.8 images D-F. 
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Figure 2.7: Flow cytometry data gating strategy for SW620 cells. A) Raw data, side 
scatter area versus forward scatter area bivariate plot (dot plot) of unstained cells, B) 
‘Live’ cell gate constructed around cell population of unstained cells, 88.4% of all cells 
are inside this gate shown on the top left of the plot, C) The live cell gate constructed 
around unstained cells is applied to cell populations probed with the lectin ConA, 58.3% 
of all cells are inside this gate shown on the top left of the plot, D) Univariate plot 
(histogram) of fluorescent intensity (FITC-A channel) of unstained cells in the live gate, 
E) Histogram of fluorescent intensity (FITC-A channel) of live cells gated for positive 
and negative populations in the unstained sample, percentage of each population 
observed in each top corner of the plot, F) The same positive and negative gates from E 
have been applied to the live gate for cells probed with the lectin ConA, percentage of 
each population observed in each top corner of the plot. 
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Once the gating strategy was completed and applied to all samples, a table was 
generated using FlowJo. This table (table 2.7) shows the percentage of cells within the 
live gate in a given sample, the percentage of FITC positive and FITC negative cells in a 
given sample and the overall mean fluorescent intensity value for FITC-A. This data is 
graphed in a bar chart format to complement histogram plots. 
 
Sample % in Live Gate % Negative % Positive Mean fluorescent intensity 
Unstained 88.4 99.9 0.01 3.7 
ConA 46.1 0.98 99 2545 
Jacalin 48.4 9.43 90.6 2318 
NPL 72.3 0.092 99.9 1185 
GSL II 83.6 99.7 0.026 10.5 
LecB 49.9 1.22 98.8 800 
Table 2.7: Flow cytometry sample data for surface lectin binding to SW480 cells. 
For each sample, 10,000-15,000 events were recorded in triplicate. This table represents 
the percentage of cells in the live gate, positive/negative gate and the mean fluorescent 
intensity of the FITC measure over the whole population in the live gate, i.e. positive 
and negative cells.  
 
The percentage of events inside the live gate for each sample is indicative of the 
cytotoxic effect that some lectins have on cells. For unstained cells, they are routinely 
between 80-90% viability inside the live gate. Some lectins, such as ConA, will 
significantly reduce the cell number inside the gate (46.1%), where as some lectins, such 
as NPL, will only have a negliable effect on the cell number inside the gate. This is 
observed in table 2.7. 
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2.29 DNA and Protein Databases 
A number of online databases and programs were used to analyse DNA and protein 
sequences.  
2.29.1 ExPASy 
Expasy allows a nucleotide sequence to be copy and pasted into a window to translate it 
to a protein sequence. Expasy provides information on each reading frame and indicates 
which reading frame is correct. Protein sequences can then be run in another program to 
analyse sequence homology and orthology. The protein sequence can also be used in 
alignment programs to compare with other sequences. 
Weblink: http://web.expasy.org/translate/ 
 
2.29.2 BLASTn and BLASTp 
Basic Local Alignment Search Tool (BLAST) is a bioinformatics system that can 
compare DNA and protein sequences with the sequence library database. A BLASTn is 
used for nucleotide sequences and BLASTp is used for protein sequences. Once the 
sequence is input it is compared to all sequences in the database and a percentage 
sequence similarity will be given. The program can search all databases or specific ones, 
i.e. human only or human, mouse and rabbit. BLAST will analyse sequence homology 
and orthology with other sequences in the database. 
Weblink: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch 
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2.29.3 Multalin 
Multalin is an online alignment program. It can align DNA and protein sequences 
inputted in a FASTA format. Multalin can align a large number of sequences and also 
produce a consensus sequence, i.e. two sequences contain the same nucleotide at 
position 33 and the third sequence contains a different nucleotide at position 33, the 
consensus will show the more common nucleotide in the reference sequence.  
Weblink: http://multalin.toulouse.inra.fr/multalin/ 
2.29.4 PyMOL 
PyMOL is an open source protein molecular visualization system. PyMOL can produce 
high quality 3D images of proteins from protein sequences. PyMOL can also create 3D 
models of small molecules and ligands. A protein sequence can be uploaded and a 3D 
image will form. Once the 3D model is displayed on the system, any section of the 
sequence can be highlighted and mutated to visualise what changes this would 
potentially make to the protein.  
Weblink: https://www.pymol.org/ 
2.29.5 Snapgene 
Snapgene is a plasmid mapping program that permits the identification of plasmid 
characteristics. Snapgene allows for in silico restriction analysis and permits the 
generation of primers for specific regions of DNA found on the plasmid. Any plasmid 
can be inputted into the Snapgene program and the program displays a number of 
features, i.e. highlight regions of interest with a specific gene or restriction site.  
Weblink: http://www.snapgene.com/ 
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2.30 Statistical calculations 
2.30.1 ANOVA single factor testing 
An ANOVA single factor test was used to identify if there were significant differences 
between two mean values with a minimum N value of 3. The ANOVA test was carried 
out in Microsoft excel using the data analysis ANOVA single factor function. The P 
value limit was set at <0.05 which signified a less than 5% chance of this difference 
being due to random chance. Any P value >0.05 was deemed to not be significant. All 
significant differences between two means is denoted with the symbol ‘*’ above the 
standard deviation error bar. Any P value < 0.001 is denoted with the symbol ‘**’. 
2.30.2 Setting a threshold limit for positive/negative ELLA readings 
ELLA (Section 2.23) is a method for detecting lectin binding to a glycoprotein with 
specific glycans on the surface. To determine if a reading was positive or negative for 
binding a lower threshold limit of detection was calculated based on the internal PBS 
control on each individual plate. PBS control absorbance readings varied from 0.05 – 0.1 
at OD 450 nm depending on which lectin was used. Due to the variance between these 
PBS controls for each individual lectin being different, the threshold was set at two 
times the baseline PBS value is each case. All readings above this threshold limit are 
denoted with the symbol ‘†’ above the standard deviation error bar.  
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Chapter 3 
Site Directed Mutagenesis of LecB  
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3.1 Overview 
This chapter describes the optimisation, expression and purification of LecB, as well as 
the site directed mutagenesis carried out on the PA-IIL (LecB) gene. The four mutants 
that were designed and generated were LecB S24T, LecB with three additional lysine 
residues (LecB 3K), LecB S23A;S24A;G25A (LecB 3A) and the fusion protein eGFP-
LecB. Each variation of the LecB protein fit a specific purpose and this chapter utilises a 
number of techniques, such as polymerase chain reaction (PCR), restriction digests, 
immobilised metal affinity chromatography (IMAC) and enzyme linked lectin assay 
(ELLA), to ensure these proteins were mutated, expressed and purified accurately and 
that the protein remained active. PCR was used to incorporate the specific mutations. 
For the eGFP-LecB fusion a number of restriction enzymes are used to cut out the LecB 
gene and cut the plasmid containing the eGFP to allow for LecB insertion. The LecB 
gene is then ligated into the open plasmid. DNA sequencing was then used to confirm 
each plasmid had the correct mutation added and that the fusion gene was generated. 
Once the plasmids had been confirmed proteins underwent expression checks to identify 
the clones expressing the most protein and then larger scale cultures allowed for 
increased protein expression and cell lysis. The cleared cellular lysate can then be used 
for IMAC purification of proteins. ELLA is a comprehensive assay that allows for the 
proteins to be validated. Each commercially purchased eukaryotic lectin was tested on 
ELLA as well as all recombinantly produced lectins. Glycoprotein targets were used to 
determine binding specificity as well as using competing and non-competing free sugars. 
The wild type LecB was first compared to other eukaryotic lectins that have similar 
specificities and then all subsequent LecB mutants produced were tested against wild 
type LecB for characterisation. Using these methods the proteins may be accurately 
mutated, purified and characterised before use in in vitro analysis (see chapters 4 and 5).  
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3.2 LecB plasmid purification and DNA sequencing 
A previous stock of JM109 E. coli containing a pQE30 plasmid with the PA-IIL (LecB) 
gene was defrosted and streaked for single colonies (see section 2.7). LecB is encoded 
on a pQE30 vector so the poly-histidine tag was located on the N- terminus of the 
protein rather than the C- terminus. The C- terminus of LecB is located close to part of 
the glycan binding region as well as the metal ion binding region of the protein. Any 
attempt to alter the C- terminus effects protein folding and results in failure of the 
protein to remain active. The pQE30 plasmid contains a T5 promoter and ampicillin 
resistance gene. These two characteristics allow for the protein to be selectively grown 
and selectively over expressed. The LecB plasmid was purified and sent for DNA 
sequencing to ensure the original glycerol stock contained the right LecB sequence. 
Once the LecB sequence was confirmed and verified using multiple online tools and 
databases (See section 2.29), the plasmid DNA was ready to undergo site directed 
mutagenesis. The LecB nucleotide sequence was aligned against the LecB reference 
sequence obtained using the basic local alignment search tool (BLAST). This alignment 
was carried out using the online alignment software Multalin and can be viewed in 
figure 3.1. Multalin gives a consensus sequence to highlight any differences between the 
compared sequences.  
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Figure 3.1: LecB nucleotide sequencing results compared to reference LecB 
sequence. Alignment is carried out using the online alignment tool mutalin. 
(http://multalin.toulouse.inra.fr/multalin/). 
  
 
Figure 3.2: Purified DNA plasmids run on a 0.7% agarose gel. Lanes; 1) 1 kb DNA 
ladder, 2) LecB plasmid, 3) LecB S24T plasmid, 4) LecB 3A plasmid, 5) LecB 3A 
plasmid.  
1  2   3      4        5 
6,000 bp 
2,000 bp 
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Purified plasmids from LecB and some of the LecB variants can be seen in figure 3.2. 
There are 2 orientations plasmids can be found in after mini-prep purification. These 
orientations are supercoiled and open-circular. Open-circular plasmids run slightly larger 
than linear DNA of that size whereas supercoiled DNA runs smaller than linear DNA of 
the same size (Simple Cloning Lab 2017). The pQE30 plasmid with the LecB gene 
added is approximately 3,800 nucleotides. Both the open-circular plasmid and 
supercoiled plasmids run at roughly 6,000 bp and 2,800 bp respectively. Through 
sequence confirmation it is assured that these samples contain the correct LecB variant 
plasmids.  
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3.2.1 Designing primers for site directed mutagenesis of LecB 
plasmid 
The wild type LecB plasmid is used as the DNA template for any polymerase chain 
reaction (PCR) that is used to introduce mutations to the sequence. For site directed 
mutagenesis the desired mutation must be incorporated into either the forward primer, 
reverse primer or both in the PCR. There were a number of mutations hypothesised 
throughout the project that would be either beneficial or detrimental to the final protein 
product. Preliminary results from past mutagenesis carried out on LecB suggested that a 
change to the Serine at position 24 would affect the proteins ability to bind its specific 
sugars. LecB, being a dual specific lectin, binds both fucose and mannose, although it 
binds mannose to a lesser degree. Originally the design for changing the serine (S) at 
position 24 to a threonine (T) was to remove mannose binding while keeping relatively 
strong fucose binding. This hypothesis was driven by the decrease in distance from the 
hydroxyl group on threonine to the sugar over serine. Both serine and threonine contain 
hydroxyl groups but in the orientation of this group on threonine at position 24 would 
change this distance possibly changing the proteins ability to bind mannose. This primer 
design was hypothesised based on the 3D model of LecB in complex with both mannose 
and fucose using the 3D modelling software PyMol. Figure 3.3 A shows LecB in 
complex with fucose. Figure 3.3 B and C show the difference in distance between the 
hydroxyl groups on the mannose sugar and the native serine amino acid and the 
threonine residue on the mutated LecB S24T. 
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Figure 3.3: LecB protein and sugar interaction structures generated using PyMol. 
A) LecB protein with  fucose sugar molecule in complex, Blue regions denote the 
protein, green regions involved in sugar binding as well as calcium binding, red regions 
denote the sugar binding regions highlighted during this project for mutagenesis and 
orange denotes the sugar molecule. B) Distance between the hydroxyl groups on both 
the mannose sugar and native serine on the LecB molecule at amino acid position 24. C) 
Distances between the hydroxyl groups on the mannose sugar and the threonine residue 
on the mutated LecB S24T. Measurements are denoted using the distance in Ångströms.  
 
 
B C 
A 
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The other mutations designed were to add multiple lysine residues between the poly-
histidine tag and start codon of the LecB gene, and to replace three of the amino acids 
involved in binding at positions 23-25 to alanine residues. Alanine scanning is used to 
replace polar amino acids with non-polar alanine to remove functionality of the protein 
(Morrison and Weiss 2001). The three residues shown to be involved in binding in LecB 
are serine, serine and glycine from positions 23-25 respectively. These three residues are 
involved in glycan binding but not involved in the proteins metal ion binding pocket. 
The original hypothesis was to allow the calcium binding pocket to remain unchanged. 
Creating a probe with a knock out mutation would allow for a control protein with no 
binding to be used as a comparison to the wild type LecB and other mutants that exhibit 
binding. Wild type LecB contains only one lysine residue in its amino acid composition. 
Standard chemical methods to biotinylated proteins use the NH
3+
 side group of lysine to 
chemically add biotin labels to proteins. Once biotinylated, streptavidin linked dyes may 
be used as fluorophores with streptavidin and biotin being one of the strongest non-
covalent bonds known in nature. All of the commercially available eukaryotic lectins 
purchased were biotinylated and engineering a protein with added lysine would facilitate 
similar biotinylation of the recombinant prokaryotic LecB being produced. Figure 3.4 
shows the five important amino acid structures used in the mutagenesis of LecB. 
 
Figure 3.4: Important amino acid structures for site directed mutagenesis. Glycine 
and alanine are non-polar amino acids, serine and threonine are polar amino acids while 
lysine is a basic amino acid. 
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Primer Name Sequence (5’-3’) Tm (°C) 
LecB S24T for. GCCAACTCGACCGGAACCCAGACGGTGAAC 68.5 
LecB S24T rev. GAAGGCGGTGACGCCGAACCG 62.2 
LecB 3K for. AAAAAGAAATCCATGGCAACACAAGGAGTGTTCA
CC 
63.3 
LecB 3K rev. TCCGTGATGGTGATGGTGATG 54.4 
LecB 3A for. GCCAACGCGGCCGCAACCCAGACGGTGAACGTG 73.1 
LecB 3A rev. GAAGGCGGTGACGCCGAACCG  62.2 
Table 3.1: Primer sequences for creating library of LecB mutants. Mutations are 
highlighted in blue. Tm is the melting temperature of the primer. 
 
In table 3.1 the primer sequences to introduce the three LecB mutations described above 
are shown. The regions highlighted represent the changes that are to be implemented 
into the plasmid (see Section 2.11). All of the mutations were added using the forward 
primer. The PCR reaction was set up as described in section 2.12. The melting 
temperature for each primer is different as can be seen in table 3.1 which leads to 
varying annealing temperatures when setting up a PCR reaction. A multi-annealing 
temperature PCR was set up using a thermocycler that allowed for a maximum of 6 
different annealing temperatures to be used. Originally three temperatures (55, 60 and 65 
°C) were used and the optimal temperature could be optimised using these temperatures. 
In figure 3.5 the PCR products for LecB with added lysine are run on a 0.7% agarose 
gel. There is product formed from 55 to 65 °C annealing temperatures but the most 
product was found in the 60 °C reaction, analysed by nanodrop (NanoDrop ND-1000). 
The primers used have a phosphorylated 5’- end. This allows for the methylated 
template DNA to be digested using the restriction enzyme DpnI (see section 2.13). DpnI 
has a proclivity for methylated DNA and digests the template DNA to only leave the 
phosphorylated PCR product that now contains a mutated region. This PCR product is 
cleaned (see section 2.9) and the linear plasmid is ligated to re-circularise the DNA (see 
section 2.14). 
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Figure 3.5: LecB PCR products for LecB 3K amplification. Lanes; 1) 1 kb DNA 
ladder, 2) PCR product annealing temperature 55 °C, 3) PCR product annealing 
temperature 60 °C, 4) PCR product annealing temperature 65 °C. Products run on a 
0.7% agarose gel. Linear plasmids run just below 4,000 bp.  
 
 
The ligated plasmid was transformed into competent JM109 E. coli cells (see Section 
2.15) and these cells now contain an intact plasmid containing the LecB gene with the 
various mutations introduced. These plasmids were sequenced to ensure the mutations 
have taken place correctly. These plasmids are shown in figure 3.2. All of the plasmids 
sequenced were compared to the original LecB plasmid sequence. Figure 3.6 shows the 
three mutated LecB sequences compared to the reference LecB sequence. The amino 
acid sequences were obtained using the nucleotide sequence reads (see Section 2.10). 
The sequences were input into the online translate tool ExPASy (see section 2.29) and 
the amino acid sequences were aligned to show the incorportation of the amino acid 
differences using Multalin.  
1 2 3 4 
4,000 bp 
3,000 bp 
3,776 bp 
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Figure 3.6: Amino acid sequence alignment of LecB and LecB mutants. LecB, LecB 
S24T, LecB 3A, LecB 3K were all aligned using the online tool multalin. Consensus 
sequences are in red while the black regions highlight the mutations.  
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3.3 Generation of eGFP-LecB Fusion Protein 
Along with the three LecB mutants generated in section 3.2, another hypothesis was to 
engineer a LecB variant that could be easily fluorescently detected. This was achieved 
by fusing LecB with a fluorescent fusion protein partner. In this case the protein fused to 
the LecB was enhanced green fluorescent protein (eGFP). GFP is a fluorescent protein 
discovered in the jellyfish Aequorea Victoria (Zimmer 2002). Specific mutations to the 
amino acid sequence of GFP have substantially increased the fluorescence to generate 
eGFP. Through introducing a fluorescent fusion partner the necessity for biotinylation of 
LecB is removed and this protein probe can be used as is. GFP has been used in a wide 
variety of ways as a fusion partner because it does not interfere with the primary proteins 
function and also in the case of non-stable proteins it can increase its stability. 
The LecB plasmid sequence contains the restriction site BamHI between the poly-
histidine tag and start codon of the gene. BamHI recognises the nucleotide sequence 
GGATCC. The restriction enzyme cuts both strands of DNA leaving 5’ prime 
overhangs. The LecB plasmid also contains a HindIII restriction site after the stop codon 
of the gene. HindIII recognises the nucleotide sequence AAGCTT. The LecB sequence 
was designed to have the GGATCC region in between the poly-histidine tag and the 
start codon of the gene sequence to allow for the gene to be excised from the plasmid. 
The sequence was also designed to have the AAGCTT region after the stop codon to 
allow the stop codon be intact when the gene is transferred into another plasmid. Using 
both of these restriction enzymes the LecB gene was successfully excised from the 
plasmid without its poly-histidine tag and with its stop codon intact. Figure 3.7 shows 
the LecB nucleotide sequence and also highlights where the restriction sites occur.   
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The eGFP gene sequence was modified to allow for it to be a fusion partner. The stop 
codon was removed and replaced with the GGATCC nucleotide sequence to allow for 
BamHI restriction. A short number of nucleotide bases after this GGATCC sequence 
there is an AAGCTT sequence that allows for HindIII restriction. Using the restriction 
enzymes BamHI and HindIII causes 5’ overhang nucleotide sequences which facilitates 
ligation of the LecB gene into the cloning site of eGFP as well as keeping the inserted 
gene in the correct open reading frame. Sticky end ligations are more desirable than 
blunt end ligations. The eGFP gene was added to a pQE30 vector to allow for an N- 
terminal poly-histidine tag. Post poly-histidine tag the amino acid sequence still 
contained the ‘GS’ residues before the genes methionine start codon. To ensure the gene 
does not get cut at this region the nucleotide sequence is changed to GGATCT so 
BamHI will not cut at this region.  
The eGFP-LecB fusion protein created retains the BamHI site between the two proteins, 
as well as the HindIII site post stop codon. These restriction sites allow for the gene to 
be removed and replaced with any BamHI and HindIII ended gene to allow for eGFP to 
be used as a fusion partner for other desired protein. Other projects running in unison 
with this project used this eGFP gene to create a similar fusion protein. The nucleotide 
sequences in figure 3.7, 3.8 and 3.9 highlight the recognition sites for the restriction 
enzymes used. 
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Figure 3.7: DNA nucleotide sequence of LecB gene. The sequence shows four codons 
past the stop codon to highlight the HindIII region. Red = start codon, Yellow = stop 
codon, Green = BamHI recognition site, Blue = HindIII recognition site.  
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Figure 3.8: DNA nucleotide sequence of modified eGFP gene. The modified eGFP 
gene contains the added restriction sites necessary to create a fusion protein. Red = start 
codon, Yellow = stop codon, Green = BamHI recognition site, Blue = HindIII 
recognition site, Purple = AccI recognition site. 
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Figure 3.9: DNA nucleotide sequence of fusion gene eGFP-LecB. The fusion protein 
still contains the BamHI and HindIII restriction sites to allow for removal of LecB gene. 
Red = start codon, Yellow = stop codon, Green = BamHI recognition site, Blue = 
HindIII recognition site. 
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In between the BamHI and HindIII recognition sites on the modified eGFP sequence 
there are a number of other restriction sites. One of interest is GTCGAC which is a 
recognition site for the restriction enzyme AccI. The pQE30 plasmid containing the 
eGFP gene contains 3 AccI recognition sites but when the plasmid is cut with BamHI 
and HindIII one of the sites is removed. The LecB gene is then ligated into the region 
between BamHI and HindIII resulting in the pQE30-eGFP plasmid containing three AccI 
recognition sites, while the pQE30-eGFP-LecB plasmid contains only two. To select 
viable clones from the transformation plate single colonies were streaked (see section 
2.6). The single colonies then found on the streak plate were used to inoculate overnight 
cultures and the plasmids from these cultures were purified (see sections 2.7). Before the 
samples were sent for sequencing, a restriction digest using AccI was carried out to 
confirm the presence of the LecB gene in the newly formed plasmid. In figure 3.12 the 
agarose gel shows the two undigested eGFP-LecB plasmids selected along with the 
control pQE30-eGFP plasmid. The AccI restriction carried out on the eGFP only plasmid 
will create three bands at sizes 2,712, 1,174 and 313 while the AccI restriction carried 
out on the eGFP-LecB plasmid will create two bands at sizes 2,712 and 1,802. Figure 
3.13 shows the 3 plasmids restricted, these are pQE30 plasmids containing either the 
eGFP-LecB fusion gene or just the eGFP gene. The smaller band of 313 base pairs did 
not appear but the smaller band of 1,174 compared to 1,802 base pairs can be visualised. 
Both of the plasmids selected indicate that the LecB gene had successfully been ligated 
into the gene. Figures 3.10 and 3.11 show whole plasmid images of pQE30 with the 
eGFP gene and the eGFP-LecB gene and where these restriction sites are as well as the 
other desirable traits of the plasmid for protein expression, namely the poly-histidine tag, 
ampicillin resistance gene and promoter region.  
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Figure 3.10: pQE30 plasmid containing the eGFP gene with restriction sites 
BamHI, HindIII and AccI highlighted. The plasmid shows the size of the plasmid as 
well as the lac operator, T5 promoter and Ampicillin resistance gene. The gene map was 
generated using Snapgene (see Section 2.29) and only some of the important features of 
the plasmid are highlighted. 
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Figure 3.11: pQE30 plasmid containing the fusion protein eGFP-LecB with 
restriction sites BamHI, HindIII and AccI highlighted. The plasmid shows the size of 
the plasmid as well as the lac operator, T5 promoter and Ampicillin resistance gene. The 
gene map was generated using Snapgene (see Section 2.29) and only some of the 
important features of the plasmid are highlighted. 
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Figure 3.12: 1% (w/v) agarose gel containing uncut supercoiled plasmids. Lanes; 1) 
1 kb DNA ladder, 2) eGFP-LecB plasmid clone 1, 3) eGFP-LecB plasmid clone 2, 4) 
eGFP plasmid. Gel indicates intact purified plasmid. 
 
Figure 3.13: 1% (w/v) agarose gel containing plasmids cut with the restriction 
enzyme AccI. Lanes; 1) 1 kb DNA ladder, 2) eGFP-LecB plasmid clone 1, 3) eGFP-
LecB plasmid clone 2, 4) eGFP plasmid. 
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The restriction digest confirmed that LecB had successfully been ligated into the 
pQE30-eGFP plasmid. Both plasmids were sent for DNA sequencing and both clones 
contained the correct plasmid in the correct reading frame. The amino acid sequences of 
eGFP, LecB and eGFP-LecB were run through alignment software to show that the 
sequences were correct. This can be seen in figures 3.14 and 3.15. LecB was introduced 
to the eGFP plasmid and not the other way around to ensure the poly-histidine tag was 
still accessible for IMAC purification. As stated previously the C- terminus of the LecB 
protein has a role in the proteins ability to bind its sugar and any changes to this region 
can have implications for the proteins ability to remain active. There are only 2 amino 
acids, the BamHI restriction site ‘GS’, between the LecB and eGFP, often there would 
be a longer linker molecule containing a stretch of amino acids that would create 
separation between both of the proteins. The BamHI restriction site allows for the option 
of addition amino acids to be added generating this linker molecule. Originally a protein 
fusion without a linker was hypothesised and a linker would be added if the protein lost 
its ability to bind its targets or there was a drop in protein binding affinity. The purified 
eGFP-LecB protein remained active and an amino acid linker was not necessary.  
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Figure 3.14: LecB and eGFP-LecB amino acid alignment. EGFP-LecB is aligned 
against the reference LecB amino acid sequence to show sequence consensus.  
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Figure 3.15: EGFP and eGFP-LecB amino acid sequence alignment. EGFP-LecB is 
aligned against the reference eGFP amino acid sequence to show sequence consensus.  
 
 
 
The library of prokaryotic LecB variants now in totality contained five different 
proteins. They are; wild type LecB, LecB S24T, LecB 3A, LecB 3K and eGFP-LecB. 
Once these sequences were confirmed through DNA sequencing and sequence 
alignment the E. coli stocks containing these proteins were cultured and two stocks were 
created, one working stock at -20 °C and one long term storage stock at -80 °C, for each 
protein. All nucleotide and amino acid sequence data is available in appendix A.2. 
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3.4 Expression and Purification of LecB and LecB variants 
After the sequences were confirmed the purified plasmid was transformed into 
competent JM109 E. coli or competent KRX E. coli for eGFP-LecB. From these 
transformation spread plates colonies were selected and re-streaked for single colonies 
(see Section 2.6). From these streak plates overnight cultures to test for expression were 
grown up (see Section 2.16). From these samples the clone that produced the most 
desired protein was kept for long term storage, again a working stock at -20 °C and a 
long term stock at -80 °C. In figure 3.16 the expression checks for different LecB S24T 
and LecB 3A clones are analysed for protein production.  
 
  
Figure 3.16: Expression analysis of different LecB S24T and LecB 3A clones on 
SDS-PAGE. A) Reference broad range protein ladder. B) Lanes; 1-2) LecB S23T clones 
1 and 2 respectively, 3) blank, 4) Broad range protein ladder, 5) blank, 6-10) LecB 3A 
clones 1-5 respectively. The white boxes highlight the protein of interest in each sample. 
66.4 and 14.3 are the kDa marker size in the ladder at those positions.  
 
66.4 
14.3 
1       2       3       4        5       6       7       8       9       10 
A) B) 
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Expression analysis was carried out on a large number of clones to select a specific 
clone that expressed high levels of the desired protein. Five clones containing the library 
of five LecB variants were selected and stored for both short and long term use. Once a 
clone is selected and confirmed to have a high level of protein expression and the correct 
plasmid with the desired mutations present it was the only clone used for future 
expression and purification. All other clones were discarded leaving the five clones with 
our five LecB variants as the only clones in short and long term storage.  
These E. coli stocks were expressed for large scale protein production and purification. 
Following the methods outlined in sections 2.16 and 2.17, cells were grown up to a large 
quantity and the protein was induced for overexpression during exponential bacterial cell 
growth. The cells are then lysed to release the cleared lysate containing our poly-
histidine tagged protein. The cleared lysate was run through a nickel IMAC column to 
selectively purify all of the desired protein (see Section 2.18). The column is subjected 
to various wash steps containing different levels of free imidazole and finally a high 
imidazole elution step to remove the bound protein. The elution fractions are collected in 
1 mL aliquots and run on an SDS-PAGE gel along with the cleared lysate, unbound flow 
through and wash steps to visualise the purity of the protein and also identify the 
fractions containing the most protein. The nickel resin had a maximum saturation point 
for allowing poly-his6 tagged proteins. If this saturation point is reached, the flow 
through of unbound protein will show our desired protein. This can be seen in figure 
3.17, which is a purification of wild type LecB, and figure 3.18, which is a purification 
of LecB S24T. The LecB protein reached saturation as did the LecB S24T to a lesser 
degree. In appendix A.1 there are images of earlier purification SDS-PAGE gels that 
contain contaminating bands in the elution fractions or that show issues encountered 
when attempting to purify each LecB variant protein. 
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Figure 3.17: Purification of N-terminally poly-his6 tagged LecB from cleared cell 
lysate using Ni-NTA resin. Analysis of fractions collected throughout purification of 
LecB on 15% (v/v) SDS-PAGE gel. Lanes; 1) Broad range protein ladder, 2) Cleared 
filtered lysate, 3) Unbound flow through, 4) Lysis buffer containing 20 mM imidazole 
wash, 5) Lysis buffer containing 50 mM imidazole wash, 6) Lysis buffer containing 80 
mM imidazole wash, 7) Lysis buffer containing 100 mM imidazole wash, 8) Elution 
fraction 1, 9-12) Elution fractions 2-5 respectively. 14.3 is the kDa marker size in the 
ladder at that position. The white box signifies the LecB protein. 
1       2          3        4         5        6       7         8         9       10        11      12 
14.3 kDa 
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Figure 3.18: Purification of N-terminally poly-his6 tagged LecB S24T from cleared 
cell lysate using Ni-NTA resin. Analysis of fractions collected throughout purification 
of LecB S24T on 15% SDS-PAGE gel. Lanes; 1) Three colour Broad range protein 
ladder, 2) Cleared filtered lysate, 3) Unbound flow through, 4) Lysis buffer containing 
20 mM imidazole wash, 5) Lysis buffer containing 50 mM imidazole wash, 6) Lysis 
buffer containing 80 mM imidazole wash, 7) Elution fraction 1, 8) Problem with the 
well no sample added, 9-11) Elution fractions 2-5 respectively. 15 and 10 are the kDa 
marker sizes in that ladder at that position. The white box signifies the LecB S24T 
protein. 
 
 
 
 
 
15 kDa 
10 kDa 
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During the original purification with LecB there were purifications that contained some 
contaminating bands and for this reason there were additional wash steps with increasing 
levels of imidazole. These increasing concentrations of imidazole were to wash away 
any higher proteins that were possibly weakly bound to the nickel resin based on surface 
histidine residues. In figure 3.17 there are LecB bands in both the cleared filtered lysate 
and the unbound flow through; this represents the LecB saturating the nickel resin. The 
elution fractions contain a high level of purified LecB. Both figures 3.18 and 3.19 show 
that the majority of the poly-his6 tagged protein was retained by the resin and very little 
was detected in the unbound flow through. In appendix A.1 other SDS-PAGE gels will 
also confirm this.  
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Figure 3.19: Purification of N-terminally poly-his6 tagged eGFP-LecB from cleared 
cell lysate using Ni-NTA resin. Analysis of fractions collected throughout purification 
of eGFP-LecB on 15% (v/v) SDS-PAGE gel. Lanes; 1) Broad range protein ladder, 2) 
Cleared filtered lysate, 3) Unbound lysate, 4) Lysis buffer containing 20 mM imidazole 
wash, 5) Lysis buffer containing 80 mM imidazole wash, 6) Elution fraction 1, 7) 
Elution fraction 2, 8) Elution fraction 3, 9) Elution fractions 4-7 pooled, 10) Elution 
fractions 8-9 pooled, 11) Purified eGFP, 12) Buffer exchanged eGFP-LecB from pooled 
elution fractions 4-7. The eGFP purified protein was used for another project in the lab 
and was used for size reference as well as the broad range protein ladder. 42.7 and 27 are 
the kDa marker size in the ladder at those positions. The white box signifies the eGFP-
LecB fusion protein. 
 
 
 
 
 
42.7 
27 
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Based on other purifications only two wash steps (see Figure 3.19), of 20 mM imidazole 
and 80 mM imidazole were used before elution. In figure 3.19 the eGFP-LecB band can 
be seen in the cleared filtered lysate but not in the unbound flow through. This shows the 
protein did not exceed the saturation point of the nickel resin and the maximum amount 
of protein was retained and purified. Both a broad range protein marker and purified 
eGFP were used as molecular size markers to compare eGFP-LecB. 
 
 
 
  
Figure 3.20: Purified fractions of the five LecB variants on a 15% SDS-PAGE gel 
using a low weight molecular marker. These are the five LecB variant protein samples 
that were purified, buffer exchanged and characterised run on a 15% SDS-PAGE gel to 
show purity. Lanes; 1) LecB, 2) LecB 3K, 3) LecB S24T, 4) LecB 3A, 5) eGFP-LecB, 
6) Blank, 7) Low weight molecular marker. The Low molecular weight marker is from 
Cell Signalling Technologies®. 
1            2           3           4           5          6       7 
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All the proteins were expressed and purified in similar ways. The only difference 
between any purification is the number of wash steps carried out with differing levels of 
imidazole. All protein elutions were carried out using 250 mM imidazole and all 
proteins were buffer exchanged and stored in PBS (see section 2.19). Figure 3.20 shows 
the library of purified LecB variants created using site directed mutagenesis. These 
proteins showed a high level of purity on SDS-PAGE gels.  
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3.5 Quantitation of purified LecB proteins 
Proteins can be quantified in a number of ways. In this project all proteins were typically 
quantified using the bicinchoninic acid (BCA) assay and supplemented by spectrometer 
absorbance readings at 280 nm (Section 2.21). To quantify proteins using a BCA assay, 
a standard curve was generated using bovine serum albumin (BSA) standards. The 
standard curve was created using a working range of 0-2000 µg/mL that created a linear 
trend line once the data points are plotted. This generates an equation of the line that was 
used to quantify protein concentrations of LecB samples. The concentration of the 
sample protein was calculated based on the standard curve.  
 
 
Figure 3.21: BCA standard curve using BSA standards. BSA standards ranging from 
0-2000 µg/mL were using to create a linear trend line. The equation of the line and R
2
 
value are displayed on the chart. The R
2
 value is a statistical measure of how close the 
data fits a regression line.  
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BSA protein concentration (µg/mL) 
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Sample Absorbance (570 nm) Concentration (mg/mL) 
LecB 4.023 3.52 
LecB S24T 4.635 4.08 
LecB S23A;S24A;G25A 0.988 0.77 
eGFP-LecB 0.881 0.67 
LecB 3K 1.882 1.58 
*LecB 3K biotinylated 1.643 1.36 
*LecB S24T biotinylated 1.502 1.23 
 
Table 3.2: Protein concentrations for the purified LecB mutants derived from BCA 
assays. Absorbance readings based off triplicate analysis of each individual protein. 
Absorbance values have been multiplied by there dilution factors. *LecB 3K that has 
gone through the biotinylation process after using the concentration of LecB 3K.  
 
All samples were tested in triplicate to increase the accuracy of the quantification. The 
samples were also tested as a neat sample as well as diluted 1:3, 1:5 and 1:10 to ensure 
the values fit within the range of standards used, i.e. if the neat sample contained above 
2 mg/mL it would not fit in our working concentration range. The proteins at lower 
concentrations per mL were lower due to the fact there was a higher volume of buffer 
exchanged protein. After quantification samples are aliquot into working stocks at 
certain concentrations, e.g. 500-1000 µg/mL. Proteins at high concentrations can 
aggregate and fall out of solution so all proteins are stored between 500-1000 µg/mL. As 
an alternative method, spectrometer readings at a 260 nm wavelength helped to confirm 
the protein concentrations were accurate (see Section 2.21).  
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3.6 Glycan binding characterisation of LecB and LecB 
mutants 
LecB is originally compared to other eukaryotic lectins to characterise its binding 
profile. LecB is known to bind fucose with a high affinity and mannose to a lesser 
affinity. It is then tested against mannose and fucose linked to BSA as well as other 
glycoproteins that are known to contain both mannose and fucose. The technique used to 
test for lectin binding is called the enzyme linked lectin assay (ELLA) which is 
described in section 2.23. This technique was used to test the activity of the various 
LecB mutants produced throughout the project as well as test the accuracy and activity 
of commercially purchased eukaryotic lectins. Aleuria Aurantia lectin (AAL) and Ulex 
Europarus agglutinin I (UEA-I) are two eukaryotic lectins that both bind fucose 
residues, although fucose residues with different linkages. AAL binds preferentially to 
fucose residues that are linked to GlcNAc through an α-1,6 linkage or fucose linked to 
N-acetyllactosamine with an α-1,3 linkage, whereas UEA-I preferentially binds to 
fucose residues linked through an α-1,2 linkage. LecB has shown to bind various L-
fucose residues with a very high affinity, while also binding to D-mannose. The ELLA 
was first carried out using commercially available eukaryotic lectins with defined 
binding specificities. Commercial glycoproteins; asialofetuin, fetuin and bovine mucin, 
were used to analyse the binding of the commercial lectins, Con A, RCA and Jacalin. 
This analysis can be viewed in figure 3.22. The binding specificity of these three lectins 
is shown in section 2.24, along with all other commercially purchased eukaryotic lectins. 
These lectins were probed at 5 µg/mL and each of their individual competitive inhibiting 
sugars was used. The sugar concentrations used were at the concentrations shown to 
have the highest inhibitory effect on the lectins. Some eukaryotic lectins show a very 
high affinity for glycans in complex and are not fully inhibited by competitive free 
sugars. Jacalin and RCA are not fully inhibited by the addition of galactose but there is a 
significant decrease in binding observed. Con A is fully inhibited by a mix of α-
methylmannoside and α-methylglucoside. The binding activity of each commercially 
purchased eukaryotic lectin was validated by ELLA analysis.  
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Figure 3.22: ELLA analysis of commercial eukaryotic lectins with their 
corresponding competitive inhibitory sugars. All lectins and glycoproteins were used 
at 5 µg/mL. The mixed sugar used for ConA inhibition is a 200 mM mix of α-
methylmannoside and α-methylglucoside. Bars on the chart; Grey = PBS, Yellow = 
Asialofetuin, Orange = Fetuin, Purple = Bovine mucin. The galactose used for RCA and 
Jacalin competitive inhibition was D-galactose. Data are means ± standard deviations. 
** represents P < 0.001, n=3. 
The first comparison carried out for LecB was to compare its binding to AAL and UEA-
I. Once purified, the recombinant lectins were used as controls to see if the anti-histidine 
antibody can successfully detect the protein. To do this the ELLA is partially changed 
with the lectin being allowed to bind to the plate and then blocking solution added. After 
this the proteins are probed with an anti-histidine antibdody to determine the available 
signal. In figure 3.23 the recombinant lectins LecB and LecB S24T confirm the 
antibodies ability to bind the His target. In figure 3.24 the three lectins, AAL, UEA-I and 
LecB, were tested for binding to three commercially purchased glycoproteins; 
Asialofetuin, Thyroglobulin and Bovine Mucin. Bovine mucin acts as a negative control 
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for LecB, while LecB binds to asialofetuin and thyroglobulin. There was also a 
competitive sugar inhibition carried out to highlight the binding specificity of the probe, 
the competitive sugar in the case of these three lectins was 100 mM L-fucose. LecB has 
a high affinity for thyroglobulin and a lesser affinity for asialofetuin. LecB doesn’t 
appear to bind to bovine mucin while both AAL and UEA-I appear to bind to bovine 
mucin with varying levels of binding observed. All three lectins were completely 
inhibited using 100 mM L-fucose proving that the binding is specific through the glycan 
binding pocket and not any other protein-protein interaction.  
 
 
Figure 3.23: ELLA analysis to determine anti-poly-histidine antibody can detect 
LecB and LecB mutants. LecB and LecB S24T were added to the F96 MAXISORP 
NUNC 96-well plate to allow the protein to bind and then after a blocking step the 
proteins were probed with anti-poly-histidine antibody (monoclonal produced in mouse 
–H1029). Data are means ± standard deviations. ** represents P < 0.001, n=3. The 
average means of LecB and LecB S24T were tested against the average mean for the 
PBS control. 
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Figure 3.24: ELLA analysis of LecB compared to other fucose binding lectins AAL 
and UEA-I with competitive free sugar inhibition. All lectins and glycoproteins were 
used at 5 µg/mL. Bars on the chart are as follows; Grey = PBS, Yellow = Asialofetuin, 
Light blue = Thyroglobulin, Purple = Bovine Mucin. The competitive inhibiting sugar 
used for the three controls was 100 mM L-Fucose. † denotes a positive value surpassing 
the threshold limit (Section 2.30). 
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Figure 3.25: ELLA analysis of LecB binding when different competitive and non-
competitive free sugars are added. Thyroglobulin was used as the positive control 
while bovine mucin was used as the negative control. All lectins and glycoproteins were 
used at 5 µg/mL. 1) PBS, 2) LecB, 3) LecB + 200 mM D-galactose, 4) LecB + 100 mM 
D-fucose, 5) LecB + 100 mM L-fucose, 6) LecB + 200 mM mix of α-methylmannoside 
and α-methylglucoside, 7) LecB + 200 mM D-glucose, 8) LecB + 200 mM D-mannose. 
Bars on the chart; Grey = PBS, Light blue = thyroglobulin, Purple = bovine mucin. † 
denotes a positive value surpassing the threshold limit (Section 2.30). 
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LecB is characterised as a fucose/mannose binding lectin, therefore free sugar L-fucose 
and D-mannose can both be used to selectively and competively inhibit LecB binding to 
its specific target. After LecB activity was proven, see figure 3.24, different sugars were 
used to highlight LecBs binding specificity. Both D-mannose and L-fucose inhibit 
LecBs ability to bind its target while D-glucose and D-fucose have no inhibitory effect 
on LecB. While LecB is characterised as a lectin that does not bind to D-galactose, D-
galactose has been shown to inhibit LecB binding when used as a free sugar (Sabin et al. 
2006). In Figure 3.25, 200 mM D-galactose is shown to inhibit LecB binding. Free sugar 
galactose has shown an ability to repeatedly inhibit LecB binding but LecB has no 
binding affinity for galactose in complex. In figures 3.26 and 3.27 the ability of LecB 
and some of its mutants to bind to mannose-linked BSA and thyroglobulin without 
showing any affinity for galactose-linked BSA. The original aim for LecB 3A was to 
knock out its binding ability by substituting some of its important binding pocket amino 
acid residues with alanine. These mutations have not proven to remove or reduce the 
proteins ability to bind to its target. Also the original aim for LecB S24T was to reduce 
LecBs ability to bind mannose while keeping its ability to bind to bind to fucose. These 
mutations again have not proven to remove or reduce the proteins affinity for mannose 
residues. Both of these proteins were used as probed against mannose-linked BSA as 
well as thyroglobulin because these are two positive controls for wild type LecB. 
Galactose-linked BSA was also used as a negative control. Competitive inhibition of 
these two LecB mutants as well as wild type LecB is also carried out to highly protein 
binding specificity. The comparison of LecB, LecB 3A and LecB S24T are shown in 
figures 3.26 and 3.27. 
 
163 
 
 
Figure 3.26: ELLA analysis of LecB mutants compared to wild type LecB using 
BSA-linked sugars. All lectins and glycoproteins were used at 5 µg/mL. Mannose-
linked BSA is used as the positive control, whereas galactose-linked BSA is used as the 
negative control. LecB 3A, LecB S24T and wild type LecB were all used as probes, with 
200 mM D-mannose or 100 mM L-fucose used as the competitive inhibitory sugar. 1) 
PBS, 2) LecB 3A, 3) LecB 3A + 200 mM D-mannose, 4) LecB S24T, 5) LecB S24T + 
200 mM D-mannose, 6) LecB S24T + 100 mM L-fucose, 7) Wild type LecB, 8) Wild 
type LecB + 100 mM L-fucose. Bars on the chart; Grey = PBS, Green = Mannose-linked 
BSA, Blue = Galactose-linked BSA. † denotes a positive value surpassing the threshold 
limit (Section 2.30). 
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Figure 3.27: ELLA analysis of LecB mutants compared to wild type LecB using 
commercial glycoprotein and BSA-linked sugars. All lectins and glycoproteins were 
used at 5 µg/mL. Thyroglobulin is used as the positive control, whereas galactose-linked 
BSA is used as the negative control. LecB 3A, LecB S24T and wild type LecB were all 
used as probes, with 200 mM D-mannose or 100 mM L-fucose used as the competitive 
inhibitory sugar. 1) PBS, 2) LecB 3A, 3) LecB 3A + 200 mM D-mannose, 4) LecB 
S24T, 5) LecB S24T + 200 mM D-mannose, 6) LecB S24T + 100 mM L-fucose, 7) 
Wild type LecB, 8) Wild type LecB + 100 mM L-fucose. Bars on the chart; Grey = PBS, 
Dark blue = Galactose-linked BSA, Light blue = Thyroglobulin. † denotes a positive 
value surpassing the threshold limit (Section 2.30). 
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Another one of the LecB mutants generated from the previous section is LecB with three 
added lysine residues between the poly-histidine tag and the start codon of the LecB 
gene. This LecB mutant is called LecB 3K representing the three additional lysine 
residues. From the animo acid sequence of LecB there is one solitary lysine residue in 
the sequence and along with the N- terminus this leaves two possible sites for 
biotinylation. Biotin molecules are commonly added to proteins via the NH
3+
 side group 
of the N- terminus amino acid and the variable group on the amino acid lysine. To create 
a LecB probe that can be successfully biotinylated in the same fashion as other 
commercially available eukaryotic lectins and recombinant prokaryotic lectins a number 
of lysine residues were added to increase the amount of available biotinylation sites. 
Three additional lysine residues were added with the biotinylation results dictating if 
more lysine residues were necessary, i.e. if protein could not be successfully biotinylated 
more lysine residues would need to be added. The lysine residues added at that position 
may also impact the poly-histidine tags ability to bind to the IMAC resin. The idea to 
add lysine was that potential biotinylation of the protein could be increased without 
reducing the proteins binding affinity or ability to be purified via its poly-histidine tag. 
In Section 2.4, the purified version of LecB 3K was observed and the protein was 
biotinylated (see section 2.22). In figure 3.28 the newly produced LecB 3K and 
biotinylated LecB 3K were tested for binding activity compared to wild type LecB using 
mannose and fucose linked BSA. The binding affinity of LecB 3K was not impacted by 
the addition lysine residues. The biotinylated version of the protein is used as a probe 
with an anti-biotin antibody, instead of the usual anti-histidine antibody used for the 
purified recombinant lectins. The binding specificity was confirmed using competitive 
free sugar inhibition (see Figure 3.28).  
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Figure 3.28: ELLA analysis of LecB 3A and biotinylated LecB 3A compared to 
wild type LecB with competitive inhibitory sugars. All lectins and glycoproteins were 
used at 5 µg/mL. The inhibitory sugar used for LecB, LecB 3K and biotinylated LecB 
3K (LecB 3K bio) is 100 mM L-fucose. Bars on the chart; Grey = PBS, Red = Fucose-
linked BSA, Green = Mannose-linked BSA, Navy = GlcNAc-linked BSA. † denotes a 
positive value surpassing the threshold limit (Section 2.30). 
The last LecB variant generated in Sections 3.3 and 3.4 is the fusion protein eGFP-LecB. 
The enhanced version of GFP has been used as a fusion partner for a range of different 
applications in research. The hypothesis for creating a fusion partner protein was to 
create a stable eGFP-LecB fusion protein that could be used for fluorescent microscopy 
and flow cytometry without needing to add an additional fluorophore. The LecB gene 
was added to the C- terminus of the eGFP gene. Similar to the other LecB variants, the 
binding specificity and affinity were tested using ELLA analysis with commercial 
glycoproteins. Thyroglobulin again was used as the positive control whereas fetuin was 
used as negative controls.  
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Figure 3.29: ELLA analysis of eGFP-LecB fusion protein activity using competitive 
and non-competitive inhibitory free sugars. Both L- and D- fucose free sugars were 
used to show competitive inhibition of eGFP-LecB. eGFP-LecB concentrations of 5 and 
10 µg/mL were used to show binding activity. Bars on the chart; Grey = PBS, Yellow = 
Asialofetuin, Orange = Fetuin, Light blue = Thyroglobulin. † denotes a positive value 
surpassing the threshold limit (Section 2.30). 
 
Considering eGFP-LecB is a larger protein than the other LecB mutants characterised in 
this section, two concentrations were tested to see if the saturation point of binding is 
reached at 5 µg/mL or is it closer to 10 µg/mL. There was no significant difference in 
binding when using a higher concentration of protein so 5 µg/mL of eGFP-LecB was 
used for all subsequent ELLA analysis using this protein.  
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3.7 Discussion 
The original LecB stock contained the correct plasmid, confirmed by DNA sequence 
analysis which allowed this to be used as the template plasmid DNA for the remainder 
of the project. All subsequent PCRs were carried out using this template DNA. In this 
project all subsequent PCRs were whole plasmid PCRs which involves introducing a 
mutation to the gene and replicating the whole plasmid. The PCR product is then a 
linearised plasmid containing the desired mutation and this can be re-circularised using 
DNA ligase to create an intact plasmid for transformation. For the fusion protein the 
unique properties incorporated into the plasmid allowed for the gene to be excised using 
the restriction enzymes BamHI and HindIII. These two restriction sites are present in the 
multiple cloning site located at the C-terminus of eGFP as well as being either end of the 
PA-IIL gene encoding LecB. Using these two restriction enzymes the eGFP plasmid can 
be opened and allow the ligation of the LecB gene into the plasmid. Incorporating the 
LecB gene into the pQE30-eGFP plasmid removed one of the three AccI restriction 
sites. Restriction analysis using AccI confirmed the LecB gene had been successfully 
ligated into the pQE30-eGFP plasmid. 
 
All sequences were confirmed using DNA sequencing. Each individual LecB mutant 
was compared to the original LecB nucleotide sequence. All DNA sequences were then 
run through the expasy online translate tool which allowed for the amino acid sequences 
to be aligned together and ensure the correct mutation had taken place at the correct 
position.  
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All of the LecB mutants created, as well as wild type LecB, were successfully purified 
and a very high level of purity was attained for each protein. In appendix A.1 there are 
some figures showing the difficulties faced in purifying certain LecB mutants. 
Increasing the number of wash steps with differing levels of imidazole or increasing the 
volume of each wash step allowed for successful purification. There was a large amount 
of LecB expressed when induced with IPTG and the LecB mutants were also easily 
overexpressed to allow for a large amount of protein to be purified. The optimisation of 
the purification method came from using lesser amounts of total cleared lysate and 
increasing the number of wash steps. The IMAC resin has a saturation point for how 
much poly-histidine tagged protein may be bound and this should not be exceeded or it 
will show an increased amount of the target protein in the flow through as well as retain 
a number of undesired proteins through proteins ‘sticking’ to each other via various 
bonds. 
During purification of LecB and the library of LecB mutants there were significant 
issues with what believed to be protein aggregation. Even at relatively low protein 
concentrations LecB was appearing to fall out of solution when in protein friendly 
buffers, i.e. PBS with added NaCl or added glycerol. No protein storage solution could 
significantly decrease this amount of ‘aggregation’. This phenomenon turned out not to 
be aggregation at all. LecB, as well as many other eukaryotic and prokaryotic lectins, 
requires a metal ion for its activity. Its metal binding pocket is so strong that while LecB 
is in complex with the nickel, via its poly-histidine tag, some of the nickel was also 
beginning to fit into its metal ion binding pocket. When the elution buffer is then added 
to elute off bound LecB this metal ion binding pocket interaction is not reversed and the 
resulting protein elution drags a small amount of resin through the filter in the IMAC 
column. This resin is now significantly heavier and settles at the bottom of elution tubes 
still in complex with the protein. The higher the concentration of protein the greater the 
amount of total resin in the sample which was misleading when determining the more 
protein in the sample the more ‘aggregation’ observed. This phenomenon was overcome 
by adding 1 mM EDTA to the elution fractions post elution and pre-buffer exchange. 
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EDTA can be damaging in high concentrations to proteins or if proteins are exposed to it 
for long prolonged periods of time. EDTA was often added to proteins for 30 minutes 
before buffer exchanging (see section 2.19). The buffer exchange then allowed for 
proteins to be separated from the nickel-resin complex as well as remove the EDTA and 
high imidazole from the solution.  
 
Once each protein was successfully stored in the right buffer conditions at an acceptable 
concentration the samples were tested using the ELLA platform. This allowed for 
validation of all commercially purchased lectins as well as all of the LecB mutants 
produced. Some eukaryotic lectins have a very strong binding affinity for glycans in 
complex and cannot be fully inhibited by using various concentrations of free sugars. 
Jacalin and RCA which both bind differently linked galactose residues are not inhibited 
fully when pre-incubated with their competitive free sugar. Through using free sugars to 
selectively inhibit lectin binding the specificity of each lectin is characterised and the 
binding is confirmed to be strictly through the binding pocket-glycan interaction.  
 
The wild type LecB and LecB mutants were characterised via their ability to bind 
specific glycoproteins or BSA-linked glycans. Each protein was individually 
characterised and validated based on its ability to bind its target glycan. The specificity 
is then confirmed using either 100-200 mM L-fucose or 200 mM D-mannose as a 
competitive inhibitory free sugar. LecB S24T had been hypothesised to have lower 
affinity for BSA-linked mannose or any mannose structure proven to have no 
fucosylation. After a number of different batches were purified and tested, the LecB 
S24T mutant was confirmed to bind BSA-linked mannose with the same affinity and 
specificity of wild type LecB. LecB S23A;S24A;G25A (LecB 3A) had been 
hypothesised to have a lower affinity or no affinity for either L-fucose or D-mannose 
due to three of the key binding residues being changed to non-polar amino acids. These 
three were selected base on their position in the protein. Other regions of the binding 
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pocket were also believed to be close to the proteins metal ion binding pocket. It was 
hoped that binding could be knocked out using mutations that did not affect the proteins 
ability to bind its desired metal ion, i.e. calcium. Again after a number of different 
purified fractions were tested, this LecB 3A was confirmed to have similar binding to 
that of wild type LecB. Both LecB S24T and LecB 3A were not used for further in vitro 
analysis based on their binding specificities.  
LecB 3K and eGFP-LecB were both designed to retain their ability to bind the same 
specific targets as wild type LecB. Both of these proteins were also validated using the 
ELLA platform to measure binding specificity. In section 3.5 both of these proteins were 
characterised and validated compared to wild type LecB. These proteins both bound 
specifically to their target and were selectively inhibited using their corresponding 
competitive free sugar. LecB 3K was biotinylated and the biotinylated version bound to 
its specific targets also. The biotinylation of this protein allowed for the use of 
streptavidin linked dyes for fluorescent visualisation. These proteins were used in the 
next two chapters, 4 and 5, for in vitro lectin staining.  
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Chapter 4 
Glyco-analysis of Colorectal Carcinoma 
Cell Lines SW480 and SW620 using 
Fluorescent Microscopy 
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4.1 Overview 
This chapter describes the recombinant and native lectin probing of colorectal carcinoma 
cell lines SW480 and SW620. These two cell lines are stage 2 and stage 3 colorectal 
adenocarcinoma cell lines, respectively. Commercially purchased eukaryotic lectins and 
recombinantly produced prokaryotic lectins were used to create a qualitative glycan 
profile for each cell type that can be used to infer differences in the glycans on the 
surface of each cell type. Cells were probed with the lectins conjugated to fluorophores 
so they can be visualised by fluorescent microscopy. All lectin probes were used on non-
fixed cells rather than fixed cells. Non-fixed cell analysis ensures only cell surface 
glycans are identified. Fixing cells causes permeabilisation that can generate false 
positive results in respect to surface binding (Holmes et al. 2001). Competitive free 
sugars were used to selectively inhibit the binding of some lectins to highlight the lectin 
binding specificity. The recombinant LecB 3K and eGFP-LecB that were generated in 
the previous chapter were used in unison with the eukaryotic lectins in glyco-profiling.  
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4.2 Cell surface glyco-analysis of SW480 and SW620 
colorectal carcinoma cell lines. 
Cells for these experiments were cultured as detailed in Section 2.25. For glyco-analysis 
the cells were seeded in 6-, 12- or 24-well plates with the concentration per well varying 
depending on the size of the well (Section 2.26). Cells were generally seeded at 50,000-
100,000 cells per well with 3 mL of supplemented medium and allowed to proliferate for 
48 hours. The time of incubation was decided upon based on cell confluency measured 
each day. Cells probed with lectin needed to be between 50-70% confluency. If the cells 
are lower than 50% confluency they may not be interacting with each other sufficiently 
and if the cells are above 70% confluency some cells may begin to show signs of early 
stage apoptosis which could give false results for surface lectin binding. Epithelial cells 
need cell to cell adhesion to ensure correct cell signaling is occurring; therefore cells 
incubated for 48 hours that achieve a confluency of 50-70% were believed to be the 
most representative for cell surface glycan patterns. Cells were trypsinised and seed and 
after 48 hours, at approximately 60% confluency, a cell count was carried out (see 
Section 2.25.3) and the cell viability always remained above 99%. The method for 
probing cells with lectins is described in Section 2.26. All lectins used throughout this 
chapter were conjugated with a dyelight-488 fluorophore which fluoresces under the 
FITC (green) channel on the fluorescent microscope. The eGFP-LecB fusion prokaryotic 
lectin was not conjugated with a fluorophore because the eGFP molecule fluoresces in 
the same FITC channel. For all cells to be visualised the cells are counterstained with 
Hoescht 33342 (NucBlue®) which fluoresces in the DAPI (blue) channel on the 
fluorescent microscope. The counter stain is used to show the location of the cells in the 
field. The nuclear stain also allows for lectin binding to be matched to cells in those 
locations. For each experiment a well containing cells was not probed with any lectin 
and this acts as a negative control. Images are taken using a bright field (White light) to 
show the cells location. Figure 4.1 shows healthy SW480 and SW620 cells, images are 
taken using white light. A nuclear counter stain is also used for these to show the 
nucleus in the DAPI channel. Images are also taken using the FITC channel to allow for 
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experimental set up to remove the potential of auto-fluorescence. The exposure time for 
FITC is dictated by the cells positively stained with lectin and the negative control cells. 
Over exposure of cells without any lectins bound to the surface can cause the cells auto-
fluoresce.  
   A)      B) 
            
Figure 4.1: Bright field microscope image of SW480 and SW620 cells. A) SW480 at 
100x magnification, B) SW620 at 100x magnification. 
 
 
Cells were first probed with commercially purchased eukaryotic lectins conjugated to a 
fluorophore. These lectins, whose specificities were validated using ELLA analysis (see 
Chapter 3), have very defined activities and are required when attempting to distinguish 
between the two different cell types. A number of these eukaryotic lectins were used to 
establish a cell surface glycan profile for each of the two cell types. Each lectin used has 
a different specificity (see Section 2.24 for lectin specificities) and the lectins ability to 
bind the specific glycans on the surface of the cells will indicate the presence, or 
absence, of individual glycans or specific glycan linkages. 
 
SW480 SW620 
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A panel of specific lectins was used to identify the presence of certain sugar residues 
(see table 4.1). Chapter One outlined that most eukaryotic glycans are made up of a 
small number of different monosaccharides. The main sugars tested for are mannose, 
galactose, fucose, GalNAc, GlcNAc and sialic acid (NeuNAc). To test for the presence 
of these sugars the panel of lectins chosen was: Con A, AAL, UEA I, Jacalin, GSL II, 
MAL II, WGA, SNA, HPA as well as the recombinant prokaryotic lectins eGFP-LecB 
and biotinylated LecB 3K. These lectins covered the majority of important sugars. The 
cells were grown in fetal calf serum that contains a number of glycosylated proteins that 
can adhere to the cell culture plates. Lectins bind to these glycosylated proteins resulting 
in high background fluorescence. In table 4.1 the specificities for the lectins used in this 
chapter are shown.  
 
Lectin Sugar specificity 
ConA Core Mannose 
AAL α-1-6-Fucose 
UEA I α-1-2-Fucose 
Jacalin T-antigen / β-1,3-N-acetylgalactosamine 
WGA GlcNAc, NeuNAc 
GSL II Terminal GlcNAc 
MAL II α-2,3-NeuNAc 
SNA α-2,6-NeuNAc 
HPA GalNAc, Tn antigen, GlcNAc 
*Biotinylated LecB 3K Fucose, mannose 
*eGFP-LecB Fucose, mannose 
Table 4.1: Specificity of lectins used to probe SW480 and SW620 for analysis by 
fluorescent microscopy. *Indicates the recombinantly produced LecB 3K and eGFP-
LecB from chapter 3. Eukaryotic lectins supplied by Vector Labs and Sigma-Aldrich. 
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4.3 Live cell glyco-analysis of SW480 and SW620 cell lines 
using fluorescent microscopy 
The panel of lectins (Table 4.1) was used to probe SW480 and SW620 cells to determine 
the presence, or absence, of specific glycans or identify specific glycan linkages. To 
prove the binding of each lectin is specifically due to its lectin-glycan interaction, and 
not non-specific protein-protein interactions, free sugar in solution at defined 
concentrations were used to selectively inhibit lectin binding. The only free sugar not 
used for competitive inhibition was sialic acid for MAL II and SNA. Sialic acid has a 
low pH and causes damage to the cells making any subsequent results difficult to 
interrupt. WGA requires and acid/salt wash (as per Vector Laboratories® guidelines) to 
inhibit lectin binding, therefore there was no competitive free sugar used for inhibition. 
In table 4.2 the sugars used for each lectin to competitively inhibit their binding is 
shown. Not all eukaryotic lectins can be inhibited fully using free sugars (see Chpater 3). 
Jacalin is an example of this and in figure 4.4 jacalin binding is still observed even in the 
presence of a high concentration of free sugar. The majority of these lectins were fully 
inhibited using their corresponding free sugar. All images are either taken at 100x 
magnification or 400x magnification. Some images obtained contain high level non-
specific background binding either caused by lectins binding to glycosylated serum 
proteins or cellular debris. All images taken for lectins that exhibit high background are 
taken at 100x magnification for clearer images.  
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Lectin Competitive inhibitory free sugar 
ConA 200 mM α-methylmannoside & α-
methylglucoside 
AAL 100 mM L-Fucose 
UEA I 100 mM L-Fucose 
Jacalin 800 mM D-galactose or 100 mM Melibiose 
WGA N/A 
GSL II N/A 
MAL II N/A 
SNA N/A 
HPA 200 mM N-acetylglucosamine or 200 mM N-
acetylgalactosamine 
Biotinylated LecB 3K 200 mM L-Fucose 
eGFP-LecB 200 mM L-Fucose 
Table 4.2: List of free sugars used to selectively inhibit each lectin. GSL II did not 
bind to either cell type so it was not necessary for an inhibitory sugar. MAL II/SNA both 
bind sialic acid and this free sugar is not used for inhibition studies. WGA requires acid 
wash step deemed too damaging for cells to carry out. The inhibitory sugars and their 
concentrations are supplied by Vector Laboratories® or were determined by ELLA 
testing in Chapter 3. 
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Figure 4.2: SW480 and SW620 cells probed with lectin AAL and AAL + 100 mM 
L-fucose. A) NucBlue nucleus stain at 400x magnification, B) AAL with dyelight-488 
at 400x magnification, C) Merged image of A and B, D) AAL with dyelight-488 with 
100 mM L-fucose at 400x magnification.  
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Figure 4.3: SW480 and SW620 cells probed with lectin UEA-I and UEA-I + 100 
mM L-fucose. A) NucBlue nucleus stain at 400x magnification, B) UEA-I with 
dyelight-488 at 400x magnification, C) Merged image of A and B, D) UEA-I with 
dyelight-488 with 100 mM L-fucose at 400x magnification.  
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Figure 4.4: SW480 and SW620 cells probed with lectin Jacalin and Jacalin + 100 
mM Melibiose. A) NucBlue nucleus stain at 400x magnification, B) Jacalin with 
dyelight-488 at 400x magnification, C) Merged image of A and B, D) Jacalin with 
dyelight-488 with 100 mM Melibiose at 100x magnification.  
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Figure 4.5: SW480 probed with lectin Con A and Con A + 200 mM α-
methylmannoside / α-methylglucoside. A) NucBlue nucleus stain at 100x 
magnification, B) Con A with dyelight-488 at 100x magnification, C) Merged image of 
A and B, D) Con A with dyelight-488 with 200 mM α-methylmannoside / α-
methylglucoside at 100x magnification.  
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Figure 4.6: SW480 and SW620 cells probed with lectin Mal II. A) NucBlue nucleus 
stain at 100x magnification, B) Mal II with dyelight-488 at 100x magnification, C) 
Merged image of A and B.  
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Figure 4.7: SW480 and SW620 cells probed with lectin WGA. A) NucBlue nucleus 
stain at 400x magnification, B) WGA with dyelight-488 at 400x magnification, C) 
Merged image of A and B.  
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Figure 4.8: SW480 and SW620 cells probed with lectin SNA. A) NucBlue nucleus 
stain at 400x magnification, B) SNA with dyelight-488 at 400x magnification, C) 
Merged image of A and B.  
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Figure 4.9: SW480 and SW620 cells probed with lectin GSL II. A) NucBlue nucleus 
stain at 400x magnification, B) GSL II with dyelight-488 at 400x magnification.  
 
GSL II was used as a negative control for both cell lines as healthy cells are not known 
to have exposed terminal GlcNAc on their cell surface (Franz et al. 2006). The 
eukaryotic lectins used to probe live cells give an indication of the specific glycans and 
glycan linkages present on the surface of SW480 cells. The recombinant prokaryotic 
lectins generated in this project (see Chapter 3) were also used to identify specific 
glycans. In figures 4.10 and 4.11 the biotinylated LecB 3K and eGFP-LecB are shown to 
bind to SW480 and SW620. AAL and UEA-I binding showed that there were fucose 
residues of differing linkages on the surface of SW480 and the LecB variants are used to 
back up this claim and validate the use of these recombinantly produced lectins in live 
cell analysis. 
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Figure 4.10: SW480 and SW620 cells probed with lectin biotinylated LecB 3K and 
biotinylated LecB 3K + 200 mM L-fucose. A) NucBlue nucleus stain at 400x 
magnification, B) LecB 3K with dyelight-488 at 400x magnification, C) Merged image 
of A and B, D) LecB 3K with dyelight-488 with 200 mM L-fucose at 400x 
magnification.  
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Figure 4.11: SW480 and SW620 cells probed with lectin eGFP-LecB and eGFP-
LecB + 200 mM L-fucose. A) NucBlue nucleus stain at 400x magnification, B) eGFP-
LecB with dyelight-488 at 100x magnification, C) Merged image of A and B, D) eGFP-
LecB with dyelight-488 with 200 mM L-fucose at 100x magnification.  
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4.4 Analysis of Helix Pomatia Agglutinin (HPA) binding to 
SW480 and SW620 cells using fluorescent microscopy 
One lectin used that shows interesting binding results was the Helix Pomatia agglutinin 
(HPA) lectin. Other studies highlighted HPA as a lectin that could distinguish between 
the non-metastatic SW480 cells and the metastatic SW620 cells. HPA was expected to 
bind a subset of the SW620 cells with a high level of fluorescence exhibited whereas it 
was expected to not bind to SW480 cells (Schumacher and Adam 1997). HPA has been 
used to distinguish between metastatic and non-metastatic cells using both SW480 and 
SW620 cells (Saint-Guirons et al. 2007; Peiris et al 2012). When the cells were probed 
with HPA and viewed using fluorescent microscopy the SW480 cells showed a low level 
of HPA binding and the SW620 cells showed some cells bound with HPA with a larger 
portion of the cells not showing HPA binding. In figure 4.12 the HPA binding of SW480 
and SW620 is shown. One difference noted when comparing these results to the 
literature that shows no HPA binding to SW480 was that the cells were fixed to the plate 
before being viewed using fluorescent microscopy (Peiris et al. 2012). This experiment 
was repeated for SW480 cells that were paraformaldehyde fixed to the 6-well plate used 
to culture the cells. In figure 4.13 the results of this experiment are shown.  
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Figure 4.12: SW480 and SW620 cells probed with lectin HPA and HPA + 200 mM 
GlcNAc. A) NucBlue nucleus stain at 400x magnification, B) HPA with dyelight-488 at 
400x magnification, C) Merged image of A and B, D) HPA with dyelight-488 with 200 
mM GlcNAc at 400x magnification.  
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Figure 4.13: Paraformaldehyde fixed SW480 cells probed with lectin HPA and 
HPA + 200 mM GlcNAc. A) NucBlue nucleus stain at 100x magnification, B) HPA 
with dyelight-488 at 100x magnification, C) Merged image of A and B, D) HPA with 
dyelight-488 with 200 mM GlcNAc at 100x magnification.  
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4.5 Discussion 
Live cell staining was carried out using eukaryotic and prokaryotic lectins to identify the 
glycans on the surface of SW480 and SW620 cells. Live cell analysis of both these cell 
types revealed the complexity of the surface glycome of mammalian cells, by showing 
the variety of different glycan residues present on the surface of the cells. Through using 
the panel of lectins chosen in Section 4.2 a select number of these sugar molecules can 
be detected on the surface. These lectins also identified different O- and N- glycosyl-
linkages found on the surface of the SW480 and SW620 cells.  
All the lectins chosen, with the exception of GSL II, were predicted to bind to these cell 
lines to varying degrees. GSL II binds to terminal GlcNAc which is predominantly the 
first sugar molecule involved in N-glycan synthesis. There is no evidence in the 
literature to suggest that these cancer cells would have terminal GlcNAc on the surface 
and this is further proven by the analysis carried out in this chapter. Cells believed to be 
undergoing late apoptosis can have exposed terminal GlcNAc but dead/dying cells are 
removed through various wash steps before lectin probing (Ise et al. 2012).  
Competitive free sugar inhibitions were carried out in order to prove the selectivity of 
the lectin binding to the cell surface. The majority of the lectins used can be selectively 
inhibited by using their corresponding free sugar, whereas some like Jacalin cannot be 
fully inhibited using free monosaccharides. Jacalin binding is decreased in the presence 
of its corresponding free sugar as shown in chapters 3 and 5 as well as figure 4.4. 
Through lectin inhibition studies the binding specificity of each lectin was validated. As 
some of the lectin probes are large proteins that could weakly bind to cells through 
various other protein-protein interactions, the use of free sugar to competitively inhibit 
the lectin binding proves the lectins are only binding through their unique glycan 
binding site or sites. As explained in section 4.2, not all lectins could be selectively 
inhibited using competitive free sugars. Live cell analysis needed to be carried out at a 
neutral pH to ensure the cells remained viable throughout the probing process. The use 
of an acidic wash to inhibit WGA binding or using sialic acid, which lowers the buffer 
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pH, to inhibit SNA or MAL II binding causes the cells to die and potentially lead to 
altered binding.  
As shown in figures 4.4 and 4.5 with Jacalin and Con A, serum proteins bound to the 
plate can cause significant background fluorescence. The plates used are treated to allow 
for surface proteins of adherent cells to attach which also allows glycosylated serum 
proteins to also attach to the surface (Zheng et al. 2006). The qualitative analysis of 
these lectins binding to the cell surface can still be observed but are impacted by these 
background lectin-serum protein interactions. This background binding is one of the 
significant drawbacks observed while carrying out live cell microscopy. In chapter 5 
when viewing cells using flow cytometry, the cells are washed and all serum proteins are 
removed. In this chapter the necessity to leave cells attached to the plate for probing and 
incubate the cells with serum proteins that also bind to the plate causes this method to be 
largely qualitative and makes any quantification difficult. Live cell analysis does not 
allow for fixation that would allow for additional wash steps and blocking that can 
reduce this background fluorescence. As mentioned previously cell fixation can cause 
issues with lectin binding to internal glycosylated proteins (Holmes et al. 2001). Other 
studies have used confocal microscopy rather than routine fluorescent microscopy due to 
the increased power of confocal microscopy to identify lectin binding (Peiris et al. 2012; 
Saint-Guirons et al. 2007). Confocal microscopy allows for more quantitative analysis of 
lectin binding as well as highlighting lectin localisation.   
There were a number of lectins used to determine the presence of glycans on the 
surfaces of each cell type. The main differences observed between the SW480 and 
SW620 cell types are the binding of MAL II and HPA. MAL II is an α-2,3-NeuNAc 
(sialic acid) binder. SNA is an α-2,6-NeuNAc (sialic acid) binder. Visually there appears 
to be similar binding of SNA to both cell types but also a decrease in the binding of 
MAL II to the surface of SW620 when compared to SW480. These comparisons were 
based off relative fluorescence for both images taken under the same conditions. No 
quantitative differences were observed in this chapter as the experiments were designed 
for qualitative results. LecB 3K and eGFP-LecB are shown in chapter 3 to bind to fucose 
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and mannose residues on mannose/fucose residues linked to BSA. For use in in vitro 
cellular analysis the probes needed to be tested against both cell types. Through the 
binding observed in figures 4.2, 4.3 and 4.5 the cells had already shown to have fucose 
and mannose present on the cell surface. Both LecB 3K and eGFP-LecB bind to these 
residues and are validated for in vitro cell binding by qualtitatively showing binding and 
competitive inhibition. The positive binding of LecB 3K to SW480 and SW620 allowed 
for it to be added to the panel of lectins used in Chapter 5 for flow cytometric analysis.  
HPA binding observed using both fixed and non-fixed SW480 cells was unexpected. In 
section 4.4 the HPA lectin was identified previously as a lectin that could determine 
between SW480 and SW620 as it would only bind to metastatic cells, i.e. the SW620 
cells. The binding profile of SW620 cells probed with HPA was as expected and in both 
cases the lectin is fully inhibited by its corresponding free sugar. HPA could be inhibited 
by both GlcNAc and GalNAc, as is shown in Section 5.5, and GlcNAc was used to 
competitively inhibit HPA in this chapter. The differential binding observed between 
both SW480 and SW620 still indicated that HPA could potentially indicate quatitative 
differences between the two cell types, even if the original expectations of HPA binding 
were not observed. A number of control experiments were designed for testing HPA 
binding to both cell lines and these will be explained and the results shown in chapter 5.   
Due to the qualitative nature of this analysis, these two lectins, MAL II and HPA, were 
identified as lectins of interest for the next chapter which attempts to use flow cytometry 
for more quantitative analysis of lectin binding using a larger panel of lectins to test 
SW480 and SW620.  
Establishing a glyco-profile using only ten different lectins and fluorescent microscopy 
is difficult. The panel chosen gives insights into the types of glycans on the surface and 
what sugar residues are present terminally. The negative control of GSL II gives more 
confidence in the binding observed with the other lectins, especially those who cannot 
be inhibited or full inhibited with a competitive free sugar. Chapter 5 will show more 
lectins that don’t bind to, or that do not bind all of, the cells when probed. The aim of 
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this chapter was to beging to characterise the two cell types based on the glycans they 
had present on their cell surface as well as indicate which lectins may show differences 
in the levels of binding observed.  
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Chapter 5 
Glyco-analysis of Colorectal Carcinoma 
Cell Lines SW480 and SW620 using Flow 
Cytometry 
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5.1 Overview 
This chapter describes the lectin probing of colorectal carcinoma cell lines SW480 and 
SW620. Throughout this project the two cell lines are stage 2 and 3 colorectal 
adenocarcinoma cell lines, respectively. Eukaryotic lectins and recombinantly produced 
lectins were used to probe live cells (non-fixed) via fluorescent microscopy and flow 
cytometry (Chapter 4). Fluorescent microscopy is a largely qualitative form of glyco-
analysis, whereas flow cytometry provides more quantitative data, allowing for specific 
changes in lectin binding between the two cell lines to be highlighted and compared. The 
binding analysis of live cells provides knowledge on what type of glycans are present on 
the cell surfaces of each cell line. Through the use of different lectins, which bind 
different target glycans, the presence or absence of specific glycans and glycan linkages 
can be observed. Additionally, the fold increase or decrease of specific glycans can also 
be observed. Competitive free sugars, as well as non-competitive free sugars are used to 
validate the lectin binding specificity through sugar inhibition studies. Recombinant 
LecB 3K, along with some other recombinantly produced prokaryotic lectins, was used 
in unison with the other eukaryotic lectins to glyco-profile the cells. In this chapter the 
lectins that show significant differences in cell surface binding are highlighted and 
discussed. The binding of HPA for both SW480 and SW620 proved to be very 
interesting and along with the data generated in the previous chapters, the HPA binding 
will be compared and contrasted with current literature.  
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5.2 Optimising the parameters for non-fixed cell probing and 
sample preparation of SW480 and SW620 for flow cytometry 
Full methodological details for this section are provided in Section 2.28. The gating 
strategy outlined in section 2.28.4 was used for all subsequent experiments using SW480 
and SW620. The forward scatter area (FSC-A) and side scatter area (SSC-A) for SW620 
and SW480 are different based on the cells being different in size. For this reason all 
gating carried out was cell line specific and the live gates were determined using 
unstained populations for each cell type (See Section 2.28). Cells were cultured as per 
section 2.25. The SW480 cells grown to 80% confluency after 48 hours routinely 
produced between 5-7 million cells per flask at approximately 98-99% cell viability. The 
SW620 cells grown to 80% confluency after 48 hours routinely produced between 9-11 
million cells per flask at approximately 98-99% cell viability as well. The methods 
outlined in section 2.28 were dictated based on various experiments carried out to 
identify the correct parameters. Due to the two cell types being adherent cells and 
needing to be trypsinised, washed, and probed all within the shortest time scale 
available, experimental parameters needed to be defined and optimised. Literature 
suggests probing with lectins at a concentration of between 1-10 µg/mL, while 
incubating the cells in the dark at 25 °C or 4 °C for 30-60 minutes (Kekalainen et al. 
2015 and Batisse et al. 2004). The variance in the cell incubation time, amount of lectin 
used and temperature of incubation time suggest a variability based on the type of cell 
and the specific lectins used in each experiment. To limit this variability experiments 
were carried out to find the optimum; cell number, lectin concentration used to probe 
and growth time of cells after seeding. The doubling time for SW620 is approximately 
26 hours, whereas the doubling time for SW480 is approximately 38 hours (American 
Type Culture Collection, 2012). To ensure the cells have attached to the plate and gone 
through one full growth phase, the cells are seeded and left to grow at 37 °C for 24, 48 
and 72 hours then probed with a small panel of six lectins to determine binding 
efficiency. The panel of lectins used were; Con A, DSL, ECL, GNL, Jacalin and PNA. 
The specificity for these lectins is shown in section 2.24. These lectins bind to a variety 
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of different cell surface glycans and show significant binding to both SW480 and 
SW620. Due to the difference in doubling time between the two cell types, the original 
seeding of the cells was adjusted to try and normalise the number of cells grown for each 
time point. In figure 5.1 the different time points are shown to highlight specific binding 
of the cells after each growth time point.  
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Figure 5.1: Lectin probing of SW480 and SW620 cells over 3 growth time points of 
24, 48 and 72 hours. Cells were grown for the specified times and probed with the same 
concentration of lectin for the same duration of time and samples were analysed using 
flow cytometry. A) Growth time 24 hours, B) Growth time 48 hours, C) Growth time 72 
hours. (n=1) 
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SW480 and SW620 cells were originally epithelial cells and behave as such in culture. 
The cells need to be attached to each other in order to ensure correct cellular function. 
After 24 hours the cells were not all attached and not given enough time to ensure a full 
growth cycle had taken place. After 48 hours the cells had undergone at least one full 
growth cycle and the cells still maintained a high level of cell viability. The mean 
fluorescent intensity values for both 24 and 48 hours were considerably higher than that 
of the samples tested after 72 hours. 48 hours was decided as the optimal growth time 
for cells before probing with lectins and sample application on the flow cytometer.  
 
After the growth time analysis was carried out, the optimal amount of cells and 
concentration of lectin per sample was investigated. A large number of cells can be 
cultivated in a relatively short period of time so the optimal number of cells probed with 
lectin is believed to be between 100,000 and 1 million cells. This study carried out lectin 
probing at four different concentrations of cells ranging from 125,000 to 1,000,000 cells. 
The study was carried out using 5 µg/mL of the lectin Con A which binds mammalian 
N-glycans. To determine the correct numbers of cells to use per sample three parameters 
were used, these were; percentage of cells in the live gate, mean fluorescent intensity 
and the ratio of mean fluorescent intensity between the two cell lines. In table 5.1 these 
values are highlighted.  
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Cell number % of cells in live gate Mean FITC intensity FITC Ratio 
(SW480:SW620) 
 SW480 SW620 SW480 SW620  
1,000,000 52.8 45.8 1257 742 1.69:1 
500,000 50.9 42.2 2551 1659 1.53:1 
250,000 47.8 45.4 4496 2678 1.67:1 
125,000 48.2 46 7148 5702 1.25:1 
Unstained 82.2 81.8 3.67 0.79 N/A 
 
Table 5.1: Lectin probing of SW480 and SW620 cells changing the number of cells 
probed. Four different amounts of cells were probed with the same concentration of the 
lectin Con A. Parameters of the experiment are cell number, percentage of cells in the 
live gate, mean fluorescent intensity and the ratio of FITC intensity between the two cell 
types.  
 
The lower the number of cells the higher fluorescent intensity observed, this is most 
likely caused by over saturation of lectin. Using a lower number of cells, 125,000, 
proved difficult due to the loss of cells at each centrifugation step and the cell death 
attributed to lectin binding. Running 10-15,000 cells on the flow cytometer per sample 
took longer and therefore increased the time between the first and last tube of the 
experiment being run on the flow cytometer. With non-fixed cell staining the shortest 
possible time between the first and last sample being run is optimal. For these reasons 
the cell number of 250,000-500,000 was determined to be the optimal for cell surface 
probing with lectins.  
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The saturation point of each cell type of each lectin is subjective and can change for 
each lectin. Some lectins cause a reduction in cell viability, as was stated in section 
2.28.4, and probing at higher concentrations causes an increase in the amount of cell 
debris and overall number of non-viable cells. Four lectins highlighted as cytotoxic and 
non-cytotoxic were used to determine an appropriate lectin concentration to probe these 
cells with. The four lectins chosen were AAL, PNA, SNA and NPL. Binding 
specificities for these four lectins are noted in Section 2.24. When the concentration of 
NPL and PNA are increased the number of cells within the ‘live’ gate remains relatively 
constant whereas when the concentration of AAL and SNA are increased the number of 
cells in the ‘live’ gate significantly diminishes. In table 5.2 the percentage of cells within 
the live gate, as well as the relative fluorescent intensities observed for varying 
concentrations of lectin are noted. Due to the decreased number of viable cells for flow 
cytometric analysis, the optimal concentration of lectin chosen for the remainder of the 
project was 5 µg/mL.  
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Concentration of 
lectin (µg/mL) 
Percentage of cells within 
the live gate 
FITC intensity 
 SW480 SW620 SW480 SW620 
SNA 1 80.7% 70.7 % 89.4 33.6 
SNA 5 77.1% 75.0 % 2327 2576 
SNA 10 45.7% 31.1 % 2381 2977 
SNA 20 33.1% 29.6 % 3099 2782 
SNA 50 30.9% 27.0 % 2758 2617 
     
NPL 1 83.0 % 83.8 % 34.3 28.1 
NPL 5 79.1 % 83.2 % 459 123 
NPL 10 78.3 % 85.1 % 506 170 
NPL 20 77.8 % 85.3 % 600 386 
NPL 50 77.5 % 81.6 % 538 405 
     
AAL 1 66.3% 57.1% 397 323 
AAL 5 47.1% 53.5% 1452 800 
AAL 10 23% 23.8% 1593 1715.5 
AAL 20 23.5% 21.5% 1579 1316 
AAL 50 23.5% 21.0% 2459 1234 
     
PNA 1 75.7% 79.3% 46.9 7.905 
PNA 5 77.4% 77.3% 789.5 1037 
PNA 10 73.9% 79.0% 768.5 807 
PNA 20 77.0% 81.6% 655.5 917 
PNA 50 74.9% 78.1% 351.5 1197 
 
Table 5.2: SW480 and SW620 cells probed using different concentrations of four 
lectins. The four lectins used are SNA, NPL, AAL and PNA at a concentration range of 
1-50 µg/mL. 
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5.3 Flow cytometric analysis of SW480 and SW620 using 
recombinant prokaryotic lectins and commercially purchased 
eukaryotic lectins 
The parameters determined in Section 5.2 were applied to all the subsequent flow 
cytometry experiments and a panel of 23 lectins (3 prokaryotic and 20 eukaryotic) was 
used to identify glycoprofile differences and similarities between SW480 and SW620. 
The lectins used in this section are shown below in table 5.3. The lectins were chosen 
due to their diverse binding affinities (Section 2.24). The most common sugars found in 
complex mammalian N- and O- linked glycans were accounted for, as well as 
determining specific glycan linkages.  
 
Lectins used as probes for flow cytometry 
AAL Con A DBA 
DSL ECL GNL 
GSL I GSL II HPA 
Jacalin LCA MAL I 
MAL II NPL PNA 
RCA SBA SNA 
UEA I WGA  
Recombinant Lectins used as probes for flow cytometry 
AAL 2 LecA LecB 3K 
Table 5.3: Eukaryotic and Prokaryotic lectins used as probes for flow cytometry. 
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The SW480 and SW620 cell lines used are significantly different in cell size, shown by 
number of available cells per plate at 80-100% confluency as well as the FSC-A and 
SSC-A of unstained populations monitored by the flow cytometer. FSC-A is generally 
used as a parameter to determine relative cell size. It is debated in the literature the exact 
size parameter it measures, i.e. is it cell surface area, cell volume or the diameter of the 
cell, all relative to the calibration beads used to ensure the lasers are correctly aligned 
(Taylor 2016; Knijnenburg et al. 2011; Biosciences 2000). Cells trypsinised and re-
suspended in buffer for analysis on the flow cytometer lead to the cells being in a 
relatively spherical state. The SW480 cells are significantly larger than SW620 cells, 
which can be seen by the difference in FSC-A values shown in figure 5.2. The difference 
in relative size of each cell type signifies a potential surface area change between the 
two cells. This surface area change allows for the additional binding of each lectin as a 
percentage of cell surface area. For this reason the absolute values for binding being 
higher in general for SW480 cells over SW620 cells do not necessarily represent an 
increase in that specific glycan target. Some of the lectins that bind with a ratio close to 
2:1 for SW480:SW620 are believed to be representing the lectins that do not highlight a 
significant difference in glycan per surface area on either cell type. Again for this reason 
the lectins binding SW480 above this relative 2:1 ratio are believed to be showing an 
increase in the presence of their glycan target on the surface of SW480. The inverse is 
also used to signify the increase in the presence of specific glycan targets on the SW620 
cell surface. These are reflected by the lectins that bind close to a 1:1 ratio for between 
the 2 cell lines. The three groups; ‘normal’ ratio binding, increased glycan targets on the 
surface of SW480 and increased glycan targets on the surface of SW620 are represented 
in figures 5.3, 5.4 and 5.5, respectively. 
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Figure 5.2: The mean FSC-A values for SW480 and SW620 cells viewed on a flow 
cytometer to determine relative cell size. Data are means ± standard deviations. * 
represents P < 0.05, n=3. 
A smaller number of lectins, three out of the panel, used showed significant increases in 
lectin binding on SW480 over SW620 whereas another small number, five out of the 
panel, of lectins showed increases in lectin binding on SW620 over SW480. Figures 5.3, 
5.4 and 5.5 show the differences in binding exhibited for different lectins on SW480 and 
SW620. All binding was expressed as a ratio of binding for SW480 compared to 
SW620. The relative fluorescent intensities recorded for each lectin on the SW620 cells 
are normalised to 1 and the fluorescent intensities recorded for SW480 are expressed as 
a ratio relative to that. Each lectin exhibits different mean fluorescent intensities due to 
the differences in each lectin. The potential binding of the fluorophores used to each 
lectin can change and each individual lectin is not compared to another lectin. Some 
lectins that did not bind were commonly used as negative controls, such as GSL I and 
GSL II. Both GSL I and GSL II showed no binding and will not be represented on any 
of the subsequent graphs. This is shown in figure 5.6 that compares the positive cells in 
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the population to the negative cells in the population. Another lectin that shows both 
relatively strong binding as well as no-binding within the cell population is PNA. PNA 
seems to bind anywhere from 40-60% of the cells in a given population, showing the 
heterogeneity in the cell lines. Due to both DBA and PNA having large numbers of 
FITC-A positive and negative cells within the live gate the mean fluorescent intensity 
for each population was not used to determine the ratio of fluorescent intensity between 
the two cell lines. WGA findings were mixed with the ratio of binding between SW480 
and SW620 cells ranging from 1:1 to 2:1. This was caused by WGA’s cytotoxic effects 
leading to low numbers of cells within the live gates. WGA is not used in figures 5.3, 5.4 
or 5.5 but its histograms are shown in figure 5.6. 
 
Figure 5.3: Lectin binding to SW480 and SW620 cells, showing a relative 2:1 
binding pattern for SW480:SW620. These nine lectins show a normal binding pattern 
for SW480 and SW620 due to the difference in cell sizes. SW620 cells have been 
normalised to 1. SW480 cells are represented by blue histograms, while SW620 cells are 
represented by red histograms. Data are means ± standard deviations. * represents P < 
0.05, n=3. (AAL 2 experiment only carried out once). 
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Figure 5.4: Lectin binding to SW480 and SW620 cells, showing an increase in 
binding for SW480 over SW620. These three lectins bind more to SW480 than SW620. 
SW620 cells have been normalised to 1. SW480 cells are represented by blue 
histograms, while SW620 cells are represented by red histograms. Data are means ± 
standard deviations. * represents P < 0.05, n=3. 
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Figure 5.5: Lectin binding to SW480 and SW620 cells, showing an increased 
binding to SW620 over SW480. Similar binding infers increased binding to SW620 
due to decreased cell size when compared to SW480. SW620 cells have been normalised 
to 1. SW480 cells are represented by blue histograms, while SW620 cells are 
represented by red histograms. Data are means ± standard deviations. * represents P < 
0.05, n=3. 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
LecA SNA SBA Jacalin MAL I
N
o
rm
al
is
e
d
 m
e
an
 f
lu
o
re
sc
e
n
t 
in
te
n
si
ty
 
211 
 
5.3.1 Histogram analysis of lectin binding to SW480 and 
SW620  
All data in figures 5.3 to 5.5 were acquired using the average of three mean fluorescent 
intensity values from different repeated experiments. These experiments allowed for the 
mean fluorescent intensity (FITC-A) values to be obtained using FlowJo, see section 
2.28. FlowJo generates histograms that allow for similarities and differences between the 
binding profiles of each lectin on the two cell lines to be compared. Some of the lectins 
bind relatively uniformly giving a sharper peak on a histogram whereas others give a 
much broader peak. For these reasons the error bars on figures 5.3 to 5.5 are greater than 
desired. The histogram figures below allow for direct comparison between the two cell 
lines for each individual lectin. The unique differences, such as binding specificity and 
available biotin labels, between each lectin means a direct comparison between lectins 
themselves is more difficult to control for.  
Figures 5.6 and 5.7 show the histograms for all the eukaryotic and prokaryotic lectins, 
excluding DBA and HPA, with the FITC-A compared to the unstained control cell 
population. Each graph is normalised to the mode to allow for clear histogram images. 
The histogram peak distribution highlights the differential binding of each lectin to that 
specific cell line. Some lectins have a smaller number of cells that have a high level of 
lectin binding. This causes a tailing effect in the histogram that shows the fluorescent 
intensity for these cells is considerably higher than the average in the population. The 
tailing effect is represented by the histograms for LCA, MAL I, PNA and ECL to a large 
extent. The amount of positive and negative cells in the live gate remained relatively 
constant for LCA, MAL I and ECL, but PNA probing varied from between 40-70% for 
relative fluorescent intensity (FITC-A).  
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Figure 5.6: Analysis of eukaryotic lectins binding to both SW480 and SW620 cells 
as represented by histograms. The histograms show Lectin probed cells as represented 
by non-filled dark blue histograms and the unstained cell population, not probed with 
lectin, are represented by filled grey histograms. The lectin name is to the left of each 
histogram. The histograms were both normalised to the mode, n = 3. Each lectin has a 
different specificity (Section 2.24). All lectins used were purchased from Vector Labs®. 
The SW480 probed cells are on the left hand side, while the SW620 probed cells are on 
the right hand side. 
The recombinant lectins used were all biotinylated (Section 2.22) so that the streptavidin 
linked fluorescent dyes could be used for both the recombinant lectins and the 
eukaryotic lectins. The three recombinant lectins were AAL 2, LecA and LecB 3K. The 
AAL 2 and LecA lectins were also recombinantly produced and purified. Figure 5.7 
shows the three histograms of these lectins compared to the unstained negative control. 
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Figure 5.7: Analysis of recombinant prokaryotic lectins binding to both SW480 and 
SW620 cells. The histograms show Lectin probed cells as represented by non-filled dark 
blue histograms and the unstained cell population are represented by filled grey 
histogram. The lectin name is to the left of each histogram. The histograms are 
normalised to the mode, n = 3. 
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DBA is another lectin that highlighted heterogeneity, similar to LCA, MAL I and PNA, 
but to a much lesser degree. DBA for SW620 shows 4-12% positively stained cells 
within the live gate whereas DBA for SW480 shows 1-3% positively stained cells within 
the live gate. Due to these cells being largely negative, the positive population was 
compared to the negative population in histogram analysis. In figure 5.8 the DBA lectin 
comparisons to its unstained negative control cannot show the significantly high binding 
targets, whereas in figure 5.9 the FITC-A positively stained cells compared to the FITC-
A negative cells show the extremely positive cells.  
 
 
SW480     SW620 
  
Figure 5.8: Analysis of DBA probing to both SW480 and SW620 cells. The 
histograms show DBA probed cells as represented by non-filled dark blue histograms 
and the unstained cell population is represented by filled grey histograms. The 
histograms have been normalised to mode, n = 3. 
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Figure 5.9: Analysis of DBA positively stained cells compared to both unstained 
cells and the DBA negative cells. A) SW480 unstained cells overlaid with FITC-A 
positive cells, B) SW480 FITC-A negative cells overlaid with FITC-A positive cells, C) 
SW620 unstained cells overlaid with FITC-A positive cells, D) SW620 FITC-A negative 
cells overlaid with FITC-A positive cells. Grey represents unstained cells, Black 
represents FITC-A negative cells probed with DBA and Pink represents FITC-A positive 
cells probed with DBA. All histograms were normalised to mode, n = 3.  
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5.4 Lectin binding inhibited using competitive free sugars 
tested using flow cytometry 
In Chapter 4 a number of lectins were pre-incubated with different concentrations of 
their corresponding free sugar. These free sugars caused inhibition in lectin binding to 
the surface of the cells. Using sugars to competitively inhibit binding signifies the 
specificity of the lectin binding and proves the lectins are binding via their sugar binding 
site and not through any other protein-protein interactions. To ensure the inhibition is 
specific each lectin chosen to be inhibited is subjected to an inhibitory sugar, as well as a 
sugar the lectin has no affinity for that will not greatly affect lectin binding, i.e. non-
inhibitory. For the same reason as in chapter 4 some lectins, WGA, SNA and MAL II, 
were not chosen for sugar inhibition due to the pH change in buffer with addition of 
sugar or where there are additional wash steps with acid or basic solutions. Out of the 
twenty three lectins used for glyco-profiling, four eukaryotic lectins (AAL, ECL, Jacalin 
and NPL) and two recombinant prokaryotic lectins (LecA and LecB) were chosen to be 
tested with two different inhibitory and non-inhibitory sugars. Some other lectins were 
tested in this way and those histograms can be seen in appendix B.1. Table 5.4 shows the 
lectins chosen as well as the two different sugars used. As in Chapter 3 and Chapter 4, 
not all lectins subjected to a high level of free sugar can be specifically inhibited. This is 
caused by the lectins need to bind complex glycans that are exhibiting specific linkages 
with the under lying glycan structure. 
Each lectin was represented by a quad-panel of histograms with 2 conditions represented 
in each panel. Panel 1 shows unstained cells overlaid with lectin stained cells; panel 2 
shows unstained cells overlaid with lectin stained cells whereby the lectin was first pre-
incubated with its corresponding inhibitory sugar; panel 3 shows lectin stained cells 
whereby the lectin was first pre-incubated with its corresponding inhibitory sugar 
overlaid with cells probed with lectin and panel 4 shows lectin pre-incubated with its 
corresponding inhibitory sugar overlaid with lectin pre-incubated with a non-inhibitory 
sugar. These panels highlight the specificity of each lectin by showing the minimal 
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amount of inhibition observed when pre-incubating a lectin with a sugar it has no 
affinity for when compared to near total inhibition when pre-incubated with a sugar the 
lectin has affinity for.  
 
Lectin sample Inhibitory sugar Non-inhibitory sugar 
AAL 200 mM L-fucose 200 mM D-fucose 
ECL 200 mM lactose 200 mM L-fucose 
Jacalin 100 mM melibiose 100 mM glucose 
NPL 200 mM α-methylmannoside / 
α-methylglucoside 
200 mM glucose 
LecA 200 mM galactose 200 mM L-fucose 
LecB 3K 200 mM L-fucose 200 mM D-fucose 
Table 5.4: Panel of lectins pre-incubated with inhibitory and non-inhibitory free 
sugars used to probe SW480 and SW620 cells. The inhibitory sugars and their 
concentrations are supplied by Vector Laboratories®. The concentration of non-specific 
sugar was determined based on the concentration suggested for inhibition.  
 
The majority of specific competitive inhibitory sugars caused lectin binding to be nearly 
completely inhibited though although there are some lectins that cannot be fully 
inhibited, such as jacalin. In figure 5.12 the green histograms that show jacalin pre-
incubated with melibiose only showed partial inhibition where there was still a 
significant amount of the cell population in the live gate fluorescently labelled. Lectin 
specificity is determined by the probes ability to bind to the cells in the presence of a 
non-competing sugar as well as its inability to bind to the cells in the presence of a 
competing sugar.  
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Figure 5.10: SW480 and SW620 cells probed with AAL and AAL pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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Figure 5.11: SW480 and SW620 cells probed with ECL and ECL pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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Figure 5.12: SW480 and SW620 cells probed with Jacalin and Jacalin pre-
incubated with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 
cells. Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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Figure 5.13: SW480 and SW620 cells probed with NPL and NPL pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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Figure 5.14: SW480 and SW620 cells probed with LecA and LecA pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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Figure 5.15: SW480 and SW620 cells probed with LecB 3K and LecB 3K pre-
incubated with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 
cells. Inhibitory and non-inhibitory free sugars are shown in table 5.4. Histogram colour 
scheme displayed in text box adjacent to A) and B). 
A) 
B) 
Colour scheme for 
sugar inhibition 
histograms; 
Grey = Unstained 
Cells 
Blue = Cells 
probed with lectin 
Green = Cells 
probed with lectin 
pre-incubated 
with inhibitory 
sugar 
Red = Cells 
probed with lectin 
pre-incubated 
with non-
inhibitory sugar 
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5.5 Analysis of Helix Pomatia Agglutinin (HPA) binding to 
SW480 and SW620 cells using flow cytometry 
The Helix Pomatia Agglutinin (HPA) lectin show some interesting results when 
compared to the other lectins. HPA is the only animal derived lectin used in the study 
and there are published reports in which it was used to distinguish between metastatic 
and non-metastatic cells, using both the SW480 and SW620 cell lines used in this study. 
Studies carried out in the past have used HPA as a negative control lectin for SW480, i.e 
it does not bind to these cells, and a positive marker for SW620 (Schnegelsberg et al. 
2011; Saint-Guirons et al. 2007; Peiris et al. 2012). HPA is a dual specific lectin that has 
a strong binding affinity for both GalNAc and GlcNAc to a lesser degree (Rambaruth et 
al. 2012; Sanchez et al. 2006). It was understood to be solely a GalNAc binder but now 
is now known to bind both of these sugars and can be fully inhibited when pre-incubated 
with either GalNAc and GlcNAc at a concentration of 200 mM (see Figure 5.16). HPA 
was used to probe both SW480 and SW620 cells and the cells were viewed using 
fluorescent microscopy, see previous chapter section 4.3, and flow cytometry. HPA 
showed low level binding for SW480 cells on the fluorescent microscope, which was 
originally not expected, whereas it showed strong binding to some SW620 cells and no 
binding to others. The profile shown on fluorescent microscopy for SW620 cells fits a 
similar binding profile to other studies (Peiris et al. 2012). The experiment was repeated 
a number of times for SW480 cells and the outcome remained the same, low level 
binding is oberserved and HPA pre-incubated with a competitive inhibitory free sugar, 
GlcNAc, the binding is not observed. HPA was used to probe cells and the cells run on 
the flow cytometer to quantitiatively analyse the HPA binding to SW480 and SW620. 
Firstly HPA was tested using the ELLA platform, see section 2.24, to ensure activity and 
test for sugar inhibition. In figure 5.16 the HPA lectin is tested on a selection of glyco-
proteins. The HPA is also pre-incubated with 200 mM of GlcNAc and 200 mM GalNAc 
to show binding inhibition. 
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Figure 5.16: ELLA analysis of HPA binding to commercial glycoproteins including 
competitive sugar inhibition. A) Asialofetuin, fetuin and thyroglobulin bound with the 
HPA lectin, B) Asialofetuin bound with the HPA lectin as well as using competitive 
sugars to inhibit HPA binding. HPA 1 representes HPA pre-incubated with 200 mM 
GlcNAc and HPA 2 representes HPA pre-incubated with 200 mM GalNAc. Bars on the 
chart; Grey = PBS, Yellow = Asialofetuin, Orange = Fetuin, Light blue = Thyroglobulin. 
† denotes a positive value surpassing the threshold limit (Section 2.30), n = 3. 
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Following the same protocol and parameters laid out in Sections 2.28 and 5.2 HPA was 
used to probe both SW480 and SW620. Figure 5.17 shows the binding profiles of HPA 
bound to SW480 and SW620 analysed through flow cytometry. After testing HPA 
binding on both cell types, the HPA was pre-incubated with 200 mM GlcNAc to ensure 
binding was lectin-glycan specific. In figure 5.18 the histograms displayed show the 
complete sugar inhibition of HPA. 
 
 
SW480     SW620 
  
Figure 5.17: Cell surface glycoprotein analysis using HPA probe to both SW480 
and SW620 cells. HPA probed cells are represented by non-filled dark blue histograms 
and the unstained cell population are represented by filled grey histograms. The 
histograms have been normalised to mode, n = 3. 
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SW480     SW620 
  
Figure 5.18: Analysis of HPA and HPA pre-incubated with 200 mM GlcNAc 
binding to SW480 and SW620 cells. The histograms show HPA probed cells as 
represented by non-filled dark blue histograms and cells probed with HPA pre-incubated 
with 200 mM GlcNAc are represented by non-filled green histograms. The histograms 
have been normalised to mode, n = 3. 
 
 
Eukaryotic lectins can have batch variation due to their source. This was hypothesised as 
one of the possible reasons for possible HPA binding to SW480, so another batch of 
HPA was purchased and used to probe the SW480 and SW620 cells. A second batch of 
HPA showed a similar binding profile for the two cell types, see figure 5.19. 
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SW480     SW620 
   
Figure 5.19: Analysis of a second batch of HPA probing to both SW480 and SW620 
cells. The histograms show HPA probed cells as represented by non-filled dark blue 
histograms and the unstained cell population are represented by filled grey histograms. 
The histograms have been normalised to mode, n = 3. 
 
A number of studies that use HPA as a negative control lectin for SW480 cells used 
paraformaldehyde fixed cells to probe with lectins. All probing is carried out on live 
cells throughout this project to ensure lectin binding was specifically on cell surface 
glycans only. SW480 cells were fixed to try and identify if cell fixation leads to a 
removal of the HPA binding observed. Both batches of HPA were used to probe fixed 
SW480 cells. It can be seen that the level of HPA binding increases when compared to 
HPA binding of non-fixed live cells, this can be seen by the reduced tailing effect in the 
histograms generated in figure 5.20. 
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Figure 5.20: Histogram analysis of HPA binding to fixed SW480 cells. A) Original 
batch of HPA compared with same batch of HPA pre-incubated with 200 mM GlcNAc, 
B) Second batch of HPA compared with same batch of HPA pre-incubated with 200 
mM GlcNAc. HPA probed cells are represented by non-filled dark blue histograms and 
the cells probed with HPA that had been pre-incubated with 200 mM GlcNAc are 
represented by non-filled green histograms. The histograms have been normalised to 
mode, n = 2. 
 
After testing the difference between fixed cells and non-fixed cells the HPA lectins were 
still found to bind to SW480 cells. The next control experiment carried out used another 
batch of SW480 cells that were originally purchased from a different lab group. The 
cells had not been co-incubated with the SW480 cells used in this project and were never 
in the same cell culture room or laboratory. The cells supplied were probed with the 
original HPA lectin and no sugar inhibition was capable of being carried out at the time. 
Figure 5.21 shows the histograms obtained from the HPA binding found on these 
alternate SW480 cells. The binding profile is slightly different but there again is a 
smaller number exhibiting high level binding and a large number exhibiting low level 
binding.  
A B 
234 
 
 
Figure 5.21: Histogram analysis of HPA binding to alternate SW480 cells. HPA 
probed cells are represented by non-filled dark blue histograms and the unstained cell 
population are represented by filled grey histograms. The histograms have been 
normalised to mode, n = 1. 
 
 
The SW480 and SW620 cell lines used in this project were authenticated by STR 
genotyping (Eurofin Genomics) and routine mycoplasma testing was carried out to 
ensure the cells were the correct cell lines and contamination free. These controls were 
all carried out and the HPA probes used in this study are found to bind to SW480 
repeatedly with the same binding profile exhibited in each case.  
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5.6 Discussion 
The growth time study showed cells grown for 48 hours after passage were the optimal 
time for lectin probing based on the binding of a small panel of different lectins at the 
same concentration. The concentration study using four different lectins, two cytotoxic 
and two non-cytotoxic, allowed for the optimal concentration of 5 µg/mL to be worked 
out. The total number of cells used per sample was between 300,000-500,000 cells based 
on experiments carried out using the lectin Con A at 5 µg/mL. These parameters were 
decided based on cell viability and mean fluorescent intensity observed using both cell 
liness and were used for the remainder of the experiments carried out.  
Flow cytometric analysis of these two cell types probed with different eukaryotic and 
prokaryotic lectins showed that there are significant differences in the glycans present on 
the cell surface. A number of lectins fit the ‘normal’ ratio of binding between the two 
cell types, see figure 5.3. Some of the lectins, both the recombinantly produced and 
commercially purchased lectins, showed a relative increase in certain target glycan 
residues on the surface of each cell type. Each cell is probed with the same concentration 
of lectin and the relative fluorescent intensity value of the fluorophore is recorded as 
well as giving the visual histograms depicting the spread of binding throughout the cell 
population. PNA, LCA, MAL I and ECL show a ‘tailing’ effect due to a larger 
population having low fluorescent intensities compared to some cells in the population 
that are exhibiting high fluorescent intensities. LCA, MAL I and ECL showed relative 
consistency when binding to the cells. PNA was not used in determining the ratio of 
binding between each cell type due to the variance displayed between each experiment. 
As mentioned in the previous sections PNA can bind as little as 40% and as high as 70% 
of cells depending on the experiment chosen. The heterogeneity in the cell lines is 
evident with this result.  
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Some lectins do not bind to either of these cell lines, such as GSL I and GSL II. There 
are no lectins used in this study that bind to one cell line and do not bind to the other. 
The lectins chosen have all been shown to bind mammalian cells. Three of lectins, GNL, 
UEA and MAL II, showed a significant increase in fluorescent intensity for SW480 over 
SW620. Their specific glycan sights are bound more on the surface of the SW480 cells 
indicating the levels of these glycans are increased. Five of lectins, LecA, SNA, SBA, 
Jacalin and MAL I, showed a significant increase in fluorescence intensity for SW620 
over SW480 based on their ratio binding. SNA, SBA and Jacalin show increased binding 
on SW620, whereas LecA and MAL I show a near 1:1 ratio of binding between the 2 
cell types. The histograms shown in figures 5.6 and 5.7 represent the binding profiles of 
each lectin for each cell type. The two cell types exhibit very similar histogram binding 
profiles. The similarities in the binding profiles give strength to the differences shown 
when comparing the binding ratios between the two cell lines.  
A decrease in MAL II binding to SW620 is evidence of a decrease in the amount of α-
2,3 linked sialic acid. This leads to an increase in the available galactose binding sites on 
SW620 which allows for increased LecA and Jacalin binding on SW620. SNA is also a 
sialic acid binder but it prefers the α-2,6 linked sugar. The increase in SNA binding 
coupled with the significant decrease in MAL II binding highlights a shift in the type of 
sialic acid capping occurring on the surface glycans of SW620 cells when compared to 
SW480 cells. 
Along with determining the glyco-profiles of each cell line this method can also 
highlight small subsets of cells with different glyco-profiles. If these subsets of cells 
exhibit a unique glycan on their cell surface, lectins can detect these glycans using flow 
cytometry. DBA bound a low percentage of SW620 cells and an even lower percentage 
of SW480 cells, see figure 5.9, showing this lectins ability to distinguish between cells 
even if the percentage of positive cells is relatively low in the whole population. DBA 
has a binding affinity for α-linked N-acetylgalactosamine which is the common starting 
sugar for O- linked glycans but rarely found terminally α-linked.  
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To prove the lectins were binding their specific glycan targets a number of lectins were 
chosen for inhibitions studies using a corresponding inhibiting sugar as well as a non-
inhibitory sugar. In section 5.4 each lectin chosen shows almost complete inhibition for 
each lectin chosen, with the exception of jacalin, when pre-incubated with its 
competitive inhibiting sugar. These lectins are also not inhibited when pre-incubated 
with a non-inhibitory sugar proving the specific lectin-glycan interaction on the cell 
surfaces of both SW480 and SW620. 
HPA probing of SW480 and SW620 cells showed a similar binding pattern to the lectins 
PNA, MAL I, LCA and ECL with a tailing effect where some cells show low or no 
fluorescence and some cells show high levels of fluorescence. As explained in section 
5.5 the HPA lectin was originally added to the panel of lectins used to act as a negative 
control for SW480 cells and show a difference in binding profiles between the two cell 
types. After testing different batches of HPA, SW480 cells from a different original cell 
stock and comparing fixed cells and non-fixed cells, all coupled with sugar inhibition 
studies, the binding of HPA to SW480 cells was validated. HPA bound to SW620 cells 
as expected and previously shown in literature (Peiris et al. 2012).  
Flow cytometric analysis, through use of binding ratios as well as histogram generation, 
allows for more quantitative analysis of lectin binding to the surface of cells. The 
histograms generated show the spread of binding within a cell sample, i.e. the peak area. 
This along with the ratio of binding of each lectin between the two cell types allow for 
comprehensive analysis of different cells using a large panel of lectins where the results 
can be compared and contrasted to identify potential glycan changes.  
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Chapter 6 
Final Discussion and Conclusions  
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In summary, the major aim of this thesis was to assess the feasibility of utilising a 
combination of lectin based probes and flow cytometry to interrogate the surface 
glycosylation of a cell. A key part of this study was to exploit the adaptability of 
recombinant probes. Therefore, this work initially describes the DNA manipulation 
carried out on the PA-IIL gene, which encodes for the LecB protein, to generate a 
number of altered LecB probes. This was carried out in an attempt to alter specific 
attributes of the protein and generate a library of probes that could be used for in vitro 
cell analysis. A number of mutations were introduced to the gene. The LecB variants 
described in chapter 3 were all purified and characterised to show if there were any 
changes in the binding specificity of the different probes. The LecB S24T mutant was an 
unsuccessful attempt at trying to create a LecB probe that is specific for a single sugar, 
which is desirable over the current dual specific wild type LecB. A knock out mutation 
was also added in the form of LecB S23A;S24A;G25A (LecB 3A) which was trying to 
alter the sugar binding pocket of the protein without impacting the calcium binding 
pocket which shares some of the other residues found in the sugar binding pocket. These 
two probes did not achieve their intended purpose. The LecB 3A protein did not reduce 
the binding when tested against the wild type LecB. The LecB S24T mutant also 
remained active and bound to both fucose and mannose with relatively similar affinity as 
the wild type LecB. Both of these probes were not used in the subsequent chapters 4 and 
5.   
The two other LecB variants were generated to use with the in vitro cell analysis carried 
out in chapters 4 and 5. Three lysine residues were added into the LecB protein between 
the poly-histidine tag and the start codon for the LecB gene. The other LecB variant 
generated was an eGFP-LecB fusion. The three lysine residues were added to aid in the 
biotinylated of the LecB protein which utilises the NH
3+
 side group of lysine to attach 
biotin labels. The eGFP-LecB protein was generated to bypass the need for direct 
chemical fluorophore labelling. Both of these LecB mutants proved to be potentially 
valuable research tools for in vitro cell surface analysis when used in conjunction with 
both fluorescent microscopy and flow cytometry.  
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This work has highlighted the malleability that some prokaryotic lectins show when 
trying to develop more unique lectin probes. Introducing a number of mutations to the 
wild type LecB protein allowed for the generation of a number of LecB variants. Though 
some of these mutations did not change the binding capabilities of the protein there are 
other potential mutations that could be introduced that could alter the specific binding of 
the lectin.  
In chapters 4 and 5 the in vitro analysis of probing non-fixed live cells with a panel of 
eukaryotic and prokaryotic lectins is carried out. The panel of lectins chosen was 
intended to try and cover the majority of important sugars involved in mammalian 
glycosylation. The main sugars involved in mammalian glycosylation are explained 
throughout section 1.2. There are 6 pivotal sugars that are present in varying amounts 
between the different types of glycosylation. Fluorescent microscopy was used for 
qualitative analysis of lectin binding to the cell surface, as well as validation for the 
prokaryotic probes generated and characterised in chapter 3. After the qualitative 
approach was used the lectin probes were used to probe cells in suspension and the 
samples analysed using flow cytometry. Flow cytometry is a more quantitative method 
to analysis cell surface binding of lectin probes. It was the intention of this research 
project to show that lectin probes could be used to establish a glycan-profile for the 
surface glycans present on each cell line. Once the glycan-profiles were outlined, these 
cell types could then be compared to each other to try and identify the changes in surface 
glycosylation.  
One problem encountered throughout chapter 5 is the potential cytotoxicity of lectins 
when used to probe live cells. The study carried out to try and find the optimal probing 
concentration shows that high levels of binding can be achieved with 5 µg/mL of lectin 
but even cells probed at this concentration with some lectins, such as AAL and WGA, 
still exhibit a high level of cell death when compared to the unstained population. The 
method of live, non-fixed cell probing was still chosen as the optimal way to interrogate 
the cell surface despite the high level of lectin toxicity. Using flow cytometry a large 
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number of cells can be analysed in a short period of time which can allow for 
statistically valid experiments to be carried out even with the potential cell lose.  
The most significant problem faced is normalising for the difference in relative cell size. 
The cells are notably different in size when compared using the forward scatter area 
parameter. The difference in relative cell size is believed to equate to a difference in cell 
surface area due to the cells being spherical when run through a flow cytometer. Figure 
5.2 shows a significant different in relative size between the two cell lines using FSC-A. 
The increased cell surface area of SW480 cells over SW620 cells means that a 
proportional increase in mean fluorescent intensity is expected. The surface of the cells 
is covered in glycoproteins and glycolipids that increase with the increase in surface 
area. 
In chapter 5 the lectins that displayed a ratio of 2:1 between SW480:SW620 cells were 
chosen as the relative ‘normal’ pattern of binding that did not highlight any significant 
changes in these sugar residues. Three lectins showed a larger increase than 2:1 when 
compared between the two cell types, these were; GNL, UEA-I and MAL II. GNL binds 
to high and core α-mannose, UEA-I binds to α-1-2-Fucose and MAL II binds to α-2,3-
NeuNAc (sialic acid). Five lectins showed a different ratio of binding between the cell 
lines which was closer to a 1:1 ratio. These lectins were; LecA, SNA, SBA, Jacalin and 
MAL I. LecA and Jacalin bind to galactose residues, with Jacalin also binding to T-
antigen. SBA binds to both α- and β- linked terminal GalNAc and to a lesser extent 
galactose. MAL I also binds galactose but with the linkage β-1,4-GlcNAc and not β-1,3-
GlcNAc which represents T-antigen. SNA binds to α-2,6-NeuNAc.  
These lectins highlight changes that relate to each other. The large decrease in MAL II 
binding indicates a reduction in the amount of sialic acid capping occurring on the now 
terminal galactose in SW620 cells. This allows for an increase in galactophilic lectins to 
bind to the exposed galactose. An increase in SNA also indicates an increase in sialic 
acid capping but with an α-2,6-NeuNAc cap rather than α-2,3-NeuNAc on SW620 cells. 
The differential binding of these lectins highlight the cell surface glycan alterations 
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found on these cancer cell lines at different stages. With this, other lectins such as PNA 
and DBA show that subsets of cells can be identified based on their surface glycans. 
These findings highlight the feasibility of using flow cytometry coupled with lectins to 
identify quantitative differences in surface glycans between different cell lines. 
Ultimately using other methods to also assess the absolute cell size would allow for 
more sensitive quantification of lectin binding to show lower increases or decreases.  
Gene expression analysis carried out on a number of different types of cancer highlight 
changes in glycan sialyation. In the literature a number of glycotransferase genes 
involved in sialyation have differential expression depending on the type of cancer 
tested. For instance, breast cancers have shown an increase in β-galactoside α-2,3-
sialyltransferase I and VI (ST3 Gal I/VI) expression, leading to an increase in α-2,3-
sialic acid capping (Pearce and Laubli 2016). This overexpression can also be seen in a 
number of different types of cancer such as cervical cancer (Wang 2004). Our findings 
showed that there was a significant decrease in α-2,3-sialylation when comparing the 
non-metastatic SW480 to the metastatic SW620 but also showed an increase in α-2,6-
sialylation. Colorectal carcinomas have been shown in the past to have an up-regulation 
of in β-galactoside α-2,6-sialyltransferase (ST6 Gal I) which differs from the other two 
cancers mentioned. In various studies carried out ST6 Gal I is found to be upregulated 
while ST3 Gal genes are found to be downregulated in colorectal carcinomas (Park and 
Lee 2013; Dall’Olio et al. 1997). Our findings of decreased MAL II binding and 
increased SNA binding along with an increase in binding of a number of galactophilic 
lectins are in broad agreement with that as reported in the literature.  
Also in chapters 4 and 5 the binding of the HPA lectin is tested against the two cell lines, 
with SW480 cells also being fixed to replicate some of the methods shown in literature. 
The binding of HPA was not expected for SW480 cells and was originally identified as a 
unique lectin that could distinguish between the non-metastatic SW480 cells and the 
metastatic SW620 cells. After testing HPA changing a number of the parameters the 
binding was validated and found to bind to SW480 cells both fixed and non-fixed. The 
control experiments included; using a second batch of HPA, using SW480 cells from 
243 
 
another source, using free sugars to competitively inhibit HPA binding and fixing the 
cells using paraformaldehyde. The two cell lines were also authenticated and the HPA 
binding remained constant throughout a number of repeat experiments. 
All experimental results for chapters 4 and 5 generated quantitative and qualitative data 
for lectin binding to both cell types. Table 6.1 highlights the lectins that bound and did 
not bind to SW480 and SW620 cells as well as highlighting the level of binding and 
lectins that showed significant differences in binding between the two cell lines.  
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Lectin Quantitative 
SW480 
Quantitative 
SW620 
Significance 
marker 
SW480 
Qualitative   
(+/-) 
SW620 
Qualitative   
(+/-) 
AAL ++ ++ * + + 
ConA ++ ++ * + + 
DBA +/- +/- N/A + + 
DSL ++ ++ - + + 
ECL + + * + + 
GNL ++ + * + + 
GSL I - - N/A - - 
GSL II - - N/A - - 
HPA +/- +/- N/A +/- +/- 
Jacalin ++ ++ - + + 
LCA + + * +/- +/- 
MAL I + + - + + 
MAL II ++ + * + + 
NPL ++ ++ * + + 
PNA +/- +/- N/A +/- +/- 
RCA ++ ++ - + + 
SBA ++ ++ - + + 
SNA ++ ++ - + + 
UEA I ++ + * + + 
WGA ++ ++ N/A + + 
AAL 2 + + N/A + + 
LecA ++ ++ - + + 
LecB + + * + + 
Table 6.1: Comparative results between SW480 and SW620 bound with eukaryotic 
and prokaryotic lectins. For quantification ++ denotes a mean fluorescent intensity 
value (FITC-A) of >500, + denotes a mean fluorescent intensity value (FITC-A) of 50-
500 and – denotes a mean fluorescent intensity value (FITC-A) of <50. For 
quantification +/- denotes to lectins that produced a mixed histogram with both FITC-A 
positive and FITC-A negative cells. Not all lectins were compared between cell lines, 
and these lectins have no significance marker denoted N/A. * denotes P value <0.05 and 
– denotes a P value of >0.05. For qualitative results + denotes positive lectin binding, - 
denotes no lectin binding and +/- denotes a mix of lectin bound and unbound cells in a 
single population.   
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The relative size difference between SW480 and SW620 cells make direct comparisons 
more difficult, but as explained in chapter 5 there were some lectins that show 
differential binding between the cells. These lectin binding profiles were statistically 
compared to each other to show significant changes in binding between the SW480 and 
SW620 cells. The lectins that show increased binding to SW480 over SW620 were; 
GNL, UEA I and MAL II. The lectins that show increased binding to SW620 over 
SW480 were; LecA, SNA, SBA, Jacalin and MAL I. The lectins that show similar 
increased binding to SW480 over SW620, signifying no significant change in the 
relative amount of glycans on the surface of each cell line, were; LecB, AAL 2, AAL, 
Con A, DSL, ECL, RCA, LCA, NPL.  
Determining the patterns of surface glycosylation on cancer cells, as well as any other 
cells, is a difficult process. There are a number of techniques currently used, such as 
lectin microarrays and mass spectrometry, which are employed to identify these surface 
glycans. The use of lectin probing coupled with flow cytometry is an under-utilised 
technique that can be used for both qualitative analysis and quantitative analysis of cell 
surface glycans. A large panel of lectins can be used in a single experiment with either 
cell lines or disaggregated tissue samples. With the continual advancements being 
achieved in the field of flow cytometry, this method for interrogation of glycans could 
be used as a reliable and useful diagnostic tool.   
If there was further time and resources to develop this work there are a number of areas 
that would be useful to explore. There were other residues that were highlighted as 
potential candidates for mutagenesis in the LecB gene. The LecB variant library should 
be expanded, utilising of these alterations. For the in vitro analysis there are a number of 
other lectins that could be added to the panel of recombinant lectins. This expanded 
panel could then be utilised to identify additional changes in surface glycosylation not 
detected in this work. It would also be useful to expand the range of colorectal 
carcinoma cell lines in order to try and identify if there are other significant changes in 
lectin binding patterns between cells from different patients. It would also be useful to 
use some more powerful analytical instrumentation. For example, the use of a state of 
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the art confocal microscope or imaging flow cytometer that would allow for more in 
depth analysis of lectin binding to the cell surface to be carried out.   
In conclusion, this research project allowed for the mutagenesis, expression, purification 
and characterisation of the prokaryotic lectin LecB. Some of these probes were 
engineered to perform better when used in vitro on SW480 and SW620 cells. Once 
characterised the probes were validated for in vitro use and then used for probing cells 
and analysing binding through fluorescent microscopy and flow cytometry. Fluoroescent 
microscopy and flow cytometry were both used for qualitative analysis of cell surface 
glycosylation and flow cytometry could also be used for quantitative analysis. The 
glycan pattern on the surface of both SW480 and SW620 cells were assessed and then 
compared to show the difference in surface glycans. The original aims at the beginning 
of the project were achieved.  
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Appendix A 
A.1 LecB and LecB mutant Purifications 
 
 
Figure A1.1: LecB purification showing contaminating larger protein bands. Lanes; 1) 
Broad range protein ladder, 2) Cleared filtered Lysate, 3) Unbound flow through, 4) 20 mM 
imidazole wash, 5) 80 mM imidazole wash, 6) Elution fraction 1, 7) Elution fraction 2, 8) 
Elution fraction 3, 9) Elution fraction 4, 10) Elution fraction 5, 11) Elution fraction 6, 12) Elution 
fraction 7. 
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Figure A1.2: LecB S23A;S24A;G25A purification showing minimal contaminating bands 
with a relative larger size. Lanes; 1) Broad range Protein ladder, 2) Cleared filtered lysate, 3) 
Unbound flow through, 4) 20 mM imidazole wash, 5) 50 mM imidazole wash, 6) 80 mM 
imidazole wash, 7-13) Elution fractions 1-7. 
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Figure A1.3: LecB S24T purification warped gel with high level of pure protein. Lanes; 
Broad range Protein ladder, 2) Cleared filtered lysate, 3) Unbound flow through, 4) 20 mM 
imidazole wash, 5) 50 mM imidazole wash, 6) 80 mM imidazole wash, 7-12) Elution fractions 1-
6. 
 
 
 
 
 
1      2       3         4          5         6          7          8        9      10      11       12 
A4 
 
 
Figure A1.4: EGFP-LecB purification showing numerous contaminating protein bands. 
Lanes; 1) Broad range Protein ladder, 2) Cleared filtered lysate, 3) Unbound flow through, 4) 20 
mM imidazole wash, 5) 50 mM imidazole wash, 6) 80 mM imidazole wash, 7-12) Elution 
fractions 1-6. 
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A.2 LecB and LecB mutants Sequence Data (both nucleotide and amino acid) 
Amino Acid sequences 
LecB wild type: 
M R G S H H H H H H G S M A T Q G V F T L P A N T R F G V T A F A N S S G T Q T V N V L V N N E T 
A A T F S G Q S T N N A V I G T Q V L N S G S S G K V Q V Q V S V N G R P S D L V S A Q V I L T N E L 
N F A L V G S E D G T D N D Y N D A V V V I N W P L G 
LecB S24T: 
M R G S H H H H H H G S M A T Q G V F T L P A N T R F G V T A F A N S T G T Q T V N V L V N N E T 
A A T F S G Q S T N N A V I G T Q V L N S G S S G K V Q V Q V S V N G R P S D L V S A Q V I L T N E L 
N F A L V G S E D G T D N D Y N D A V V V I N W P L G 
LecB 3K (added lysine): 
M R G S H H H H H H G K K K S M A T Q G V F T L P A N T R F G V T A F A N S S G T Q T V N V L V N 
N E T A A T F S G Q S T N N A V I G T Q V L N S G S S G K V Q V Q V S V N G R P S D L V S A Q V I L T 
N E L N F A L V G S E D G T D N D Y N D A V V V I N W P L G 
LecB S23A;S24A;S25A (LecB 3A): 
M R G S H H H H H H G S M A T Q G V F T L P A N T R F G V T A F A N A A A T Q T V N V L V N N E T 
A A T F S G Q S T N N A V I G T Q V L N S G S S G K V Q V Q V S V N G R P S D L V S A Q V I L T N E L 
N F A L V G S E D G T D N D Y N D A V V V I N W P L G 
eGFP-LecB: 
M R G S H H H H H H G S M S K G E E L F T G V V P I L V E L D G D V N G H K F S V S G E G E G D A T 
Y G K L T L K F I C T T G K L P V P W P T L V T T L T Y G V Q C F A R Y P D H M K Q H D F F K S A M P 
E G Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L V N R I E L K G I D F K E D G N I L G H K L 
E Y N Y N S H N V Y I M A D K Q K N G I K V N F K I R H N I E D G S V V Q L A D H Y Q Q N T P I G D 
G P V L L P D N H Y L S T Q S A L S K D P N E K R D H M V L L E F V T A A G I T H G M D E L Y K G S 
M A T Q G V F T L P A N T R F G V T A F A N S S G T Q T V N V L V N N E T A A T F S G Q S T N N A V 
I G T Q V L N S G S S G K V Q V Q V S V N G R P S D L V S A Q V I L T N E L N F A L V G S E D G T D N 
D Y N D A V V V I N W P L G 
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eGFP: 
M R G S H H H H H H G S M S K G E E L F T G V V P I L V E L D G D V N G H K F S V S G E G E G D A T 
Y G K L T L K F I C T T G K L P V P W P T L V T T L T Y G V Q C F A R Y P D H M K Q H D F F K S A M P 
E G Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L V N R I E L K G I D F K E D G N I L G H K L 
E Y N Y N S H N V Y I M A D K Q K N G I K V N F K I R H N I E D G S V Q L A D H Y Q Q N T P I G D G 
P V L L P D N H Y L S T Q S A L S K D P N E K R D H M V L L E F V T A A G I T H G M D E L Y K G S A C 
E L G T P G R P A A K L N 
 
Nucleotide sequences 
Note areas of interest are highlighted in specific ways; Red signifies a start codon, Yellow 
signifies a stop codon, Green signifies a BamHI restriction site, Blue Signifies a HindIII 
restriction site, Pink signifies an AccI restriction site and all underlined sequences signify where 
a mutant or insertion has been introduced. 
LecB wild type: 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC ATG GCA ACA CAA GGA GTG TTC ACC CTT CCC 
GCC AAC ACC CGG TTC GGC GTC ACC GCC TTC GCC AAC TCG TCC GGA ACC CAG ACG GTG AAC GTG CTG 
GTC AAC AAC GAG ACG GCC GCG ACC TTC AGC GGG CAA AGC ACC AAT AAC GCC GTC ATC GGC ACC CAG 
GTG CTC AAC TCC GGC AGC AGT GGC AAG GTA CAG GTC CAG GTC AGC GTC AAC GGC CGC CCC TCG GAT 
CTG GTC TCG GCA CAG GTA ATC CTG ACC AAC GAG CTG AAC TTC GCC CTG GTC GGC TCT GAA GAC GGC 
ACC GAC AAC GAC TAC AAC GAC GCC GTC GTG GTG ATC AAC TGG CCG CTC GGC TAG TAA AAG CTT AAT 
 
LecB S24T: 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC ATG GCA ACA CAA GGA GTG TTC ACC CTT CCC 
GCC AAC ACC CGG TTC GGC GTC ACC GCC TTC GCC AAC TCG ACC GGA ACC CAG ACG GTG AAC GTG CTG 
GTC AAC AAC GAG ACG GCC GCG ACC TTC AGC GGG CAA AGC ACC AAT AAC GCC GTC ATC GGC ACC CAG 
GTG CTC AAC TCC GGC AGC AGT GGC AAG GTA CAG GTC CAG GTC AGC GTC AAC GGC CGC CCC TCG GAT 
CTG GTC TCG GCA CAG GTA ATC CTG ACC AAC GAG CTG AAC TTC GCC CTG GTC GGC TCT GAA GAC GGC 
ACC GAC AAC GAC TAC AAC GAC GCC GTC GTG GTG ATC AAC TGG CCG CTC GGC TAG 
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LecB 3K (added lysine): 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA AAA AAG AAA TCC ATG GCA ACA CAA GGA GTG TTC 
ACC CTT CCC GCC AAC ACC CGG TTC GGC GTC ACC GCC TTC GCC AAC TCG TCC GGA ACC CAG ACG GTG 
AAC GTG CTG GTC AAC AAC GAG ACG GCC GCG ACC TTC AGC GGG CAA AGC ACC AAT AAC GCC GTC ATC 
GGC ACC CAG GTG CTC AAC TCC GGC AGC AGT GGC AAG GTA CAG GTC CAG GTC AGC GTC AAC GGC CGC 
CCC TCG GAT CTG GTC TCG GCA CAG GTA ATC CTG ACC AAC GAG CTG AAC TTC GCC CTG GTC GGC TCT 
GAA GAC GGC ACC GAC AAC GAC TAC AAC GAC GCC GTC GTG GTG ATC AAC TGG CCG CTC GGC TAG 
 
LecB S23A;S24A;G25A (LecB 3A): 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC ATG GCA ACA CAA GGA GTG TTC ACC CTT CCC 
GCC AAC ACC CGG TTC GGC GTC ACC GCC TTC GCC AAC GCG GCC GCA ACC CAG ACG GTG AAC GTG CTG 
GTC AAC AAC GAG ACG GCC GCG ACC TTC AGC GGG CAA AGC ACC AAT AAC GCC GTC ATC GGC ACC CAG 
GTG CTC AAC TCC GGC AGC AGT GGC AAG GTA CAG GTC CAG GTC AGC GTC AAC GGC CGC CCC TCG GAT 
CTG GTC TCG GCA CAG GTA ATC CTG ACC AAC GAG CTG AAC TTC GCC CTG GTC GGC TCT GAA GAC GGC 
ACC GAC AAC GAC TAC AAC GAC GCC GTC GTG GTG ATC AAC TGG CCG CTC GGC TAG 
 
eGFP-LecB: 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCT ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA 
GTT GTC CCA ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG 
GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA AAA CTA CCT 
GTT CCA TGG CCA ACA CTT GTC ACT ACT CTC ACT TAT GGT GTT CAA TGC TTT GCG AGA TAC CCA GAT 
CAT ATG AAA CAG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA AGA ACT ATA 
TTT TTC AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT 
AAT AGA ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTT GGA CAC AAA TTG GAA 
TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA ATC AAA GTT AAC 
TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT 
CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCG 
AAA GAT CCC AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GAG TTT GTA ACA GCT GCT GGG ATT ACA 
CAT GGC ATG GAT GAA CTA TAC AAA GGA TCC ATG GCA ACA CAA GGA GTG TTC ACC CTT CCC GCC AAC 
ACC CGG TTC GGC GTC ACC GCC TTC GCC AAC TCG TCC GGA ACC CAG ACG GTG AAC GTG CTG GTC AAC 
AAC GAG ACG GCC GCG ACC TTC AGC GGG CAA  AGC ACC AAT AAC GCC GTC ATC GGC ACC CAG GTG CTC 
AAC TCC GGC AGC AGT GGC AAG GTA CAG GTC CAG GTC AGC GTC AAC GGC CGC CCC TCG GAT CTG GTC 
TCG GCA CAG GTA ATC CTG ACC AAC GAG CTG AAC TTC GCC CTG GTC GGC TCT GAA GAC GGC ACC GAC 
AAC GAC TAC AAC GAC GCC GTC GTG GTG ATC AAC TGG CCG CTC GGC TAG 
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Modified eGFP  
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCT ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA 
GTT GTC CCA ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG 
GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA AAA CTA CCT 
GTT CCA TGG CCA ACA CTT GTC ACT ACT CTC ACT TAT GGT GTT CAA TGC TTT GCG AGA TAC CCA GAT 
CAT ATG AAA CAG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA AGA ACT ATA 
TTT TTC AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT 
AAT AGA ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTT GGA CAC AAA TTG GAA 
TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA ATC AAA GTT AAC 
TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT 
CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCG 
AAA GAT CCC AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GAG TTT GTA ACA GCT GCT GGG ATT ACA 
CAT GGC ATG GAT GAA CTA TAC AAA GGA TCC GCA TGC GAG CTC GGT ACC CCG GGT CGA CCT GCA GCC 
AAG CTT AAT TAG 
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A.3 Supplementary ELLA data for recombinant prokaryotic lectin 
characterisation 
 
 
Figure A3.1: ELLA analysis to determine the minimum level of glycoprotein needed for 5 
µg/mL wild type LecB to have binding saturation. Increasing concentrations of BSA-linked 
mannose were added to the plate and probed with 5 µg/mL of LecB wild type. 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
PBS 15 µg
Mannose
10 µg
Mannose
5 µg
Mannose
1 µg
Mannose
0.5 µg
Mannose
A
b
so
rb
an
ce
 4
5
0
 n
m
 
Analysis of wild type LecB binding to increasing 
concentrations of BSA-linked Mannose 
A10 
 
 
Figure A3.2: ELLA analysis to determine the minimum level of glycoprotein needed for 5 
µg/mL LecB 3A to have binding saturation. Increasing concentrations of BSA-linked mannose 
were added to the plate and probed with 5 µg/mL of LecB 3A. 
 
 
Figure A3.3: Preliminary ELLA analysis of LecB with added lysine probed against BSA-
linked fucose, mannose and GlcNAc. Bars on the chart; Grey = PBS, Red = BSA-linked 
Fucose, Green = BSA-linked Mannose, Navy = BSA-linked GlcNAc. 
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Appendix B 
B.1 Sugar inhibition studies for lectins tested using flow cytometry.  
 
 
Figure B1.1: SW480 and SW620 cells probed with PNA and PNA pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Competitive inhibitory sugar use for PNA is 200 mM galactose. The non-inhibitory 
sugar used for PNA is 200 mM L-fucose.
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Figure B1.2: SW480 and SW620 cells probed with UEA and UEA pre-incubated 
with inhibitory and non-inhibitory sugars. A) SW480 cells, B) SW620 cells. 
Competitive inhibitory sugar use for UEA is 200 mM L-Fucose. The non-inhibitory 
sugar used for UEA is 200 mM D-fucose.  
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B.2 MTS and fluorofire blue assays to determine lectin cytotoxicity 
 
 
Figure B2.1: Fluorofire blue toxicity assays for lectins MAL II, WGA, AAL I and 
Jacalin with SW620 cells. The percentage reduction of resazurin is measured and 
calculated to show the level of metabolically active cells in the sample. 
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Figure B2.2: Fluorofire blue toxicity assays for lectins MAL II and WGA with 
SW480 cells. The percentage reduction of resazurin is measured and calculated to show 
the level of metabolically active cells in the sample. 
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